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9PROLOGUE
Before you start reading this thesis, I would like to share some of my experiences during 
the years I was working on the various projects that form the basis for this thesis. 
How it all started…
Before I applied to medical school I said I would never be interested in doing research. 
However, my perception of research changed quickly enough; in June 2006 Heleen Blussé 
needed students to interview postoperative patients for her awareness study in the Erasmus 
MC - Sophia Children’s Hospital. I decided to apply. That was the first research project I 
worked on. 
Shortly after Heleen introduced me to Tom de Leeuw. He was looking for a student to assist 
with his study on Bispectral index monitoring in intellectually disabled children. I recruited 
patients for this study before, sometimes during, and after my classes. One of the recovery 
nurses once joked with me “Does your mother know you’re here”?
Supervisors
At some point it became clear that the Bispectral index monitoring study wouldn’t be my 
last research project. Prof. Tibboel asked me if I would consider doing a PhD on pain in 
intellectually disabled children. Something I didn’t have to thing about for too long! Dr. 
Monique van Dijk would be my copromotor (supervisor).
In 2008, Prof. Tibboel sent in a proposal for the Academische Jaarprijs; a competition for 
teams from Dutch universities. The project aimed at creating awareness for pain in neo-
nates, intellectually disabled children and cognitively impaired elderly patients. Although 
we left without the money, this was the start of the Meetbus project. 
“De Meetbus”
The Meetbus is a Citroen HY van; build in 1974 and once owned by landscape photographer 
Hans Aarsman. 
Ingeborg Griffioen from Panton and her husband Wouter transformed the van into the 
Meetbus; a beautifully designed mobile research unit. The Meetbus enabled us to visit the chil-
dren with Down syndrome and their siblings at home so they did not have to come down 
to the hospital to participate in the study. The official launch party in June 2010 was a great 
event. Everyone loved the Meetbus and it received a lot of attention. There was one thing I 
didn’t realize at the time, that it is not easy to drive a 1974 Citroen HY. 
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Launch party of the Meetbus
With Brendan O’Hare and  
Cormac Breatnach
Weekend with PhD students from 
Erasmus MC -Sophia Children’s Hospital
With Heleen Blussé
With Monique van Dijk and 
Prof. Tibboel
11
Our Lady’s Children’s Hospital Crumlin
Monique had visited the PICU of Our Lady’s Children’s Hospital in Dublin to advise on pain 
and distress assessment with the COMFORT-B scale. This marked the start of an interna-
tional collaboration between the two PICUs. In March 2011 Monique and I went over to talk 
about the ideas for a study on morphine pharmacokinetics and the analgesia and sedation 
requirements of children with Down syndrome after cardiac surgery.
This was the first of many visits to Dublin and in December 2011 I moved to Dublin. The 
local hospital ethics committee had already approved the study and the National Children’s 
Research Centre kindly provided funding. I could start recruiting patients in January 2012. 
Dr. Cormac Breatnach and Dr. Brendan O’Hare were my local supervisors; they made sure 
that I not only learned everything about cardiac anesthesia and intensive care medicine, but 
also about one of the three national sports in Ireland - rugby. 
Moving to Ireland brought me to an exciting workplace, a new city, and a new country. I en-
joyed every minute of working in Crumlin. Children and their families from all over Ireland 
travel to Crumlin for cardiac surgery, it has a big impact on the entire family. 
Three other things I learned in Ireland:
1. Part of working in Crumlin is going for breakfast. I so enjoyed having a planned break-
fast at work. And during the weekends the nurses manage to prepare a full Irish in the 
tiny kitchen. It is the best break of the day.
2. “And where are ye from?” Number one question in Ireland. It might sound trivial, but 
it is not. There is nothing so important as “home”. Whether it is in Mayo, west Cork or 
Zwolle. 
3. Things will be ok. Stop worrying. Seen from here, the Netherlands looks so organized. 
Perhaps there is less need to be so organized. 
Looking back at my PhD period
The research aimed at learning more about pain assessment and appropriate management in 
intellectually disabled children. I hope this thesis shows caregivers that assessing pain and 
distress in intellectually disabled children requires a little extra attention, but that current 
perceptions of different analgesia and sedation requirements seem to not necessarily be true. 
I absolutely enjoyed doing the research, writing this thesis, but most of all working together 
with so many people. Prof. Tibboel and Dr. Monique van Dijk taught me a great deal about 
doing clinical research. Their feedback, innovative ideas and support were key ingredients for 
this thesis. 
A good preparation is essential, but things will be ok and a little bit of patience and persis-
tence goes a long way. 
Bram
Prologue
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“Common sensation is generally much less acute than in ordinary persons. 
Pain is born with wonderful callousness. It is not uncommon for children 
of this class to allow a thecal abscess to be opened with a scalpel without a 
grimace or without uttering a word.” 
This is what John Langdon Down back in 1887 wrote in his treatise on what we now refer to 
as individuals with Down syndrome(1). Around 1 in every 700 children is born with trisomy 
21 (Down syndrome), which makes it the primary cause of congenital intellectually disabil-
ity. The vast majority of children with Down syndrome is intellectually disabled; the mean 
intelligence quotient (IQ) is 50 (range 30 to 70)(2). 
More than 80 different comorbidities have been associated with Down syndrome(3) and 
some – such as a congenital heart defect – are present in the majority of the children with 
Down syndrome(4). Up to 20 years ago, Down syndrome was a reason to withhold surgery 
for congenital duodenal obstruction or congenital heart defects(5). This is no longer the 
case; together with improved therapy for pulmonary hypertension and leukemia the 10-year 
survival of children with Down syndrome improved to 91%(6). Morbidity is higher in those 
who survive; therefore adequate pain assessment and management is highly relevant in 
these children. 
The studies in this thesis address pain assessment and management, as well as general 
anesthesia and sedation, in intellectually disabled children - with a focus on children with 
Down syndrome. Furthermore, there are parallels with pain assessment and management 
in neonates and infants. The different topics are introduced below. 
Measuring depth of anesthesia 
General anesthesia is a drug-induced, reversible condition that includes specific behav-
ioral and physiological traits - unconsciousness, amnesia, analgesia, and akinesia - with 
concomitant stability of the autonomic, cardiovascular, respiratory, and thermoregulatory 
systems(7). Several electroencephalogram (EEG)- derived monitors have been developed 
to measure depth of anesthesia; predominantly the depth of the hypnotic component of 
anesthesia. Bispectral index (BIS) monitoring, initially developed to prevent intraoperative 
awareness, is the best studied instrument to measure depth of anesthesia in children(8).
Given the high incidence of comorbidities in intellectually disabled children, they will often 
require general anesthesia for surgery, dental treatments or diagnostic procedures(9). An-
esthesiologists could well face communication problems, difficulties in assessing the level 
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of consciousness, and unexpected consequences of pharmacokinetic or pharmacodynamic 
interactions when caring for intellectually disabled children. A reliable measure of depth of 
anesthesia could help titrate anesthetic agents in these children. However, it has been noted 
that BIS values tend to be lower in intellectually disabled patients(10, 11). The validity of BIS 
in these patients requires therefore more attention. 
Clinical aspects of pain assessment and management
Although self-report is the gold standard for pain assessment, it is not always feasible or 
appropriate. Health professionals have had to find other methods to assess pain in infants 
and young children, in mechanically ventilated or sedated patients, and in intellectually 
disabled patients. Consequently, various observational pain assessment tools have been 
developed and validated to measure pain in these groups, such as the COMFORT-B scale 
for children below the age of 3 years(12) and various scales for intellectually disabled chil-
dren(13-15). Nevertheless, there is still a paucity of evidence for the proper pain manage-
ment in intellectually disabled patients and they are often excluded from prospective rand-
omized trials on analgesic regimens. Their participation in such trials is badly needed since 
retrospective studies revealed that intellectually disabled children received lower doses of 
intraoperative opioids compared to controls(16, 17). Furthermore, Malviya et al. reported 
that 89% of the physicians they surveyed tended to prescribe sub-therapeutic doses of anal-
gesics to children with an intellectual disability(18). 
Especially children with Down syndrome are often described as more agitated and “dif-
ficult to sedate” after surgery(19). This was confirmed in a retrospective chart review study; 
it showed that children with Down syndrome more often received sedatives and muscle 
relaxants after cardiac surgery than children without Down syndrome(20); however, these 
claims have not been evaluated in prospective trials.
Experimental pain research
Since 1960 we have seen substantial growth in the research on pain in humans (see Figure 
1). Initially focusing on adults, 20 years later this research picked up on pain in children, 
with for example the key publications by Anand and colleagues on pain in neonates(21, 22). 
The output is in sharp contrast with the number of studies in intellectually disabled chil-
dren: between 2005 and 2009 no more than 30 of the 100 000 articles on pain in humans 
addressed pain in this vulnerable patient group. We are still waiting for the dashed line in 
the graph to incline. 
Since the publication of John Langdon Down’s report in 1887(1), the pain sensitivity of 
intellectually disabled children and adults has been widely debated but rarely studied(23, 
24). The first systematic investigation of their pain sensitivity was published in 2000; it 
showed that individuals with Down syndrome have more problems to localize pain and 
perceived an ice-cold stimulus later as painful than controls(25). Defrin et al. were the first 
to apply quantitative sensory testing (QST) and found that intellectually disabled adults are 
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even more sensitive to painful stimuli than controls(26). The QST procedure systematically 
documents alterations and reorganization in nervous system function and, in particular, 
the nociceptive system(27). One of the most frequently applied QST modalities in both 
children and adults is the assessment of the thermal detection and pain thresholds with the 
Thermal Sensory Analyser(28, 29). 
Pain sensitivity has also been investigated in one of the mouse models for Down syndrome. 
Compared to control littermates, the Tn65Dn mouse showed an overall reduced respon-
siveness to painful stimuli(30). However, the claim that children with Down syndrome are 
less sensitive to pain has not been systematically evaluated. 
 
FIGURE 1 Publications on pain in PubMed between 1960 and 2009
Adapted from Belew et al.(31) The dotted line represents numbers of publications on adults and children 
together; the solid line numbers of publications in children separately; and the dashed line publications 
on pain in intellectually disabled children. The upper diagram shows the number of publications for the 
three groups and the lower diagram only publications on children and intellectually disabled children. 
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Pain in neonates and infants
Pain management can be challenging as well in other groups of pediatric patients in which 
self-report of pain is not an option. Randomized controlled trials have investigated the 
optimal analgesic therapies in neonates and infants(32, 33). However, concerns have been 
raised that analgesic and anesthetic agents might have long-term adverse effects on the 
developing nervous system of neonates and infants, in particular the induction of neuroa-
poptosis(34). Analgesics are titrated based on observational pain assessments; neverthe-
less observational pain assessment is regarded as a silver standard; one keeps searching 
for a more objective method to measure pain such as skin conductance(35), near-infrared 
spectroscopy(36), or heart-rate variability(37). However, Berde and McGrath recently 
emphasised that “there is a strong bias among clinicians and clinical researchers to find an 
objective measure of pain”(38). They postulated criteria for the ideal physiologic measure 
of pain intensity (See Table 1).
TABLE 1  
Criteria for physiologic measures of pain intensity
Adapted from Berde and McGrath(38)
1 Low cost, portable, reliable, easy to use, low risk
2  Strong agreement with self-report pain scales in articulate subjects ages 4 years and older.
 Strong agreement means: 
  - High sensitivity and high specificity
  -  Excellent positive and negative predictive value over the full range from mild to 
severe pain intensities
  - For patients/subjects with:
   • Experimental pain, including repetitive stimulation
   • Acute postoperative pain
   •S everal distinct types of recurrent episodic pain and chronic  
persistant pain
Chapter 1
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 STUDY QUESTIONS
The studies presented in this thesis addressed the following questions:
Part II Assessment
-  Are instruments for pain and distress assessment, such as BIS-monitoring, the COM-
FORT-B scale and skin conductance monitoring, also valid in non-verbal infants and 
children?
Part III Quantitative sensory testing
-  Do children with Down syndrome show reduced sensitivity to pain according to their 
parents and in experimental pain tests?
-  Does continuous morphine administration at neonatal age affect thermal detection and 
pain thresholds, chronic pain, or neurological functioning at 8-9 years of age?
Part IV Management
-  Do postoperative analgesia and sedation requirements or the morphine pharmacokinetics 
of children with Down syndrome differ from those of other children?
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OUTLINE
Part I introduces the topic of pain assessment and management in intellectually disabled 
children. Chapter 2 is a review of the literature on pain assessment, management and trans-
lational research in these children. The results of a survey among Dutch anesthesiologists 
on their perceptions and practice with regard to pain management in intellectually disabled 
children are presented in Chapter 3. 
Part II reports on the validation and use of pain and distress assessment tools. The use of 
BIS-monitoring to measure the depth of the sedative component of anesthesia is reported 
in Chapters 4 and 5. The COMFORT-B scale is evaluated for the assessment of pain and 
distress in children with Down syndrome in Chapter 6. Skin conductance monitoring as 
a real-time measure of sympathetic nervous system activations (such as pain and distress) 
was applied in Chapter 7.
Part III focuses on quantitative sensory testing. The study in Chapter 8 describes the ther-
mal detection and pain thresholds as well as the results of parental questionnaires on the 
pain behaviour of children with Down syndrome versus siblings. The study in Chapter 9 
evaluates the effects of neonatal continuous morphine infusion on thermal detection and 
pain thresholds, chronic pain and neurological functioning at 8 to 9 years of age.  
Part IV describes the results of a retrospective study on the analgesia and sedation require-
ments of neonates with Down syndrome in Chapter 10 and the results of a prospective 
study on the pharmacokinetics and pharmacodynamics of morphine after cardiac surgery 
in infants and children with and without Down syndrome in Chapter 11. 
Part V discusses the results of this thesis in a broader perspective and gives an overall sum-
mary of the thesis in Chapter 12 and 13.  
Chapter 1
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‘ I put you from your 
pain, I can no more.’

PAIN MANAGEMENT IN INTELLECTUALLY 
DISABLED CHILDREN: ASSESSMENT, 
TREATMENT, AND TRANSLATIONAL 
RESEARCH
Abraham J. Valkenburg, Monique van Dijk, Annelies de Klein,  
Johannes N. van den Anker, Dick Tibboel 
Developmental Disabilities Research Reviews (2010); 16: 248 - 257
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ABSTRACT
The primary focus of pain research in intellectually disabled individuals is still on pain 
assessment. Several observational pain assessment scales are available, each with its own 
characteristics, its own target group and its own validated use. Observational studies report 
differences in the treatment of intra- and postoperative pain of intellectually disabled 
children and almost all children with intellectual disability have comorbidities that need 
to be addressed. The scope of research has started to broaden. In this review we aim to 
answer the question: Can we integrate validated ways of pain assessment and postopera-
tive pain treatment in intellectually disabled children in order to develop specific analgesic 
algorithms? Regrettably there is little knowledge on possible interaction effects and other 
relevant pharmacological issues. Possible genotype-phenotype associations related to pain 
in children with Down’s syndrome have several promises as six possible candidate genes 
are located on chromosome 21. 
In conclusion, the pain assessment tools for intellectually disabled children are there. We 
should now focus on tailoring the pain treatment. To this aim we need to perform pharma-
cokinetic and pharmacodynamic studies of analgesics and obtain information about the 
genotype - phenotype relationships for pain. This can lead to the development of specific 
analgesic algorithms. 
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INTRODUCTION
Pain in intellectually disabled individuals
What makes pain management in intellectually disabled individuals so challenging? Are 
there alterations in neurobiological processes involved in nociception, is it more difficult 
for them to express pain or are caregivers unaware of methods to assess pain? More than 
half a century ago, Couston presented seven cases of intellectually disabled adults who 
did not show any pain in situations where he expected pain expression(1). But times have 
changed and several pain assessment tools specially geared to persons with an intellectual 
disability are available now. These pain assessment tools rely on observation by caregivers, 
as self-report usually is not possible or is considered to be unreliable nowadays. The pri-
mary focus of pain research in intellectually disabled individuals is still on pain assessment. 
The scope of research has started to broaden. Several experimental pain studies have been 
reported, for example a quantitative sensory testing (QST) study among individuals with 
Down’s syndrome (2), the postoperative pain treatment has retrospectively been evaluated 
(3, 4) and the first steps towards translational genetic studies have been made(5).
Epidemiology
The American Association on Intellectual and Developmental Disabilities (AAIDD) defines 
intellectual disability as “A disability characterized by significant limitations both in intel-
lectual functioning and in adaptive behavior, which covers many everyday social and practi-
cal skills. This disability originates before the age of 18.” Epidemiological studies have 
reported prevalence of intellectual disability ranging from 0.3% to 0.78%(6, 7). The causes 
of intellectual disability are very diverse, from chromosomal abnormalities to hereditary 
diseases or acquired disorders. Westerinen et al. provide a number of inclusion diagnoses 
based on the International Classification of Diseases (ICD) 10 that are used for the epide-
miological analysis(6). Another aspect is the epidemiology of health conditions among 
intellectually disabled children. For example gastroesophageal reflux disease, a condition 
that will cause significant discomfort and pain, is present in up to 50% of intellectually 
disabled children and adults(8, 9). Albeit that children with an intellectual disability form a 
heterogeneous group, it would be worthwhile to identify common traits in pain expression 
and grounds for tailor-made pain management of this group. 
Outline of this review
First, recent advances in pain assessment of intellectually disabled children will be ex-
plored. The second part of this review will evaluate the pain treatment and the influence 
of co-medication in this group. Third, (translational) genetic studies in Down’s syndrome 
will be discussed from the perspective of pain research. In this review we aim to answer the 
question: Can we integrate validated ways of pain assessment and postoperative pain treat-
ment in intellectually disabled children in order to develop specific analgesic algorithms?
Chapter  2
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PAIN ASSESSMENT
 
Why focus on assessment?
The International Association for the Study of Pain considers a person’s self-report of pain 
as the gold standard for pain assessment. Apart from the presence of pain, medical profes-
sionals will want to know the location, duration, intensity, type of sensation and so on. 
There are self-report tools to quantify the intensity of pain, for example the Visual Analogue 
Scale or Numeric Rating Scale(10). After surgery for example, patients should be assessed 
on a regular basis and pain scores should be recorded. Pain assessment is an essential part 
of history taking and daily clinical practice. Providing adequate analgesic therapy is virtually 
impossible when not based on reliable pain assessment. In addition, reassessment of pain 
after intervention is important to ensure effective and safe pain management(11). 
What if people cannot say they have pain or what if we have reasons to doubt that the 
answer is reliable? This is considered to be the case in young children up to the age of three 
years, intellectually disabled children and adults and cognitively impaired elderly persons 
as well as patients who are sedated during intubation for artificial ventilation. In this review 
article we will focus on intellectually disabled children. Kingston et al. state that caregiv-
ers should take care not to regard the behavior of persons with intellectual disability as 
challenging only, because that brings the risk of ‘diagnostic overshadowing’(12). In other 
words, clinicians shouldn’t attribute all symptoms to the intellectual disability, but see it as 
an attempt to communicate. A survey among parents about pain in intellectually disabled 
children made clear that the degree of intellectually disability influences the pain expres-
sion of their child. Children with mild or moderate intellectually disability made verbal 
statements about pain and children with profound intellectual disability used indirect be-
haviors (crying, behavioral and emotional changes) to express pain(13). In a recent review 
article about pain assessment in intellectual disabilities the results of the two studies that 
examined the quality of self-report are found inconclusive(14). More evidence is needed be-
fore self-report can be recommended as a first-line assessment approach for children with 
even mild intellectual disability. How do we then assess their pain? The answer is observa-
tional assessment. 
Observational pain assessment
Several observational pain assessment scales are available, each with its own characteris-
tics, its own target group and its own validated use. But all of them are based on observa-
tion of manifestations that are considered indicators of pain. Our own research group has 
developed and validated the Checklist Pain Behavior for intellectually disabled children(15).
Postoperative pain assessment
The presence of intellectual disability influences the decisions of caregivers regarding pain 
assessment and treatment(16, 17). Caregivers should use appropriate and valid observa-
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TABLE 1  
Validated Observational Pain Assessment Scales for Intellectually Disabled Children
 DESS PICIC  NCCPC-PV  PPP  CPB  rFLACC INRS
Age range 6-33  Mean age 3 -19 1 - 18 3-19  4-19  6 -18 
in years  10 years
Number of 112 49 24 140 73  52 50
patients
Patient 
group
Indications Pain Pain Postopera- (Postopera Postopera-  Postopera-  Postopera- 
   tive Pain tive) Pain tive Pain tive Pain tive Pain
Indicators       
Facial x x x x x x 
Activity x x x x x x 
Vocal x x x x x x 
Social x  x x  x 
Consolability  x  x  x 
Physiological x x x x x x 
Individual   x    x x
indicators 
Items 10 (0 - 10) 6 (0 - 24) 27 (0 - 81) 20 (0 – 60) 10 (0 - 10) 5 (0 - 10) Variable 
(score range)
Clinical 
cut-off 
scores
(Echelle 
Douleur 
Enfent San 
Salvadour) 
Collignon 
2001
(Pain 
Indicator for 
Commu-
nicatively 
Impaired 
Children) 
Stallard 
2002
(Non-com-
municating 
Children’s 
Pain Check-
list–Post-
operative 
Version) 
Breau 2002
(Paediatric 
Pain Profile) 
Hunt 2004
(Check-
list Pain 
Behaviour) 
Terstegen 
2003;  
Duiven-
voorden 
2006
(Revised 
Face, Legs, 
Activity, Cry, 
Consolability) 
Malviya 2006
(Indivualized 
Numeric 
Rating Scale) 
Solodiuk 2010
non-verbal 
patients 
with 
cerebral 
palsy
non-verbal 
intellectu-
ally disabled 
children
non-
verbal 
intel-
lectually 
disabled 
children 
non-verbal 
intel-
lectually 
disabled 
children
non-ver-
bal intel-
lectually 
disabled 
children
non-verbal 
intel-
lectually 
disabled 
children
intel-
lectually 
disabled 
children
2/10: 
Pain is 
possible
6/10: 
Definite 
pain that 
requires 
treatment
4/10: 
Moderate 
pain (not 
based on 
sensitivity/
specificity)
Not 
available 
11/ 81: 
Moderate to 
severe pain
14/60: 
Moderate 
or worse 
pain 
Not avail-
able
Not 
available 
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tional postoperative pain assessment scales immediately after surgery. Table I provides 
an overview of validated observational pain assessment skills for intellectually disabled 
children. The review articles of Voepel-Lewis et al., Ghai et al., Breau et al., and Van Dijk et 
al., and the book chapter by Breau et al. discuss the characteristics of the different scales in 
a solid way(14, 18-21). Complexity, clinical utility, compatibility, validity and the items of the 
scales are topics that have been addressed in the reviews. 
Behavioral versus physiological indicators of pain 
Pain assessment scales are either unidimensional or multidimensional. This classifica-
tion refers to the factor structure (are all items a measure for the same construct?), to the 
construct of the results (only pain or pain and, for example, distress) or to the nature of the 
items (behavioral or physiological) Most of the above mentioned pain assessment scales 
are composed of behavioral indicators of pain. Physiological indicators such as heart rate 
variability(22), skin conductance(23) and near-infrared spectroscopy (NIRS)(24) could be 
seen as biomarkers of both the stress or pain system. Stevens et al. identified three dif-
ferent purposes of biomarkers, namely as outcome measure, as predictor of health and 
development, and as probe of central nervous system integrity(25). Anand et al. state that a 
physiological response to a painful stimulus should be regarded as evidence of pain reactiv-
ity(26). Researchers generally seem to be biased towards physiological measures(27). They 
provide a list with criteria that should be met for a candidate physiologic measure of pain 
intensity. Based on these criteria a well-validated multidimensional pain assessment scale 
should be developed, including behavioral indicators and for example skin conductance or 
heart rate variability measurement. 
Recent advances in pain assessment
Recent advances in pain assessment include a pain assessment protocol and the Individual-
ized Numeric Rating Scale (INRS). The peer reviewed pain assessment protocol of King-
ston et al. includes a pain diary kept by caregivers, a pain story, assessment of chronic pain, 
a baseline pain assessment, a simple visual analogue scale, the pain faces tool and a body 
map. Especially the pain diary and pain story with the appropriate use of symbols could 
improve communication of pain in intellectually disabled children. However, this protocol 
should be prospectively evaluated to validate its use(12). The INRS is based on individual 
pain indicators that parents and caregivers proposed(28). The individual descriptions are 
ranked on a scale from 0 to 10. This makes the INRS an observational pain assessment tool, 
not a self-report tool. The INRS was validated in a study exploring postoperative pain in 50 
children with profound intellectual disability, aged 6 - 18 years. In the accompanying edito-
rial, Breau points out that there will always be a pull between clinical utility and psychomet-
ric soundness of a pain assessment scale(29). Furthermore, she states that standardized 
scales are possible for this population and that individualized pain tools are not necessary. 
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Individualized pain assessment
The question remains how individualized the pain assessment should be. On the one hand, 
standardized scales can easily be implemented in clinical practice. Nurses and doctors can 
be trained to use the scale, and the results can be used to guide pain management or serve 
as an outcome parameter in research. On the other hand, we should not forget the individu-
al patient. Such standard scales will never cover the wide variability in the degree of intellec-
tual disability. It could be helpful to use information about a child’s adaptive behavior. The 
Vineland Adaptive Behavior Scale assesses domains of adaptive behavior such as commu-
nication and social skills that are also necessarily to convey pain(30, 31). The Pediatric Pain 
Profile also makes it possible to relate a child’s normal behavior with his/her pain behavior. 
The profile is completed by parents and yields information about a child’s behavior when it 
is on its best and when it suffers from pain(32). 
Experimental Research (Quantitative Sensory Testing)
Pain assessment can now encompass more than just measuring the frequency and intensity 
of pain by behavioral parameters. A psychophysical method has been introduced, Quantita-
tive Sensory Testing (QST), which systematically documents alterations and reorganization 
in nervous system function and, in particular, the nociceptive system(33). It is hoped that 
its application will clarify the mechanisms involved in nociception. In their review article, 
Arendt-Nielsen et al. distinguish three different purposes of QST regarding pain assess-
ment: First, basic mechanistic studies in healthy volunteers. Second, clinical studies for di-
agnostic and monitoring purposes. Third, pharmacological studies to evaluate analgesic ef-
ficacy of new and existing compounds. As QST quantifies the reactions to sensory stimuli, 
it is well suited to measure a person’s pain sensitivity, for example. Results of standardized 
QST measurements could be compared between persons and between groups. The Ger-
man research network on neuropathic pain has published reference values for their QST 
protocol in healthy children(34), healthy adults(35) and in adults with neuropathic pain 
syndromes(36). Nielsen et al. state in a review article that both clinical and experimen-
tal pain studies consistently reveal large individual differences in reported pain(37). It is 
recommended to study the sources of variation (for example environmental and genetic 
factors), so that measures of pain sensitivity could be used to predict clinical outcomes and 
to individualize pain treatment regimens. A systematic review by Werner et al. revealed that 
preoperative pain tests may predict 4 to 54% of the variance in postoperative pain experi-
ence, depending on the stimulation methods and test paradigm used(38). This predictive 
strength is higher than demographics or psychological factors. This is a promising field 
that needs evidence from more and larger studies with an appropriate design. 
QST in intellectually disabled persons
Through the years, conflicting reports about the pain sensitivity of intellectually disabled 
persons have been published. In 1954 Couston reported reduced pain sensations in seven 
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adults(1). In 1958 Stengel et al. reported that insensitivity to pain was not observed in any 
of the 97 intellectually disabled patients in their study(39). Several decades later, Biersdorff 
estimated that the incidence of pain insensitivity/indifference in intellectually disabled 
persons was 25.2%(40). Quantitative sensory testing can help us to quantify and study the 
reaction to nociceptive stimuli in intellectually disabled. In a QST pilot study, Hennequin 
et al. found that individuals with Down’s syndrome (n=26), aged 4 to 30 years, expressed 
pain more slowly and less precisely than did control subjects (n=75)(2). Defrin et al. found 
that the heat pain thresholds in 25 intellectually disabled adults (11 of them had Down’s 
syndrome) were lower than those in the 14 control subjects, i.e. when assessed with the 
reaction-time independent method. The heat pain thresholds assessed with the reaction-
time dependent method were comparable, but this could be explained by the longer reac-
tion times of the intellectually disabled subjects(41). In a sham-controlled sensory-testing 
protocol, Symons et al. studied the facial behavior of 44 intellectually disabled adults be-
fore, during and after sensory-stimulation modalities(42). This study shows that individu-
als with significant intellectual impairments are sensitive to tactile stimulation consistent 
with QST protocols. In conclusion, QST is feasible in intellectually disabled. Studying the 
influences of developmental age, earlier painful events and major surgery, reaction time 
and genetic factors on the reaction to nociceptive stimuli might be worthwhile. 
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PAIN TREATMENT
The area of postoperative pain treatment is as broad as or even broader than the area of 
pain assessment. There are many different analgesics, dosages, routes of administration 
and almost each hospital has its own pain protocols. There are only a few randomized con-
trolled trials in this area, but other types of studies provide evidence for the most appropri-
ate analgesia for specific groups and indications. 
Taddio and Oberlander provide an overview of most used medications for chronic condi-
tions in intellectually disabled children and specific considerations to assure good analge-
sia(43). As to the latter, would they need adapted postoperative analgesia because of their 
intellectual disability? 
What do we know from chart review studies?
A review article about Down’s syndrome and anesthesia provides a nice overview on the 
implications of Down’s syndrome for perioperative management(44). Apart from the 
notice that these children are regarded as gregarious and friendly and the mention of a 
higher incidence of postoperative agitation, Mitchell et al. do not report any other recom-
mendations regarding postoperative analgesia. Gakhal et al. reported that children with 
Down’s syndrome (n=16) were more likely to receive morphine on postoperative day 3 after 
cardiac surgery and received more additional sedatives and muscle relaxants than children 
without Down’s syndrome (n=16)(3). Malviya et al. found that intellectually disabled chil-
dren (n=19) received smaller doses of opioids after spinal fusion surgery than did children 
without intellectual disability (n=23) and that fewer intellectually disabled children were 
assessed for pain after surgery(45). Koh et al. prospectively evaluated the intra- and post-
operative pain treatment of 152 children with intellectual disability (mean age 10 years old) 
and 138 children without (mean age 8 years old)(4). During surgery, children with intel-
lectual disability received less amounts of opioids. The researchers found no differences in 
the amounts and types of postoperative analgesics. However, of the children who received 
morphine postoperatively, children with intellectual disability were less likely to receive 
it by a patient controlled analgesia (PCA) pump. The authors acknowledge the concern 
of many pediatric anesthesiologists that intellectually disabled children are more sensi-
tive to respiratory and CNS depressive effects of opioids as a possible explanation for the 
difference in intraoperative opioid administration. The lesser use of the PCA pump might 
be explained by the difficulty in explaining its concepts to intellectually disabled children. 
Czarnecki et al. have evaluated the safety of postoperative parent/nurse-controlled anal-
gesia (PNCA) in 71 intellectually disabled children (mean age 10 years)(46). Two patients 
needed naloxone administration because of respiratory depression or sedation. The authors 
conclude that through proper education and diligent monitoring, PNCA may be a safe and 
effective modality for postoperative analgesia in intellectually disabled children(46). 
A recent study by Long et al. examined intra- and postoperative analgesia for orthopedic 
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surgery in 71 children with cerebral palsy and 77 children without. Of the children with cer-
ebral palsy, 41% were intellectually disabled(47). However, the findings of Long et al. were 
comparable to those of Koh et al. since children with cerebral palsy received less amounts 
TABLE 2 
Comparison of analgesic consumption between intellectually disabled children  
and controls
 Gakhal Malviya Koh Long Valkenburg
 1998 2001 2004 2009 2012
Study 
design 
Study  
group
Control 
group
Type of 
surgery
Intra-
operative 
analgesia 
of the study 
group A
Post - 
operative 
analgesia 
of the study 
group A 
Retrospective 
case-control 
study
16 children with 
Down’s syn-
drome (mean 
age: 5 years) 
16 children 
without Down’s 
syndrome (mean 
age: 5 years)
Cardiac surgery
Not available
q
Retrospective 
cross-sectional 
study
19 intellectually 
disabled children 
(mean age: 11 
years) 
23 children with-
out intellectual 
disability (mean 
age: 11 years)
Spinal fusion 
surgery
=
r
Prospective 
cohort study
152 intellectu-
ally disabled 
children (mean 
age: 10 years)
148 children 
without intel-
lectual disabil-
ity (mean age:  
8 years) 
Various
r
=
Retrospective 
cross-sectional 
study
71 children with 
cerebral palsy 
(29 intellectually 
disabled) (mean 
age: 11 years)
77 children 
without cerebral 
palsy (mean age: 
11 years)
Orthopedic  
surgery
r 
=
Retrospective 
cross-sectional 
study
24 children with 
Down’s syndrome 
(median age: 3 
days)
43 children with-
out Down’ syn-
drome (median 
age: 2 days)
Congenital duo-
denal obstruction 
repair
=
=
A Analgesic doses compared to the control group
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of opioids intraoperatively and comparable amounts of postoperative analgesia(4). Also 
the children with cerebral palsy were less often assessed for postoperative pain, as reported 
by Malviya et al. as well. Our own research group compared the analgesic consumption 
after congenital duodenal obstruction repair between neonates with and without Down’s 
syndrome. We observed no differences in morphine doses or pain scores between the two 
groups(48). 
Table II provides a summary of the results of these comparative studies regarding periop-
erative pain treatment in intellectually disabled children versus controls.
In conclusion, these observational studies report differences in the treatment of intra- and 
postoperative pain of intellectually disabled children. It seems that intellectually disabled 
children receive less intraoperative analgesia and fewer of them are assessed for postopera-
tive pain. No differences in the amount of postoperative analgesia have been reported, but 
children with intellectual disability are less likely to receive a PCA pump. Most importantly, 
it is not clear in any of these studies why the children with intellectually disability received 
less intraoperative analgesia. Do pediatric anesthesiologists only belief that those children 
need less analgesia or is this finding a result of methodological issues of those studies or 
do they really need less amounts of analgesia for the same analgesic effect?
Co-medication in intellectually disabled children
Almost all children with intellectual disability have comorbidities that need to be ad-
dressed. For example, about 10% of the intellectually disabled children in a Dutch cohort 
study were treated with psychotropic drugs(49). The nature of the comorbidity depends 
mostly on the underlying cause of the intellectual disability. Thyroid disorders have been 
reported in up to 54% of children with Down’s syndrome (50) and they are therefore more 
often treated with supplemental thyroid hormones(51). There is, however, one comorbid-
ity that is more common among all individuals with intellectual disability, namely epilepsy. 
A review article by Beavis et al. reported a 14 to 75% prevalence of epilepsy in patients with 
intellectual disability(52). For example, in a cohort of 48 children with spastic tetraplegia 
50% suffered from epilepsy and all of them were treated with antiepileptic drugs(53). A 
larger study described that 20% of 818 children with cerebral palsy had seizures in the 
past 12 months(54). Glaze et al. found that 60% of 602 patients with RETT syndrome had 
seizures. Eighty percent of the patients with seizures were treated(55). Lastly, 8% of 350 
children with Down’s syndrome suffered from seizures and all of them received antiepilep-
tic drugs(56). 
 
Chronic treatment with antiepileptic drugs could have implications for anesthetic and 
postoperative care. Antiepileptic drugs have many physiologic and pharmacologic effects 
that can have impact on an anesthetic. Kofke et al. described that the protein binding and 
enzyme induction effects of common antiepileptic drug, could influence the pharmacoki-
netics of sedative and analgesic drugs used for anesthesia and postoperative analgesia(57). 
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Tempelhoff et al. found that patients treated with antiepileptic drugs required higher doses 
of fentanyl for maintenance of general anesthesia compared with patients who had never 
received antiepileptic drugs(58). Eriksson et al. found lower plasma concentrations of clon-
azepam in children treated with lamotrigine(59). The use of antiepileptic drugs has also 
been associated with different pharmacodynamic effects such as depth of anesthesia(60). 
This area definitely will need more attention, as all children treated with those drugs will 
benefit from this information. 
Pharmacological research in children 
Regrettably there is little knowledge on possible interaction effects and other relevant 
pharmacological issues. Up to 70% percent of the drugs used in a children’s hospital are 
unapproved or off-label(61). Tailor-made drug therapy in children, first of all requires more 
information about the drugs that are used in children. We must know what the body does 
with the drug, the pharmacokinetics, and what the drug does to the body, the pharmaco-
dynamics. These processes considerably change when a newborn develops into a child, an 
adult and an elderly person. Apart from the developmental stage, also body composition, 
use of co-medication, presence of hepatic or renal failure are known to influence a drug’s 
pharmacokinetics and pharmacodynamics(62). Combining the information on the phar-
macokinetics and pharmacodynamics of a drug could lead to a model that describes the 
efficacy and concentrations of that drug. Based on this model, dosing recommendations 
can be generated. The validity of these dosing recommendations should then be tested in 
a prospective study. The process leading to validated dosing recommendations used to be 
long and difficult in children(63), but is made easier by recent advantages such as better 
sample analysis equipment and statistical software packages(64, 65). This will also benefit 
the patient since fewer and smaller blood samples are required. A good example is the 
pharmacology of morphine, a widely used analgesic in children and adults of any age. A 
recent study by Knibbe et al. provided new dosing recommendations based on a population 
pharmacokinetic model of intravenous morphine in children up to the age of three years 
old. Simulations showed that a different dosing regimen would result in a more narrow 
range of morphine and metabolite concentrations(65).
We have learned that healthcare professionals assess and treat pain differently in intellectu-
ally disabled children. This is why special pain assessment scales have been developed for 
this group of children. Some researchers might have anticipated the question if analgesic 
dosing regimens need to be adjusted for intellectually disabled children since they excluded 
these children from analgesics pharmacokinetics and pharmacodynamics studies(66-70). 
Evidence for (hypothetical) differences in pharmacokinetics and pharmacodynamics in in-
tellectually disabled children is very scarce. We know that co-medication can influence the 
pharmacokinetics of analgesics. Measuring the pharmacodynamic effects requires the use 
of adjusted pain assessment tools. Few studies have investigated the pharmacokinetics of 
specific drugs in children with Down’s syndrome. A small study on vincristine, a chemo-
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therapeutic, found no altered pharmacokinetics in children with Down’s syndrome(71). 
Three other studies reported only subtle alterations in children with Down’s syndrome. 
Griener et al. reported that only the metabolism of the acetaminophen could be increased 
to glutathione-derived conjugates and decreased to the sulfate-derived conjugates(72). 
Clearance of theophylline, a drug that treats reactive airway diseases, was found to be pro-
longed in children with Down’s syndrome(73). The clearance of methotrexate in children 
with Down’s syndrome was 5% lower than in children without Down’s syndrome(74). The 
authors of the latter study conclude they found no evidence for differences in the pharma-
cokinetics of methotrexate that explained lower tolerance in children with Down’s syn-
drome for this drug. 
In conclusion, the advanced methods of pharmacological research make it possible to 
study smaller groups of patients. The focus of pharmacological research should be on the 
influence of co-medication on analgesics. Both children with and without intellectual dis-
abilities will benefit from these studies. 
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DOWN’S SYNDROME
What is so special about children with Down’s syndrome?
Down’s syndrome, occurring in about 1 in 700 live births, is the most common genetic 
cause of intellectual disability. Each year 275 - 300 children with Down’s syndrome are born 
in the Netherlands(75). About 95% of the individuals with Down’s syndrome have a tri-
somy 21, the others show Robertsonian translocation involving chromosome 21 or mosaic 
trisomy 21. 
Despite the shared genetic cause, the phenotype of children with Down’s syndrome is 
highly variable. Therefore we will address several possible risk factors for altered pain 
experience and pain expression in these children. Throughout their whole life children with 
Down’s syndrome are more at risk to experience pain. Several major congenital abnormali-
ties that require surgical intervention occur more often in children with Down’s syndrome 
than in the general population. For example, from a large population-based study in the 
US(76) it appeared that 6.7% of the children with Down’s syndrome were born with a con-
genital gastrointestinal defect such as duodenual atresia and Hirschsprung’s disease(77). 
Furthermore, many more children with Down’s syndrome are born with congenital heart 
defects(78-80). Especially atrial septal defects, ventricular septal defects, and atrioventricu-
lar septal defects are more common in this group. These defects will require endovascular 
or surgical treatment. These children with Down’s syndrome are more at risk to develop 
pulmonary hypertension compared to children without Down’s syndrome(80). Pulmonary 
hypertension requires adjusted management during intensive care treatment or surgery 
since this state is associated with more perioperative complications.(81) Also later in life, 
several specific diseases that might cause pain are more common in children with Down’s 
syndrome. For example, they have an increased risk of developing acute leukemias(82). 
Both the disease and its treatment might cause pain. Ear, nose and throat problems, such 
as chronic middle ear disease and chronic rhinorrhoea, are frequently seen in children with 
Down’s syndrome and cause considerable morbidity(50). Orthopedic problems such as 
upper cervical spine instability, scoliosis, hip problems or foot problems are present in ap-
proximately 20% of the children with Down’s syndrome. A great deal of these disorders can 
become symptomatic, cause pain and disability and require surgical intervention(83). 
Intellectual disability is present in almost all children with Down’s syndrome. However, 
there is a great variety in development of these children. Intelligence Quotients average 50 
with a range from 30 to 70(84). Children with Down’s syndrome are especially delayed in 
expressive communication and some researchers suggest this delay increases when the 
children get older(30). Dykens et al. suggested that there is an age-related plateau in the de-
velopment of adaptive behavior during the middle childhood years. Chapman et al. provide 
a useful overview of the developmental emergence of the behavioral phenotype of Down’s 
syndrome from infancy to adulthood(84). Other associated disorders such as hearing 
and visual impairments, hypothyroidism, seizures and obstructive sleep apnea can have a 
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negative impact on cognitive functioning(85). The developmental delay across the different 
domains will certainly influence the pain expression abilities of most children with Down’s 
syndrome. 
On the one hand, children with Down’s syndrome are more at risk to experience pain due 
to, for example, associated congenital abnormalities and orthopedic problems. On the 
other hand, they face more challenges in expressing their pain due to the developmental 
delay, poor expressive language and speech intelligibility skills, and hearing and visual 
impairments(86). 
Translational research and pain management
Mouse models for Down’s syndrome are more and more used to study the genotype - phe-
notype relationships(87). Murine chromosome 16 contains about 80% orthologous genes 
of human chromosome 21. 
One of the mouse models for Down’s syndrome has been used for studying the pain 
responsiveness compared to control litter-mates(5). Pain behavior was tested by the hot 
plate test and exposure to tonic pain from a formalin injection in a paw. Responsiveness to 
these nociceptive stimuli was overall decreased in the Down’s syndrome mice compared to 
control litter-mates. The authors suggest that overexpression of several genes might alter 
transmission of sensory and nociceptive stimuli. The human orthologues of these genes are 
located on chromosome 21 and could affect in a similar manner pain perception in Down 
syndrome patients.
This is just one example of translational pain research focused on pain and Down’s syn-
drome. The Pain Genes Database gives access to all published pain-related phenotypes of 
mutant mice(88). Six possible candidate genes for further research about genotype-pheno-
type relationships for pain in Down’s syndrome emerge from combining the information 
of the DNA sequence of human chromosome 21(89), the orthologues genes on murine 
chromosome 16(87), the Pain Genes Database(88) and the study about the pain responsive-
ness of the mouse model for Down’s syndrome(5). Table III provides further information 
about these six genes and the phenotype of the specific mice models. These six genes can 
be explored for alterations in the genome, for example the presence of polymorphisms in-
fluencing the level of gene expression of these genes in the dorsal root ganglia and periph-
eral nerve fibers, in combination with information about the pain phenotype. This research 
can be conducted both in humans using quantitative sensory testing (see above) or in the 
mouse model using tests as described by Martinez-Cue et al. 
Studies in humans by Hennequin and Defrin showed that overall the reaction of adults with 
Down’s syndrome to nociceptive stimuli differs from the reaction of control individuals(2, 
41). Combining this finding with that from the study of Martinez-Cue et al. about the reac-
tion to nociceptive stimuli of the mouse model for Down’s syndrome, one could suggest 
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Symbol
ADAMTS5
GRIK1
S100B
RUNX1
KCNJ6
KCNE1
Full name 
A disintegrin 
and metallo-
proteinase with 
thrombospondin 
motifs 5
Glutamate 
receptor, iono-
tropic, kainate 1 
S100 calcium 
binding protein B 
Runt-related 
transcription 
factor 1
G protein-
activated inward 
rectifier potas-
sium channel 2
Potassium 
voltage-gated 
channel subfa-
mily E member 1
Nociception
No differences
Mutant less 
sensitive
Not tested 
Mutant less 
sensitive
Mutant more 
sensitive
Hypersensitivity 
Mutant less  
sensitive
No differences
Mutant less  
sensitive
Mutant less  
sensitive
Not tested
Analgesia
Not tested
Not tested
Not tested
Not tested
Mutant less 
sensitive
Suggestion from Martinez-Cue et al.; No information from 
knockout mice study.
TABLE 3 Possible candidate genes for the study of genotype - phenotype relationships 
in Down’s syndrome
Encodes for 
Enzyme that 
functions as 
aggrecanase to 
cleave aggre-
can, a major 
proteoglycan of 
cartilage
1 of the 4 subu-
nits of a gluta-
mate receptor 
Member of the    
S100 family of 
proteins contain-
ing 2 EF-hand 
calcium-binding 
motifs. 
Ơsubunit of core 
binding factor;  
3 isoforms
Integral mem-
brane protein and 
inward-rectifier 
type potassium 
channel
Transmembrane 
protein known to 
associate with 
the product of the 
KVLQT1 gene to 
form the delayed 
rectifier potassium  
channel
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that there is a pain phenotype in Down’s syndrome. It will be very difficult to distinguish 
the effects from the pain phenotype on the pain expression from those of the intellectual 
disability. Yet, if it would be possible, one could study the variability of the pain phenotype 
across children with Down’s syndrome taking into account information about the genotype 
of for example the six candidate genes. This translational approach would provide valuable 
information about genotype - phenotype relationships for pain in Down’s syndrome. 
 
TAILOR-MADE PAIN TREATMENT
The time has come to move on from studying pain assessment to studying postoperative 
pain treatment in intellectually disabled children. In the first part of this review, it appeared 
that self-report is seen as unreliable or impossible in intellectually disabled children and 
that therefore researchers put a big effort in developing observational pain assessment 
tools. Information about the adaptive behavior of a child could help selecting the appropri-
ate assessment tool for that individual. Future research will need to focus on multimodal 
pain assessment and quantitative sensory testing, but for now, the observational pain as-
sessment tools make it possible to assess pain in intellectually disabled children. 
The second part of this review summarized the knowledge about postoperative pain treat-
ment in intellectually disabled children. The observational studies reported conflicting 
results about the pain treatment. Considering the significant use of co-medication and the 
possible pharmacokinetic nuances, we think it is time to prospectively evaluate these chil-
dren’s pain treatment. The pharmacokinetics and pharmacodynamics of analgesics should 
also be examined in intellectually disabled children. We should start with studies in chil-
dren with Down’s syndrome as they are frequently subjected to major surgical procedures. 
This brings us to the third part of this review, from which it is clear that it will be possible 
to examine pain in children with Down’s syndrome more precisely - i.e. by studying geno-
type - phenotype relationships for pain in Down’s syndrome. 
In conclusion, the pain assessment tools for intellectually disabled children are there. We 
should now focus on tailoring the pain treatment. To this aim we need to perform pharma-
cokinetic and pharmacodynamic studies of analgesics and obtain information about the 
genotype - phenotype relationships for pain. This can lead to the development of specific 
analgesic algorithms. 
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ABSTRACT
Background
Intellectually disabled children are more likely to undergo surgical interventions and almost 
all have comorbidities that need to be managed. Compared with controls, intellectually 
disabled children tend to receive less intraoperative analgesia and fewer of them are as-
sessed for postoperative pain. 
Aim
To evaluate perceptions and practices of anesthesiologists in the Netherlands concerning 
pain management in intellectually disabled children.
Methods/Materials
We surveyed members of the Section on Pediatric Anesthesiology of the Netherlands Soci-
ety of Anesthesiology in 2005 and 2009, using a self-designed questionnaire. 
Results
The response rate was 47% in both years. In 2005, 32% of the anesthesiologists rated 
intellectually disabled children as “more sensitive to pain” than non-intellectually disabled 
children - versus 25% in 2009. But no more than 7% in 2005 versus 6% in 2009 agreed with 
the statement “children with intellectually disabled children need more analgesia”. Most 
anesthesiologists gave similar doses of intraoperative opioids for intellectually disabled and 
non-intellectually disabled children, 92% in 2005 versus 89% in 2009. In 2005, only 3% 
applied a pain assessment tool validated for intellectually disabled children, versus 4% in 
2009. 
Conclusions
Anesthesiologists in the Netherlands take a different approach when caring for intellectu-
ally disabled children and they were not aware of pain observation scales for these children. 
However, the majority think intellectually disabled children are not more sensitive to pain 
or require more analgesia. These opinions did not change over the four-year period. One 
way to proceed is to implement validated pain assessment tools and to invest in education. 
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INTRODUCTION
In 1954, Couston postulated that intellectually disabled persons are indifferent to pain(1). 
Over the years, however, opinions have changed; caregivers now generally consider that 
intellectually disabled children experience pain as other children(2). The American Asso-
ciation on Intellectual and Developmental Disabilities (AAIDD) defines intellectual dis-
ability as ‘‘a disability characterized by significant limitations both in intellectual function-
ing and in adaptive behavior, which covers many everyday social and practical skills. This 
disability originates before the age of 18.’’(3). Around 18 of 1000 children are intellectually 
disabled(4). Intellectually disabled children often suffer from conditions that require pain-
ful and surgical interventions(5). Several observational pain assessment tools have been 
developed for these patients as recently reviewed by Voepel-Lewis et al.(6) and us(7). Epi-
lepsy is also common and chronic treatment with anticonvulsants may have consequences 
for anesthetic and postoperative care(8-10). Compared to controls, intellectually disabled 
children tend to receive less intraoperative analgesia and fewer of them are assessed for 
postoperative pain(7). Justification for this disparity is lacking, apart from observations 
that intellectually disabled adults show altered pain sensitivity(11, 12). For this and other 
reasons we were interested in current practices of anesthesiologists treating intellectually 
disabled children. 
Aim
The primary aim was to evaluate perceptions and practices of anesthesiologists in the Neth-
erlands concerning pain management in intellectually disabled children. The secondary 
aim was to study changes in perceptions and practices between 2005 and 2009.  
Chapter 3
54
METHODS/MATERIALS
We surveyed the members of the Section on Pediatric Anesthesiology (SKA) of the Neth-
erlands Society of Anesthesiology (NVA) in 2005. According to Dutch law Institutional 
Review Board (IRB) approval was not required. The survey was repeated in 2009 to evaluate 
if perceptions or practice have changed over time. On both occasions, a questionnaire was 
sent by mail. The anesthesiologists were asked to complete the questionnaire – anony-
mously – and to return it in a prepaid return envelope. A reminder was sent to all SKA 
members a few weeks later.
The 29-item questionnaire was developed in 2005 by our research group consisting of an 
experienced pediatric anesthesiologist (T.d.L.), a psychologist (M.v.D.) and a health scien-
tist (J.P.). They all worked in the Erasmus University Medical Center – Sophia Children’s 
Hospital (Rotterdam, the Netherlands). 
The respondents were asked about their perceptions on the pain sensitivity of intellectu-
ally disabled children, their pre-, intra- and post-operative practices when caring for these 
children, and any pain assessment tools they used. 
Returned questionnaires were handled anonymously. Questionnaires of anesthesiologists 
who indicated they did not treat children with intellectual disability were excluded, and so 
were questionnaires in which more than 25% of the closed questions were not answered.
Two researchers (S.v.d.K., A.V.) independently analyzed the responses to the open questions 
and the free text responses and grouped these using the thematic analysis method(13). The 
classifications were compared and any discrepancies were resolved by discussion between 
the two researchers. 
Data were analyzed using SPSS version 18.0 (SPSS Inc., Chicago, IL, US). The results from 
the survey in 2005 were compared to those from 2009 using the t-test. The Chi-square test 
(or Fisher exact test in the case of predicted cell counts lower than 5) was used to compare 
nominal data for the two years. All reported P values are two-sided, and P values of less 
than 0.05 are considered to indicate statistical significance.  
55
RESULTS
In 2005, the questionnaire was sent to all 192 SKA members; in 2009 to all 214. The 
response rate was 47% in 2005 as well as in 2009. On both occasions only one respondent 
stated never to have treated intellectually disabled children. These two questionnaires were 
excluded. Furthermore, one 2009 questionnaire was excluded because more than 25% of 
the closed questions were not answered (see Figure 1). 
The background characteristics of the anesthesiologists, such as years of experience and 
type of hospital, were statistically not significantly different between the two evaluations 
(see Table 1). 
 2005 (n=89) 2009 (n=98) P value
Experience in years, mean (SD) 13.8 (8.3) 14.8 (8.3) 0.40a
Type of hospital   
    District hospital, n (%) 51 (57.3) 60 (61.9) 
    Specialist pediatric hospital, n (%) 23 (25.8) 19 (19.6) 0.78b
    Teaching hospital, n (%) 15 (16.9) 18 (18.6) 
Number of times of giving anesthesia
to intellectually disabled children, per year   
    <20, n (%) 36 (40.4) 42 (43.3) 
    20-50, n (%) 30 (33.7) 36 (37.1) 0.67b
    50-100, n (%) 12 (13.5) 12 (12.4) 
    >100, n (%) 11 (12.4) 7 (7.2) 
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Returned questionnaires: 
n=90 (2005); n=100 (2009) 
Questionnaires sent: 
n=192 (2005); n=214 (2009) 
 
 
Included questionnaires:  
n=89 (2005); n=98 (2009)  
Excluded questionnaires: 
- No experience with intellectually 
disabled children: n=1 (2005); n=1 
(2009) 
-  >25% missing answers: n=1 (2009) 
a t-test 
b Chi-square test
TABLE 1 Characteristics of the anesthesiologists, by year 
FIGURE 1  Flow diagram of inclusion in 2005 and 2009
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Perceptions
In 2005, 32% of the anesthesiologists rated the pain sensitivity of intellectually disabled 
children as “more sensitive” than that of non-intellectually disabled children versus 25% in 
2009 (P = 0.31) (see Figure 2). Moreover, 7% in 2005 and 6% in 2009 (P=0.25) agreed with 
the statement “children with intellectual disabilities need more analgesia than children 
without intellectual disabilities” (see Table 2). Thematic analysis of an open question re-
vealed that anesthesiologists ask more involvement of parents, that they pay more attention 
and take more time when caring for an intellectually disabled child (see Table 2). 
FIGURE 2 Anesthesiologists’ perceptions about the pain sensitivity of intellectually disabled children 
compared to nonintellectually disabled children
Pre- and intra-operative
Most anesthesiologists continue the co-medication of the patient preoperatively, namely 
99% in 2005 and 97% in 2009 (P=0.62). However, if patients use co-medication, 80% of 
the anesthesiologists in 2005 versus 86% of the anesthesiologists in 2009 (P=0.28) adjust 
the dose of anesthetics. In Table 3 the policy for different types of co-medication is further 
detailed. 
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 2005 (n=89) 2009 (n=98) P value
  n (%) 
Intellectually disabled children are at
high risk for pain because of... a   
     less developed communication skills 85 (96.6) 92 (94.8) 0.56 b
     co-morbidity 30 (34.1) 37 (38.1) 0.57 b
     pain is considered to be less important 23 (26.1) 25 (25.8) 0.96 b
     other reasons 8 (9.1) 9 (9.3) 0.97 b
The lower the level of functioning the
lower the pain sensitivity   
     Disagreed 66 (75.0) 76 (78.4) 0.48 c
     Neither agreed nor disagreed  16 (18.2) 19 (19.6) 
     Agreed 6 (6.8) 2 (2.0) 
The lower the level of functioning the harder it
is to distinguish pain from other emotions   
     Disagreed 14 (15.9) 9 (9.4) 0.55 b
     Neither agreed nor disagreed 11 (12.5) 9 (9.4) 
     Agreed 63 (71.6) 78(81.2) 
Intellectually disabled children need more analgesia   
     Disagreed 44 (50.0) 49 (50.0) 0.25 b
     Neither agreed nor disagreed 38 (43.2) 43 (43.9) 
     Agreed 6 (6.8) 6 (6.1) 
Differences in approach a   
    No differences in treatment 36 (43.9) 28 (35.9) 0.30 b
    Ask more involvement of the parent(s)/caretaker(s) 22 (26.8) 21 (26.9) 0.99 b
    Less developed communication skills 12 (14.6) 21 (26.9) 0.06 b
    Pay more attention  9 (11.0) 9 (11.5) 0.91 b
    More time 8 (9.8) 10 (12.8) 0.54 b
 
a More than one answer possible
b Chi-square test
c Fischer exact test
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TABLE 2 Anesthesiologists’ perceptions on pain management in intellectually disabled 
children compared to non-intellectually disabled children, by year
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TABLE 3 Preoperative continuation and dose adjustments in children with chronic use of 
co-medication, by year
a More than one answer possible
b Chi-square test
c Fisher-exact test 
In both evaluations, 99% of the anesthesiologists used inhalational agents for induction of 
anesthesia (P=1.00). Furthermore, 98% of the anesthesiologists in 2005 versus 93% in 2009 
(P=0.17) used intravenous sedative agents for induction of anesthesia. Twelve anesthesiolo-
gists (15%) in 2005 versus 10 (10%) in 2009 (P=0.33) used other sedative agents for induc-
tion in intellectually disabled children. Dose adjustments of sedative agents for induction 
of anesthesia were more common. In 2005 26% of the anesthesiologists used other doses 
in intellectually disabled children, versus 25% of the anesthesiologists in 2009 (P=0.92). 
In 2005, 8% responded they use lower doses versus 11% in 2009 (P=0.93). Seven per cent 
responded in 2005 they use higher doses versus 10% in 2009 (P=0.57). 
For maintenance of anesthesia, only four anesthesiologists in 2005 (4%) versus three in 
2009 (3%) gave other sedative agents to intellectually disabled children (P=0.71). They ex-
plained this as follows: “For dental surgery I prefer intravenous agents”, “No inhalational 
anesthetics for children with a neuromuscular disorder”, “No propofol for children with 
mitochondrial disorders”, “No long-acting agents”, “No sevoflurane in children with a 
syndrome”, “Another agent in children with epilepsy” and “Only another agent in children 
with mitochondrial disorders”. Differences in dosing of maintenance were more common: 
 2005 (n=89) 2009 (n=98) P value
  n (%) 
Dose adjustment of anesthetics in patients that usea   
    Analgesics 67 (93) 64 (77) 0.004 a
    Benzodiazepines 59 (82) 71 (85) 0.91 a
    Spasmolytics 33 (46) 32 (38) 0.62 a
    Antiepileptic drugs 54 (76) 66 (79) 0.71 a
    Anti-reflux drugs 14 (20) 12 (14) 0.37 a
Preoperative continuation of... a   
    Analgesics 85 (97) 91 (96) 1.00 b
    Benzodiazepines 81 (92) 88 (92) 0.93 a
    Spasmolytics 77 (88) 86 (90) 0.66 a
    Antiepileptic drugs 85 (97) 93 (97) 1.00 b
    Anti-reflux drugs 89 (100) 90 (94) 0.03 b
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14 (16%) of the anesthesiologists in 2005 versus 10 (11%) in 2009 (P=0.30) used other doses 
in intellectually disabled children to maintain anesthesia. In 2005, 6% responded they use 
lower doses versus 7% in 2009 (P=0.93). In 2005, 3% responded that they use higher doses 
versus 1% in 2009 (P=0.57). 
The majority of anesthesiologists used similar doses of intraoperative opioids for intellec-
tually disabled and non-intellectually disabled children, 77 (92%) in 2005 versus 83 (89%) 
in 2009. In 2005, 6 (7%) of the anesthesiologists prescribed lower doses to intellectually 
disabled children versus 9 (10%) in 2009 (See Table 4). The differences between both evalu-
ations were statistically non-significant (P=0.80). In both years, the main reasons for a 
higher or lower dose were the chronic use of co-medication, the underlying syndrome and 
the type of procedure. 
TABLE 4 Dosing of intraoperative opioids in intellectually disabled children compared to 
non-intellectually disabled children, by year
 2005(n=84) 2009(n=93) P value
  n (%) 
Similar dose 77 (91.7) 83 (89.2) 
Lower dose 6 (7.1) 9 (9.7) 0.80a
Higher dose 1 (1.2) 1 (1.1) 
a Fischer Exact Test
Anesthesiologists used intraoperative bispectral index (BIS) monitoring in 2005 as often in 
intellectually disabled children (27%) as in non-intellectually disabled children (28%). This 
was also the case in 2009, but BIS monitoring was now significantly more often applied: in 
43% of intellectually disabled children (up from 27%; P=0.04) and in 45% of non-intellec-
tually disabled children (up from 28%; P=0.03).  
Postoperative 
In 2005, 6% of the anesthesiologists were aware of a special pain assessment tool for intel-
lectually disabled children (FLACC, CPB or COMFORT-B) versus 16% in 2009 (P=0.02). 
Only 3% in 2005 and 4% in 2009 actually used one of these tools (P=1.00). 
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DISCUSSION
In this survey we asked anesthesiologists in the Netherlands about their opinions on pain man-
agement in intellectually disabled children. We also asked whether they adapted their practice, 
for example by adjusting dosing of analgesic and sedative agents. The key finding is that per-
ceptions do not fully match practice of anesthetic care for intellectually disabled children. 
Perceptions
Around a third of the anesthesiologists in our survey thought that intellectually disabled 
children are more sensitive for pain (see Figure 2). A previous study, by Malviya et al., re-
ported that 89 per cent of a group of nurses and physicians believed intellectually disabled 
children experience pain in the same way as other children(2). Findings cannot be validly 
compared, however, because our target group consisted of anesthesiologists only. Further-
more, definitions differed: Malviya et al. asked about ‘pain experience’ whereas we used the 
term ‘pain sensitivity’. 
More and more, anesthesiologists take the less developed communication skills of intel-
lectually disabled children into account; in 2005 15% reported a different approach for this 
reason, versus 27% in 2009 (P=0.06). Although a third of the surveyed anesthesiologists 
considered intellectually disabled children more sensitive to pain, but no more than 6 per 
cent thought they need more analgesia. A recent systematic review found that preopera-
tively measured thermal pain sensitivity correlates with postoperative analgesic require-
ments in adults(14). Thus there could be a mismatch between perceived pain sensitivity and 
the analgesia intellectually disabled children receive, however experimental pain is not the 
same as postoperative pain. A promising avenue of research would be quantitative sensory 
testing in verbal children with intellectual disabilities to determine thermal detection and 
pain thresholds(15). 
Practices
Seven percent in 2005 and 10% in 2009 gave lower doses of intraoperative opioids to intel-
lectually disabled children. This could be seen as an improvement, since a previous survey 
found that 89% of the physicians have a tendency to prescribe subtherapeutic doses of 
opioids(2). In addition, two other studies report lower doses of intraoperative opioids in 
intellectually disabled children(16, 17). One previous study by Malviya et al. reported that 
anesthesiologists gave comparable doses of intraoperative opioids to intellectually disabled 
children and non-intellectually disabled children undergoing spinal fusion surgery(18). 
Around a quarter of the respondents adjust doses of sedative agents for induction of gen-
eral anesthesia and around 15% adjust doses of sedative agents for maintenance of general 
anesthesia. The dosing of sedative agents used during general anesthesia was not evaluated 
in the previous studies. 
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More than half of the respondents in both evaluations report that they pay more attention, 
take more time, and ask more involvement of parents, when caring for intellectually disa-
bled children. A possible explanation is that it requires more effort to explain to intellectu-
ally disabled children the need for general anesthesia and to make sure they are as com-
fortable as possible at induction of general anesthesia. It might be necessary to adapt the 
education materials preparing intellectually disabled children for anesthesia and to study 
whether these children are more distressed or anxious than other children.
Previous studies found that the majority of intellectually disabled children have comorbidi-
ties such as thyroid disorders, gastro-intestinal diseases, psychiatric disorders or epi-
lepsy(7). Epilepsy rates from 14 to 75% have been reported(19). Most children with epilepsy 
are chronically treated with a combination of antiepileptic drugs. The protein binding and 
enzyme inducing properties of antiepileptic drugs could influence the pharmacokinetics 
of drugs used for anesthesia and postoperative analgesia(9, 10). Seventy-six percent of the 
respondents in 2005 and 79% in 2009 adjusted the dose of anesthetics in children treated 
with antiepileptic drugs. 
Based on our results and previous studies, we conclude that intellectually disabled chil-
dren tend to receive lower doses of intraoperative opioids and sedatives. There is hardly 
any evidence for these dose adjustments, apart of the few studies in adults who are treated 
with antiepileptic drugs(9). Pharmacokinetic and pharmacodynamic evaluations should 
provide evidence for dose adjustments in intellectually disabled children. For children who 
are chronically treated with antiepileptic drugs, interactions with anesthetics as well as pos-
sible toxicity and side effects need to be studied. 
Pain assessment
Pain assessment is a corner stone of adequate postoperative treatment(20). As reliable 
self-report of pain is impossible in most intellectually disabled children, observational 
pain assessment tools have been developed and validated for this group(21-23) as recently 
reviewed by us(7). Although up to 27% of the respondents adapt their practice in intellectu-
ally disabled children because of perceived less developed communication skills, no more 
than 4% of all respondents uses such a tool. A recent developed observational pain assess-
ment scale is the individualized numeric rating scale (INRS)(24). It is based on individual 
pain indicators that parents and caregivers proposed. The individual descriptors are ranked 
on a scale from 0 to 10. Postoperative pain management protocols should include the use of 
a pain assessment tool that has been validated for intellectually disabled children. 
BIS monitoring
Anesthesiologists in our survey use BIS monitoring as often in intellectually disabled chil-
dren as in non-intellectually disabled children. Moreover, in 2009 they used it significantly 
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more than in 2005. Nevertheless, the value of BIS monitoring in intellectually disabled 
patients remains debatable. Choudhry et al. observed that BIS values of intellectually disa-
bled children did not differ from those of controls(25). Saricaoglu et al. found that children 
with cerebral palsy needed less propofol than controls to reach a BIS value of 35(26). Our 
group observed that BIS values in intellectually disabled children were lower than those in 
controls(27). Most recently, Ponnudurai et al. found that degree of intellectual disability did 
not influence BIS values in intellectually disabled adults(28). Although the BIS monitor still 
is being used as a device to measure depth of anesthesia in intellectually disabled children, 
it is not clear whether the commonly used target values for general anesthesia (40 to 60) 
should be aimed for in intellectually disabled children as well. Frei et al. found lower MAC 
values for halothane in intellectually disabled children(29). One way to proceed could be to 
investigate the MAC values of different volatile anesthetics in patients treated with anticon-
vulsants and the relationship with BIS values.
Education
We observed only minor differences between the survey in 2005 and the survey in 2009 
although the intervening period saw the publication of several important articles about 
pain assessment in intellectually disabled children, namely the validation of the revised 
FLACC(22), the Checklist Pain Behavior(30), a review about pain assessment scales(6) as 
well as the book about pain in children and adults with developmental disabilities by Ober-
lander and Symons(31).
Our institution has developed an observational tool for use in intellectually disabled chil-
dren entitled ‘Checklist Pain Behavior’. It was widely distributed since its publication in 
2006 and train-the-trainer sessions for caregivers are frequently held. In spite of all this, 
the Dutch anesthesiologists’ knowledge on pain in intellectually disabled children does not 
seem to have much improved, given the results of the survey in 2009. Dutch national guide-
lines for postoperative pain treatment were published in 2003(32). These guidelines are 
currently being revised to include a section about pain assessment in intellectually disabled 
children.
In the near future we should invest in targeted education and training of anesthesiologists 
and other caregivers, for example by offering Continuing Medical Education (CME) mod-
ules(33). 
Limitations
A weakness of this survey was that we asked questions about intellectually disabled chil-
dren in general. Intellectual disability encompasses a few common etiologies (for example 
Down’s syndrome or cerebral palsy) and a variety of very rare etiologies. In a large propor-
tion of children with an intellectually disability the origin is unknown. In addition, it is a 
very heterogeneous group with varying levels of intellectual functioning and a variety of 
comorbidities and comedications. Therefore we chose to develop a survey that evaluates 
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the care for intellectually disabled children in general. Around 40% of the respondents 
reported they treat less than 20 intellectually disabled patients per year (see Table 1). There-
fore it is difficult to expect them to have sufficient experience with all the different etiolo-
gies. Future prospective studies should account for the level of intellectual functioning 
and the cause of intellectual disability, by studying for example, only children with Down’s 
syndrome. Second, selection bias may have occurred. The response rate was 47% on both 
occasions, comparable to other survey studies in the field of pediatric anesthesia(34, 35). 
Thirdly, we did not ask questions about the use of opioids in the postoperative period. 
Postoperative pain management is as well highly relevant in these children and studies are 
needed to provide an evidence base. In the fourth place, we cannot rule out bias since we 
did not investigate the internal or external validity of the questionnaire that was used for 
this survey(36-38). 
Conclusions and implications
We conclude that there are differences in anesthetic care for intellectually disabled children 
in the Netherlands compared to non-intellectually disabled children. Respondents tend 
to use a different approach when taking care for these patients and they were not aware 
of pain observation scales for intellectually disabled children. However, the majority of 
respondents think that intellectually disabled children are not more sensitive to pain or 
require more analgesia. These opinions did not change over the four-year period. 
We acknowledge, however, the paucity of evidence in this field. With limited research 
resources, we feel it is more and more important to select the most important questions. It 
will be impossible to study the pharmacokinetics and pharmacodynamics of each anes-
thetic agent in the heterogeneous population of intellectually disabled children. Therefore, 
we should strive to establish valid pharmacodynamic outcome measures that may be used 
to titrate anesthetics, taking into account their specific metabolic disease influencing drug 
metabolism and/or the way the abnormally developed CNS processes nociceptive stimuli. 
One way to proceed is to actively implement validated postoperative pain assessment tools 
and to invest in education of anesthesiologists and caregivers. 
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PART 2
ASSESSMENT
yW.B.YEATS 
What calculation, 
number, measurement, 
replied?

EXTREMELY LOW PREANESTHETIC BIS 
VALUES IN TWO CHILDREN WITH WEST 
SYNDROME AND LISSENCEPHALY
Abraham J. Valkenburg, Tom G. de Leeuw, Andreas Machotta, Frank Weber 
Pediatric Anesthesia (2008); 18: 446 - 448
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Infantile spasms (IS) is a convulsive disorder of infancy and early childhood. The spasms 
involve the muscles of the neck, trunk and extremities. Most children with IS have the elec-
troencephalographic (EEG) pattern known as hypsarrhythmia. A classic hypsarrhythmia 
pattern consists of high voltage slow waves and spikes, present in all cortical areas. The 
EEG can show ictal and interictal patterns of hypsarrhythmia. The combination of spasms, 
hypsarrhythmia and arrest of psychomotor development is known as West syndrome. Hra-
chovy et al.(1) described in a review of 67 studies the long-term outcome of IS, with an aver-
age follow-up of 31 months. The mortality rate was 13%, 51% continued to have seizures, 
persistent neurological deficits were present in 44% of patients and 61% had abnormal 
EEG findings.
Miller Dieker syndrome is an autosomal recessive syndrome, associated with a deletion on 
chromosome 17p13.3. It is a combination of epilepsy like West Syndrome, lissencephaly 
and severe mental deficiency.
Anticonvulsants such as vigabatrin and phenobarbital exert their effect by facilitating gam-
ma aminobutyric acid (GABA) mediated inhibition via allosteric interaction with neuronal 
postsynaptic GABAA receptors. Barbiturates can also, in the absence of GABA, activate the 
GABAA receptor directly, an effect that may underlie their sedative properties(2).
Propofol and volatile anesthetics also act on the GABAA receptor in the central nervous 
system. In this way anticonvulsants may influence the depth of anesthesia.
An objective measure of the effects of anesthetics on the brain and the level of conscious-
ness is the Bispectral Index (Aspect Medical Systems, Natick, MA, USA). BIS is an empiri-
cally calibrated number derived from adult EEG data that correlates with the depth of the 
sedative component of general anesthesia in adults. It is validated for children older than 
one year(3).
Choudhry et al.(4) demonstrated that during general anesthesia in children with quadriple-
gic cerebral palsy and mental retardation (CPMR) BIS values exhibit a pattern of change, 
similar to that observed in normal children. The mean BIS value after premedication in 
the CPMR group was 92 compared to 97 in the group of normal children. It is question-
able if this significantly lower BIS value is also clinically relevant because it is still a normal 
preanesthetic value. Saricaoglu et al.(5) described that children with cerebral palsy needed 
less propofol during induction of general anesthesia to obtain a BIS value between 35 and 
45 than otherwise healthy children.
Many children with mental retardation also have seizures as a comorbidity of their disease 
and use anticonvulsants. One questions the validity and usefulness of BIS as a measure of 
sedation in this particular group of patients.
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CASE 1
A 2 years and 7 months old boy, weighing 15 kg, diagnosed with West syndrome and lissen-
cephaly. He was born at a gestational age of 37 weeks, there were no perinatal problems. 
After an admission for his spasms he was diagnosed with West syndrome and lissenceph-
aly. Despite anticonvulsant medication, oral valproic acid (2 x 360 mg/day) and phenobar-
bital (2 x 30 mg/day), convulsions still occurred at a frequency of 8–10 times a day. Because 
of feeding difficulties and recurrent aspiration pneumonias he received a percutaneous 
gastrostomy (PEG).
He was scheduled for a PEG replacement under general anesthesia. The anticonvulsants 
were continued until the evening before the procedure. No additional sedatives were given. 
With approval from the local medical ethics committee and written informed parental con-
sent (as for case 2), the BIS electrodes (BIS Pediatric Sensor, Aspect Medical Systems) were 
placed on the patient’s forehead and temple according to the manufacturers recommenda-
tion, before inhalational induction of general anesthesia. The range of BIS values before 
induction was 28–33.
Because of anticipated difficulties in obtaining venous access, we choose an inhalational 
induction with 8% sevoflurane (fraction inspired) in 100% oxygen with a fresh gas flow of 
10 L/min. During inhalational induction we observed a significant increase of BIS values, 
after loss of consciousness (LOC), up to a maximum of 67. Thereafter BIS values returned 
to a range of 33–45.
Intravenous access was obtained after which alfentanil (20 mcg/kg) and propofol (2 mg/
kg) were administered to facilitate tracheal intubation. The inspiratory sevoflurane con-
centration was decreased to 4%. Pulse oximetry, noninvasive blood pressure, ECG, BIS and 
endtidal concentration of sevoflurane, oxygen and CO2 were monitored throughout the 
procedure. All these physiological parameters were within age related normal limits. Dur-
ing the procedure, the patient’s hypnotic level was assessed by measures of the University 
of Michigan Sedation Scales (UMSS)(6). Anesthesia was maintained with isoflurane 1.5% 
expired fraction and prior to the introduction of the gastroscope another dose of alfentanil 
(10 mcg/kg) was administered. The PEG was replaced endoscopically. During the proce-
dure, the BIS values showed a range of 37–53 with a mean of 45. The patient was extubated 
once he was fully awake. After the patient returned to his preanesthetic level of conscious-
ness, BIS values showed a range of 17–51 with a mean value of 35. The time course of BIS 
values of this patient is displayed in Figure 1. 
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FIGURE 1 Time course of BIS values of patient 1 
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CASE 2
We report about a 2 years and 4 months old boy, weighing 15 kg, diagnosed with Miller 
Dieker syndrome, confirmed by a deletion on chromosome 17p13.3. He was born at a 
gestational age of 42 weeks, in the presence of meconium stained amniotic fluid. Magnetic 
Resonance Imaging (MRI) showed lissencephaly. Despite anticonvulsant medication, oral 
valproic acid (2 x 200 mg/day), vigabatrin (2 x 750 mg/day) and nitrazepam (2 x 1.25 mg/
day), convulsions still occurred at a frequency of 5–10 times a day. Because of feeding dif-
ficulties and recurrent aspiration pneumonias he received a PEG.
He was scheduled for a PEG replacement under general anesthesia. After our experience 
with the previous case we decided to place the BIS monitor the evening prior to the day 
of the procedure, in order to measure BIS values while the patient was fully awake, dur-
ing natural sleep and probably during an episode of epilepsy. The range of the awake BIS 
values was 14–22 and the range of the BIS values during natural sleep was 14–33. During an 
observed spasm there was no change in the BIS values. The anticonvulsants were continued 
until the morning of the procedure. No additional sedatives were given. After venous access 
was obtained, induction of general anesthesia was performed as follows: an initial dose of 
alfentanil (20 mcg/kg) was administered, followed by propofol (4 mg/kg). After LOC, we 
administered isoflurane (3% fraction inspired) in 100% oxygen with a fresh gas flow of 10 
L/min. During the intravenous induction, the range of the BIS values was 3–35. The patient 
was intubated two minutes after LOC.
Intraoperative monitoring and the anesthesia technique was exactly the same as for patient 
1. The PEG was replaced endoscopically. During the procedure, the BIS values showed a 
range of 1–23. The level of anesthesia was also scored using the UMSS(6), during anesthe-
sia the patient was unarousable. The patient was extubated once he was fully awake. After 
the patient had returned to his preanesthetic level of consciousness, BIS values showed a 
range of 30–36.
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DISCUSSION
To our best knowledge no case reports have described the use of BIS monitoring in children 
with West syndrome and lissencephaly. Having measured extremely low BIS values prior to 
anesthesia, we advise a preassessment of the BIS values in these children during states of 
wakefulness.
It is difficult to communicate with children with severe psychomotor retardation. In order 
to obtain information regarding the level of consciousness before and after anesthesia we 
asked the parents to assign their children to a particular level. Parents are better able to 
assess their child’s level of consciousness since they see them every day and recognize re-
sponses of their children during verbal and nonverbal communication. The parents of both 
children confirmed that their children were awake before and after anesthesia at the same 
moment that we thought they were awake.
Kochs et al.(7) described the tendency of the EEG power spectrum to shift towards higher 
frequencies with a concentration 1.2% isoflurane compared to a concentration of 0.6%. 
Furthermore paradoxical increases of the BIS during increasing isoflurane concentration 
(8) have been published. This might be an explanation for the increase of the BIS during the 
induction with sevoflurane in case 1. After a decrease of the inspired sevoflurane concentra-
tion to 4% the BIS value decreased.
We have no definite explanation for extremely low preanesthesia BIS values in these two 
children. We think it might be a consequence of the EEG abnormalities in children with 
West syndrome, with their reduced cortical neuronal mass, and partially a result of anticon-
vulsive medication, but there is no evidence in the literature.
Because of limited experience with the use of the BIS monitor in patients with a combina-
tion of neurological disorders, epilepsy and regular anticonvulsant medication, ASPECT 
Medical Systems advises caution in the interpretation of BIS values in this group of patients 
(http:// www.biseducation.com/assets/collaborate/2005/10/17/ Trifold-English.PDF). Fur-
ther research of BIS monitoring in this particular group of patients is necessary.
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yW.B.YEATS 
Take, if you must, this 
little bag of dreams;
Unloose the cord, and 
they will wrap you 
round.

LOWER BISPECTRAL INDEX VALUES IN 
CHILDREN WHO ARE INTELLECTUALLY 
DISABLED
Abraham J. Valkenburg, Tom G. de Leeuw, Dick Tibboel, Frank Weber
Anesthesia & Analgesia (2009); 109: 1428 - 1433
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ABSTRACT
Background
Very few data are available on the use of Bispectral index (BIS) monitoring in children who 
are intellectually disabled. Epileptiform electroencephalogram activity, underlying cerebral 
pathology, or anticonvulsant/spasmolytic therapy might influence BIS monitoring.
Our aim in this exploratory study was to first compare BIS values at 4 different stages of 
anesthesia between intellectually disabled children and controls. Our second aim was to 
investigate the discriminative properties of BIS between consciousness and unconscious-
ness for intellectually disabled children and for controls.
Methods
Eighteen intellectually disabled children and 35 control children, aged 2–13 yr, were 
included. BIS values, landmark events, and standard monitoring values of vital functions 
were recorded throughout the whole procedure. The performance of BIS in distinguishing 
between a conscious and unconscious state was assessed from receiver operating character-
istic curves.
Results
Median (interquartile range) BIS values for the intellectually disabled group were signifi-
cantly lower than those for controls in the awake state (72 [48–77] vs 97 [84–98], P<0.001), 
during stable intraoperative anesthesia (34 [21– 45] vs 43 [33–52], P=0.02), and during re-
turn of consciousness (59 [36 – 68] vs 73 [64 –78], P=0.009). The discriminative properties 
of the BIS monitor for the state of consciousness were comparable between the 2 groups 
according to the receiver operating characteristic curves. Nevertheless, the optimal cutoff 
BIS value for discrimination between conscious and unconscious state was 28 points lower 
for the intellectually disabled group.
Conclusions
We advise anesthesiologists to be alert to possible lower BIS values in intellectually disabled 
children. There is a risk that they will inadvertently misinterpret the state of consciousness 
in intellectually disabled children. New multicenter studies must find the optimal manner 
of evaluating (un)consciousness in intellectually disabled patients with documented and 
confirmed specific etiologies of their intellectual disability.
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In pediatric anesthesia, monitoring the depth of anesthesia has received increasing atten-
tion with the advent of electroencephalogram (EEG)-derived devices(1). One of these is 
the bispectral index monitor (BIS, Aspect Medical Systems, Newton, MA). The BIS is an 
empirically calibrated number, derived from adult EEG data, which correlates with depth of 
the hypnotic component of general anesthesia in adults. It is a validated monitor of depth 
of anesthesia for children older than 1 yr(2).
In children with intellectual disability, the EEG could show abnormal activity due to the 
underlying cerebral pathology and/or epileptiform activity. Many intellectually disabled 
children also have epilepsy or cerebral palsy(3, 4) and thus may be treated with anticonvul-
sants and/or spasmolytics. As a consequence, one might question the validity and useful-
ness of BIS as a measure of sedation in this particular group of patients.
There is little evidence about the use of BIS in children with intellectual disability and/or 
those who are treated with anticonvulsants. Choudhry and Brenn(5) described BIS values in 
20 children with quadriplegic cerebral palsy and mental retardation changing similarly to 
those in 21 nonretarded children during general anesthesia. After premedication, the mean 
BIS value in the cerebral palsy and mental retardation group was 92 compared with 97 in 
the group of normal children. Saricaoglu et al.(6) demonstrated that 20 children with cer-
ebral palsy needed less propofol to obtain a BIS value between 35 and 45 during induction 
of general anesthesia than did 20 otherwise healthy children. Twelve of the children with 
cerebral palsy had a history of seizures, 10 of whom were treated with anticonvulsants.
Because of limited experience with the use of the BIS monitor in patients with a combina-
tion of neurological disorders, epilepsy, and regular anticonvulsant medication, ASPECT 
Medical Systems, the manufacturer of the BIS monitor, advises caution in the interpretation 
of BIS values in this group of patients.
A reliable depth of anesthesia monitor would be very helpful in titrating anesthesia in 
children with intellectual disability for various reasons. First, they often present with many 
congenital anomalies, syndromes, and disorders that might require surgical intervention. 
Second, anesthesiologists face communication problems, difficulties in assessing level of 
consciousness, and unexpected consequences of pharmacodynamic interactions when an-
esthetizing children with intellectual disability, severe neurological disorders, or epilepsy.
The first aim of this exploratory study was to compare BIS values at different stages of 
anesthesia between intellectually disabled children and controls. The second aim was to 
investigate the discriminative properties of BIS between consciousness and unconscious-
ness for intellectually disabled children and for controls.
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METHODS
This prospective, observational study was performed at the Erasmus University Medical 
Center–Sophia Children’s Hospital, Rotterdam, The Netherlands, between September 2006 
and September 2007.
The study protocol and data collection were approved by the local ethics review board. Writ-
ten informed consent was obtained from the parents.
Study Population
Children eligible for this study (aged 2–13 yr) were scheduled for elective, diagnostic 
gastroduodenoscopy under general anesthesia and when indicated combined with percu-
taneous endoscopy gastrostomy (PEG) placement. Any contraindication for the standard 
anesthetic regimen was an exclusion criterion. The study group included intellectually disa-
bled children who underwent gastroduodenoscopy combined with PEG placement because 
of severe feeding difficulties and inability to adequately feed those children(7). The control 
group included children without intellectual disabilities, neurological diseases, or epilepsy, 
and who were not being treated with anticonvulsant medication or spasmolytics.
Diagnosis of Intellectually Disabled
The diagnosis of intellectually disabled was made by a pediatric neurologist after multiple 
patient clinic visits. In 16 of 17 patients, this diagnosis was further supported by magnetic 
resonance imaging and/or specific genetic or serum tests.
Study Protocol
All patients received a standardized anesthetic regimen without premedication. Immediate-
ly before induction of general anesthesia, BIS electrodes (BIS Pediatric Sensor [4 sensors], 
Aspect Medical Systems) were placed on the patient’s forehead and temple, as recom-
mended by the manufacturer. However, if a child resisted placement, no other attempt was 
made until after loss of consciousness (LOC, defined as loss of eyelash reflex). Electrodes 
were connected to a BIS monitor (A-2000, version 3.2; Aspect Medical Systems). Before 
induction of general anesthesia, 1 attempt was made to secure IV access. If successful, the 
patients received alfentanil (20 mcg/kg IV) and propofol (2–4 mg/kg IV) to facilitate tra-
cheal intubation. Whenever IV access could not be achieved in 1 attempt, inhaled induction 
with 8% sevoflurane (fraction inspired) in 100% oxygen with a fresh gas flow of 10 L/min 
was chosen and IV access was secured after LOC. In the case of inhaled induction, tracheal 
intubation was also facilitated by alfentanil (20 mcg/kg) and propofol (2–4 mg/kg).
After tracheal intubation, anesthesia was maintained with isoflurane (1.5% fraction 
expired). The timepoint of stable intraoperative anesthesia was defined as 30 s before in-
troduction of the gastroscope. Administration of anesthetics was then stable and a (surgi-
cal) painful stimulus was absent. All children received another dose of alfentanil (10 mcg/
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kg) before introduction of the gastroscope. Patients’ lungs were mechanically ventilated 
to normocapnia (end-tidal CO2 35–40 mmHg). Pulse oximetry, noninvasive arterial blood 
pressure, electrocardiogram, BIS, and concentrations of isoflurane, carbon dioxide, and 
oxygen were monitored throughout the procedure. At the end of the procedure, isoflurane 
administration was discontinued. After sufficient spontaneous breathing returned, the 
anesthesiologist checked for a response to verbal commands. Return of consciousness was 
identified on the basis of the patient’s preoperative reactions to verbal commands. Patients 
were tracheally extubated immediately after return of consciousness and then transferred to 
the postanesthesia care unit.
Statistical Analysis
Data for previously defined landmark events (all medication administrations, loss of 
consciousness, intubation, start and end of the procedure, discontinuation of isoflurane 
administration, return of consciousness, extubation, and unexpected events) were recorded 
using Rugloop software (Demed, Temse, Belgium). Recorded data included BIS and related 
values (signal quality, electromyography, and suppression ratio) and standard monitoring 
values (pulse oximetry, non-invasive arterial blood pressure, electrocardiogram, and con-
centrations of isoflurane, carbon dioxide, and oxygen).
Data were analyzed using SPSS version 15.0 (SPSS, Chicago, IL) and Labgrab (Demed). A P 
value less than 0.05 was considered statistically significant.
Normal distribution of the data was tested by the 1-sample Kolmogorov-Smirnov test. To 
compare frequencies of normally distributed data, parametric tests (independent-samples 
t-test) were used. Non-parametric tests (Mann-Whitney U-test) served to compare the 
frequencies of ordinal data (e.g., all BIS values). A Fisher’s exact test was used to test dif-
ferences in the distribution of nominal data. Data are given in mean (standard deviation) or 
median (interquartile range), as appropriate. For compensating the considerable time delay 
of signal processing,(8) BIS values 0 and 30 s after each landmark event were analyzed.
For both groups, we used a receiver operating characteristic (ROC) curve to describe the 
discriminating performance of the BIS monitor between consciousness and unconscious-
ness. We used 4 BIS values per patient in this analysis. The awake value and the value 30 
s after return of consciousness were marked as conscious values, and the value 30 s after 
LOC and intraoperative values were marked as unconscious values. First, we plotted the 
true-positive rate against (sensitivity) the false-positive rate (1-specificity) for the measured 
BIS values. Second, for each group, the BIS value with the highest combination of sensitiv-
ity and specificity was selected as the optimal cutoff BIS value for discrimination between 
conscious and unconscious state. Third, the area under the curve (AUC) was calculated. A 
large AUC corresponds with high discriminative properties. Fourth, we compared the ROC 
curve of the intellectually disabled group with the ROC curve of the control group by testing 
the statistical significance of the difference between the AUCs.
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FIGURE 1 Bispectral index values for both groups during different stages of anesthesia. Median (horizon-
tal line), 25th and 75th percentiles (box), and range (whiskers) of Bispectral index values for the intel-
lectually disabled (ID) and the control group. * = P<0.05 (from Mann-Whitney U-test). LOC= Loss of 
consciousness; RoC = Return of consciousness
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 RESULTS
Patient Characteristics
Seventeen patients were enrolled in the intellectually disabled group and 35 in the control 
group. The demographic characteristics of both groups were comparable (Table 1). None of 
the children in the control group was treated with anticonvulsants or spasmolytics. Ten in-
tellectually disabled patients were treated with anticonvulsants (benzodiazepines, barbitu-
rates, and/or antiepileptic drugs) for seizure control and 3 other patients with spasmolytics 
(baclofen). The etiology of underlying neurological disorders in the intellectually disabled 
group comprises 12 different disorders (Table 2). 
TABLE 1 Characteristics of the 52 subjects by group
Characteristic ID group (n=17) Control group (n=35) P value
Male sex, n (%) 12 (71) 19 (54) 0.37
Age (yr), mean (SD) 5.4 (3.6) 6.2 (3.8) 0.50
Weight (kg), median (IQR) 17 [14 to 26] 19 [14 to 37] 0.68
Duration of anesthesia (min),  54 (25) 44 (15) 0.12
mean (SD)
Duration of gastroscopy (min),  8 [7 to 13] 10 [8 to 16] 0.25
median (IQR)
Intravenous induction 13 (76) 27 (77) 1.00
of anesthesia, n (%)
ID = Intellectually Disabled; IQR = Interquartile Range
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TABLE 2 Underlying neurological disorders in the intellectually disabled group (n=17)
 Neurological disorder n
Congenital Metachromatic leukodystrophy 1
  Carbohydrate-Deficient Glycoprotein Syndrome Type 1c 1
  Triple A Syndrome 1
  Lesch-Nyhan Syndrome 1
  Lissencephaly + Epilepsy 1
  Miller-Dieker Lissencephaly Syndrome  2
  Klinefelter syndrome 1
  West syndrome  1
Posthypoxic encephalopathy  Perinatal  3
  Post resuscitation  3
Other Syndromal disorder of unknown origin 1
  Neurodegenerative disorder of unknown origin 1
Differences in BIS values between the intellectually disabled and control groups
BIS values (median [interquartile range]) for the intellectually disabled group were sig-
nificantly lower than those for controls in the awake state (72 [48–77] vs 97 [84 –98], 
P<0.001), during stable intraoperative anesthesia (34 [21–45] vs 43 [33–52], P=0.02), and 
during return of consciousness (59 [36–68] vs 73 [64–78], P=0.009) (Table 3 and Fig. 1).
The Fisher’s exact test revealed that the proportion of missing awake BIS values was sig-
nificantly higher in the control group:24 of 35 vs 5 of 17 in the intellectually disabled group 
(P=0.02). In the intellectually disabled group, 8 of 17 of the loss of consciousness values 
was missing versus 25 of 35 in the control group (P=0.13). None of the intraoperative 
values was missing in the intellectually disabled group versus 3 of 35 in the control group 
(P=0.54). On the return of consciousness values, 3 of 17 were missing in the intellectually 
disabled group versus 5 of 35 in the control group (P=1.00).
89
TABLE 3 Bispectral index values at four stages of anesthesia, by group
Stage ID group (n=17) Control group (n=35) P valuea
 Median (IQR) 
Conscious   
Awake 72 (48 to 77) 97 (84 to 98) <0.001
30 s after return 59 (36 to 68) 73 (64 to 78) 0.009
of consciousness
Unconscious   
30 s after loss of consciousness 41 (32 to 61) 56 (42 to 71) 0.15
Intraoperative 34 (21 to 45) 43 (33 to 52) 0.02
ID = Intellectually Disabled; IQR = Interquartile Range
a Mann-Whitney U test
ROC analysis
The discriminative properties of the BIS monitor for the state of consciousness were com-
parable between the groups. The AUC for the control group was not statistically signifi-
cantly larger than the AUC for the intellectually disabled group (0.92 vs 0.78, P=0.07). In 
Figure 2, the ROC curve for each group is displayed and optimal cutoff BIS values have been 
marked.
For the control group, the optimal cutoff BIS value was 65 (sensitivity=0.81 and specific-
ity=0.93) and for the study group it was 47 (sensitivity=0.73 and specificity=0.81).
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FIGURE 2 Discriminative properties of the Bispectral index monitor between consciousness and uncon-
sciousness in the intellectually disabled and control group. Receiver operating characteristic curve of the 
intellectually disabled and the control group. 
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DISCUSSION
BIS values observed in the awake state, during stable intraoperative anesthesia, and during 
return of consciousness were significantly lower for intellectually disabled children com-
pared with controls. The differences between the 2 groups ranged from 9 to 25. BIS distin-
guished the conscious and unconscious state equally well in the 2 groups. Nevertheless, the 
optimal cutoff BIS value for discrimination between the conscious and unconscious state 
was 28 points lower for the intellectually disabled group.
On the BIS scale from 100 (fully awake) to 0 (isoelectric EEG), differences of these magni-
tudes could easily give rise to misinterpretation of the patient’s state of consciousness.
Comparison with previous studies
These data confirm and supplement the observations of Choudhry and Brenn(5) and Sari-
caoglu et al.(6). Both groups reported lower BIS values in intellectually disabled children. 
However, contrary to our findings, in those previous studies, the BIS values of intellectually 
disabled children remained within the defined ranges for the different stages of anesthesia.
Still, we should be aware of essential differences between these 2 studies and this study. 
First, anesthesia management was substantially different. We administered both IV and 
inhaled anesthetics, whereas Saricaoglu et al. administered only propofol. Patients in the 
study by Choudhry and Brenn were premedicated with midazolam, received inhaled induc-
tion with sevoflurane, and tracheal intubation was facilitated with rocuronium. Second, 
children in the study groups of both previous studies had been diagnosed with cerebral 
palsy and intellectual disability, but details on the underlying causes of cerebral palsy or the 
severity of intellectual disability were lacking.
Possible explanations for lower BIS values in intellectually disabled children
The small sample size and the heterogeneity of the group of intellectually disabled children 
in this study do not allow establishing causal relationships that might explain the lower BIS 
values in this group. Alternatively, we suggest 3 possible explanations based on findings 
from the literature. 
1. A review by Dahaba(9) summarizes a large variety of conditions (anesthetic   
drugs, clinical conditions, and electric device interference) that could result in the BIS 
indicating an incorrect hypnotic state. The effect of most of those conditions on the 
EEG signal is clear. Dahaba gives no definite explanation for lower BIS values in intel-
lectually disabled children. We suggest that the underlying cerebral pathology could 
cause epileptiform and nonepileptiform EEG abnormalities and thus affect BIS values. 
For example, nonepileptiform EEG abnormalities were observed in the majority of a 
cohort of children with tetraplegia/diplegia(10). 
2. Epileptiform activity during general anesthesia has been reported to affect BIS values. 
Verma and Radtke(11) reviewed studies about ictal and interictal EEG activity. Interictal 
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activity in partial epilepsy concerns several patterns of ƣ waves. The frequency band 
forƣ waves is between 1 and 4 Hz. Those low-frequency waves are generated dur-
ing natural sleep but are also seen during general anesthesia as an effect of hypnotic 
drugs(9, 12). These interictal ƣ waves could artificially decrease BIS values in children 
with epilepsy. 
3. Not only epileptiform activity but also anticonvulsants might influence BIS values. 
Most anticonvulsants exert their effect by facilitating Ȉ-aminobutyric acid (GABA)-
mediated inhibition via allosteric interaction with neuronal postsynaptic GABAA recep-
tors. Propofol and volatile anesthetics also act on the GABAA receptor in the central 
nervous system. In this way, anticonvulsants may directly influence depth of anesthe-
sia. Ten of the intellectually disabled children in our study were treated with anticon-
vulsants versus none of the control children.
Limitations of this study
Major Limitation
A considerable number of awake BIS values for the control group is missing. However, 
the obtained BIS values in the control children were comparable to those reported in other 
pediatric studies(13, 14). We assume that the awake BIS values of the other control chil-
dren in our study would have been comparable to those reported by Denman et al.(13) and 
by Blussé et al.(14). The crux of the matter is that the awake BIS values of intellectually 
disabled children were much lower than the ones measured in the control group. Further-
more, for logistical reasons and the fact that one-quarter of the patients received inhaled 
induction, a larger proportion of the loss of consciousness data is missing for both groups. 
Therefore, the loss of consciousness data should be interpreted with caution.
Second Limitation
Heterogeneity in neurological diagnoses (Table 2) is a realistic reflection of the intellectu-
ally disabled patient population in need of a PEG but makes it difficult to generalize the 
results of the study to all intellectually disabled patients.
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 CONCLUSIONS
We advise anesthesiologists to be alert to possible lower BIS values in children who are 
intellectually disabled. There is a risk that they will inadvertently misinterpret the state of 
consciousness in these children.
Given the variety and rarity of underlying neurological disorders, only large multicenter tri-
als might provide decisive information about BIS monitoring in intellectually disabled chil-
dren. In addition, the effects of epileptiform EEG activity and anticonvulsant therapy on BIS 
should be studied. It would also be advisable to study other depth of anesthesia monitors 
in an attempt to find the optimal manner of evaluating (un)consciousness in intellectually 
disabled patients with documented and confirmed specific etiologies of their intellectual 
disability.
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yW.B.YEATS 
In toils of measurement
Beyond eagle or mole,
Beyond hearing or seeing
Or Archimedes’ guess,
To raise into being,
That loveliness?
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ABSTRACT
Many pediatric intensive care units use the COMFORT-behavior scale (COMFORT-B) to as-
sess pain in 0- to 3-year old children. The objective of this study was to determine whether 
this scale is also valid for the assessment of pain in 0 to 3 year old children with Down 
syndrome. These children often undergo cardiac or intestinal surgery early in life and 
therefore admission to a pediatric intensive care unit. Seventy-six patients with Down syn-
drome were included and 466 without Down syndrome. Pain was regularly assessed with 
the COMFORT-B scale and the Numeric Rating Scale (NRS). For either group, confirma-
tory factor analyses revealed a 1-factor model. Internal consistency between COMFORT-B 
items was good (Cronbach’s Ơ=0.84 to 0.87). Cutoff values for the COMFORT-B set at 17 or 
higher discriminated between pain (NRS pain of 4 or higher) and no pain (NRS pain below 
4) in both groups. We concluded that the COMFORT-B scale is also valid for 0-to 3-year old 
children with Down syndrome. This makes it even more useful in the pediatric intensive 
care unit setting, doing away with the need to apply another instrument for those children 
younger than 3.
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INTRODUCTION
Children receiving intensive care often undergo many painful, invasive procedures, includ-
ing mechanical ventilation. Many are recovering from major surgery. The resulting pain and 
distress are treated with analgesic and or sedative agents. Assessment of pain and distress 
is therefore an important cornerstone of pediatric intensive care treatment and is increas-
ingly used as a performance indicator. Observational tools are needed in preverbal infants 
and nonverbal children - i.e. mechanically ventilated or sedated children(1). The Multidi-
mensional Assessment of Pain Scale (MAPS) (2) and the COMFORT-behavior (COMFORT-
B) scale are suitable to assess pain and have been validated for the pediatric intensive care 
unit (PICU) setting(3-6). These instruments are based on the observation of typical pain 
behaviors such as grimacing, cry, body movements and muscle tension. 
Other tools may be needed in critically ill infants with intellectual disabilities or neuro-
logical impairment because their pain expression may be atypical or less vigorous(7). The 
Non-communicating Children's Pain Checklist-Postoperative Version (8), the Paediat-
ric Pain Profile (9), the revised Faces, Legs, Activity, Cry and Consolability (10), and the 
Checklist Pain Behavior (11, 12) have been validated for postoperative pain in children with 
intellectual disabilities, from the age of 3 to 4 years onwards. These scales require a long 
observation period, up to 10 minutes, or require a description of idiosyncratic behaviors. To 
our knowledge, no such tools are available for younger children with a suspected or known 
intellectual disability, let alone for the intensive care unit (ICU) setting. 
Individuals with Down syndrome have a 40 to 60% risk of congenital heart diseases and 
congenital gastrointestinal anomalies that require surgical repair at a young age (13). We 
have been using the COMFORT-B scale in daily practice since 1999 in 0 to 3 year old chil-
dren with Down syndrome as well. The manual of the original COMFORT scale does not 
exclude children with this condition, but validity of the scale for use with Down syndrome 
patients was not analyzed separately (Dr. Bruce Ambuel, personal communication). Many 
of those children show hypotonia, which could affect their behavior, and thus the score on 
the item ‘Muscle Tone’ (14). Also, Down syndrome has been associated with a low-pitched, 
hoarse cry, which could affect the score on the item ‘Crying’ (15). We wondered, there-
fore, whether the COMFORT-B scale is really valid in 0-to 3-year old children with Down 
syndrome. 
The objective of the study reported here was to evaluate the psychometric properties of the 
COMFORT-B scale for the assessment of pain and distress in 0-to 3-year old children with 
Down syndrome and to determine whether different cut-off values should apply for them. 
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METHODS
Subjects and Setting
The ICU of Erasmus University Medical Center - Sophia Children’s Hospital, Rotterdam, 
the Netherlands serves as the only level III facility for children in a referral area comprising 
about 4 million inhabitants and 35 000 newborns per year. Admission criteria are major 
surgery or other conditions requiring intensive care such as trauma, sepsis and the need 
for mechanical ventilation. Treatment almost always involves painful and invasive proce-
dures. To counteract the consequences, we introduced a standardized pain and distress 
management protocol in 1999, which has not changed substantially since that time. The 
key element is application of the COMFORT-B scale and Numeric Rating Scale by observa-
tion (NRSobs) for pain every 8 hour shift at set times (2-10-18 hrs) and on suspicion of pain 
or distress (3, 5, 16). Since November 2002, all COMFORT-B and NRSobs scores are being 
prospectively recorded in our Patient Data Management System (PDMS). 
The study was approved by the local ethics committee of Erasmus University Medical 
Center. The need for informed parental/guardian consent was waived.   
 
The study group consisted of patients with Down syndrome, who met the following crite-
ria: ICU stay between November 2002 and April 2009, confirmed diagnosis of trisomy 21 
by genetic analysis, age 0 to 36 months and scores of at least two assessments available. 
Children without Down syndrome admitted in the reference year 2007 served as a control 
group. This year is the middle year of the period 2005 (start of PDMS) up to and includ-
ing 2009. We assume that 2007 is a representative reference year because the standardized 
mean differences (SMD) in COMFORT-B scores between 2007 versus the other years were 
small (0.02 to 0.08). Inclusion criteria for the control group were: ICU stay between January 
2007 and January 2008, age 0 to 36 months and scores of at least two assessments available. 
Instruments 
The COMFORT-B scale is a pain and distress assessment instrument that asks observers 
to consider intensity of six behavioral manifestations: Alertness, Calmness, Respiratory 
response (for mechanically ventilated children) or Crying (for spontaneously breathing 
children), Body movements, Facial tension and Muscle tone. For each of these items, five 
descriptions, rated from 1 to 5, are provided reflecting increasing intensity of the behavior 
in question. Summating the ratings of the six behavioral manifestations leads to a score 
ranging from 6 to 30. Clinical cutoff scores for the COMFORT-B and NRSobs for pain have 
been determined. The pain management protocol dictates some kind of intervention (non-
pharmacological and/or pharmacological) when COMFORT-B scores of 17 or higher are 
combined with NRSobs pain ratings of 4 or higher(16). 
All nurses undergo a 2 hour COMFORT-B training program when they start to work in our 
unit. The program includes 10 assessments in different patients, with a qualified nurse 
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performing the same assessments. Agreement is assessed from the linearly weighted 
Cohen’s kappa calculated from these 10 paired assessments. This coefficient corrects for 
chance agreement (17). The minimal Cohen’s kappa that nurses needed to reach was 0.65. 
If Cohen’s kappa value was below 0.65, the nurse was asked to repeat assessments until the 
required kappa value had been reached. Median linearly weighted kappa values were 0.81 
(interquartile range 0.77 to 0.87) for 103 nurses.
The NRS is a validated tool that asks patients themselves or proxies to rate pain intensity by 
number (0=no pain at all and 10= worst imaginable pain)(18). We refer to the NRS as ap-
plied by proxy raters as NRSobs to avoid confusion with the NRS for self-report. The NRSobs 
expresses the observer’s expert opinion of the patient’s level of pain, taking the patients’ 
circumstances (disease-related, treatment related, environmental and patient specific) into 
account. Several studies compared the NRSobs or observed visual analog scale to observa-
tional pain assessment tools in 0 to 3 year old children(19). These NRSobs assessments – 
part of the pain management protocol since 1999 – serve to differentiate between pain and 
distress. For instance, a high COMFORT-B score may coincide with a low NRSobs for pain 
if the nurse knows that the child requires sedation rather than analgesia. The nurse takes 
this knowledge into account when applying the NRSobs. Repeating the assessments after 
interventions is required to monitor the effect of the intervention.
The Nurses Interpretation of Sedation Scale (NISS) is the nurse’s expert opinion of the level 
of sedation, reflected by one of these categories: Insufficient sedation, Adequate sedation, 
Oversedation. The NISS is applied to infants who receive sedatives and/or opioids. This 
instrument is comparable to the one used by Marx et al.(20). The NISS was validated in our 
unit in 2005 (5). 
Procedure
All COMFORT-B, NRSobs and NISS scores for the included patients were retrieved from our 
PDMS. The following patient data were collected from the medical records: sex; age at first 
assessment; reason of admission to the PICU; opioid, sedative and paracetamol adminis-
tration during admission; and ventilatory status. 
Statistical analysis
Data were analyzed using SPSS version 18.0 (SPSS Inc., Chicago, IL, US). All reported P 
values are two-sided, and P values of less than 0.05 are considered to indicate statistical 
significance. Summary statistics (mean values and percentages) of repeated pain assess-
ments per patient served to compare results among groups and to correlate COMFORT-B 
scores with NRSobs pain scores at patient level (21). Pearson product moment correlation 
coefficient was applied to test the linear association between continuous variables. 
The Chi-square test (or Fisher exact test in the case of low predicted cell counts) was used 
to compare nominal data for the two independent groups. Continuous data were presented 
Chapter 6
104
as median [IQR]. Data were compared between the two independent groups with the 
Mann-Whitney test or with the t test for normally distributed variables. 
For these tests, we used all scores of the first seven days of a patient’s admission. If patients 
had been admitted more than once, the data of the longest admission were used. This strat-
egy was aimed at limiting the variability in number of assessments per patient.  
First, to test the internal consistency of the COMFORT-B scale, Cronbach’s Ơ and corrected 
inter-item correlations were calculated for each of the two groups. 
Second, to test whether the factor structure of the COMFORT-B scale is comparable 
between the two groups, a confirmatory factor analysis was performed with the Mplus 
software version 5.21 (Muthén & Muthén, Los Angeles, CA, US). This analysis was based on 
a maximum of 5 COMFORT-B scores per patient, randomly selected from all scores of the 
first seven days of the patient’s longest admission. The following method was applied: each 
score was assigned a random number using the UNIFORM function in SPSS. The scores 
numbered 1 through 5 were entered in the analysis. Seventeen percent of patients had been 
assessed only 2 or 3 times because of a short admission. In those cases all scores were used 
in the analysis. The analysis aimed at finding a parsimonious factor model that adequately 
represents the empirical structure of the COMFORT-B scale for both the Down syndrome 
and the control group. We also tested a 1-factor model, because Van Dijk et al. earlier found 
a 1-factor model that adequately described the COMFORT-B scale (3). The following per-
formance measures of overall fit were used: 1.Ƶò test for model fit: a non-significant value 
indicates that the model at issue cannot be rejected. To account for the effect of sample size 
on Ƶò test, the Ƶò/df was also used. 2. Standardized root mean square of residuals (SRMR): 
the lower the SRMR the better the model fits. 3. Root mean squares error of approximation 
(RMSEA): A value of 0.05 indicates a close fit and values up to 0.08 represent reasonable 
errors of approximation in the population. Parameters were estimated by the maximum 
likelihood mean and variance adjusted procedure. 
Four models were tested: 1. Invariant error variances for corresponding items across 
groups; 2. Equal factor loadings across groups; 3. Equal factor means across groups; 4. 
Invariant residual variances for corresponding items across groups. Because the prefinal 
model showed that the residual covariances of two items were substantial, the final model 
allowed for freeing the residual covariances of these two items. 
Third, for each group, the COMFORT-B score with the optimal combination of sensitiv-
ity and specificity was selected as the clinical cut-off score for pain. NRSOBS values of 4 or 
higher served as reference value for pain. Furthermore, the positive and negative predictive 
values of the COMFORT-B scale were determined for either group.
The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the 
Down syndrome group was compared with the AUC of the control group by testing the 
statistical significance of the difference between these two groups. 
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FIGURE 1 Receiver operating characteristic curve for COMFORT-Behavior with NRSobs pain of 4 – 10 as 
state variable. Down syndrome group (solid line) and control group (dashed line). 
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RESULTS
Patient characteristics
Seventy-six patients with Down syndrome and 466 without Down syndrome were included. 
The demographic characteristics are listed in Table 1. A total of 46.8% of children in the 
control group were mechanically ventilated, versus 73.7% in the Down syndrome group  
(P<0.001). Children with Down syndrome underwent significantly more often surgery for 
associated congenital anomalies (P<0.001). Morphine administration was significantly 
more frequent in the Down syndrome group (62% versus 45%, P=0.006); the same held 
true for midazolam (68% versus 51%, P= 0.005). 
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TABLE 1 Characteristics of the 542 subjects, by group
 Down Controls (n=466) P value
 syndrome (n=76)
Male sex, n (%) 45 (59.2) 273 (58.6) 0.92 a
Age in days, median [IQR] 81 [42 to 273] 119 [22 to 355] 0.22 b
Study period, median [IQR] 3 [1 to 6] 1 [1 to 6] 0.014 b
Mechanically ventilated, n (%) 56 (73.7) 218 (46.8) <0.001 a
Morphine, n (%) 47 (62) 209 (45) 0.006 a
Paracetamol, n (%) 58 (76) 332 (71) 0.36 a
Midazolam, n (%) 52 (68) 238 (51) 0.005 a
ECMOd treatment, n (%) 4 (5.3) 21 (4.5) 0.77 c
Reason of admission    
Total surgical, n (%) 54 (77.1) 313 (67.2) 0.014 a
Cardiothoracic  32 (59.3)  73 (23.3) <0.001 c
Gastrointestinal  15 (27.8)  102 (32.6) 
Ear-nose-throat  5 (9.3)  23 (7.3) 
Craniofacial  2 (3.7)  99 (31.6) 
Other surgerye  0 (0)  16 (5.1) 
Total non-surgical, n (%)  22 (28.9) 153 (32.8) 0.014 a
Cardiorespiratory failure  17 (77.3)  102 (66.7) 0.29 c
Gastrointestinal / urogenital  3 (13.6)  11 (7.2) 
Metabolic  2 (9.1)  5 (3.3) 
Trauma  0 (0)  13 (8.5) 
Infection / sepsis  0 (0)  11 (7.2) 
Other f  0 (0)  11 (7.2) 
a Chi-square test
b Mann-Whitney test
c Exact test 
e Extracorporeal Membrane Oxygenation
f Other surgery includes urogenital, orthopaedic, dermatological surgery and tumor extirpations
g Other diagnoses includes intoxication, neurological problems and malignancies 
Pain assessments
Median number of COMFORT-B scores significantly differed between the two groups 
(P=0.023): a median [IQR] of 9 [4 to 22] in the control group versus a median (IQR) of 16 
[8 to 22] in the Down syndrome group. Mean COMFORT-B score was 12.1 (SD 1.7) in the 
Down syndrome group versus 12.3 (SD 1.8) in the control group (P=0.31). A total of 7% 
of the 7439 COMFORT-B scores across both groups were 17 or higher. The percentage of 
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COMFORT-B scores of 17 or higher was calculated for each patient. Median (IQR) percent-
age per patient was 8.3 (0 to 20) in the Down syndrome group versus 6.7 (0 to 20) in the 
control group (P=0.48). The median percentage of NRSobs ratings of 4 or higher per patient 
was 0 in both groups. NRSobs pain ratings of 4 or higher were seen in 4.8% of all 6954 NR-
Sobs pain assessments.
The Pearson product moment correlation between mean NRSobs for pain and mean COM-
FORT-B scores per patient was 0.45 for the Down syndrome group (P<0.01) and 0.57 for 
the control group (P<0.01).  
TABLE 2 COMFORT-B item scores and internal consistency measures, by group
 Down Controls P value a SMD b
 syndrome (6276 scores)
 (1163 scores)
Items, mean (SD)    
Alertness 2.2 (1.1) 2.1 (1.1) 0.10 -0.05
Calmness 1.3 (0.7) 1.4 (0.7) 0.50 0.02
Respiratory response c 1.8 (0.8) 1.8 (0.8) 0.61 0.02
Crying c 1.3 (0.7) 1.5 (1.0) <0.001 0.23
Physical movements 2.3 (1.0) 2.2 (0.9) <0.001 -0.12
Facial tension 2.0 (0.6) 2.0 (0.6) <0.001 0.12
Muscle tone 2.8 (0.6) 2.9 (0.5) <0.001 0.21
Corrected item-total correlation  0.54 to 0.72 0.57 to 0.76  
Cronbach’sƠ unstandardized  0.84 0.87  
Cronbach’s Ơ standardized  0.86 0.88 
a t test
b  Standardized Mean Difference (SMD): Values of Down’s syndrome group minus values of control group
c  54.6% of the scores were scored in mechanically ventilated patients (respiratory response) and 45.4% 
in spontaneously breathing patients (crying)
Sedation assessments
A median [IQR] number of 10 [1 to 41] NISS assessments in 41.1% of the 542 patients 
(37.7% in the control group versus 44.7% in the Down syndrome group) were recorded 
in the PDMS. The median [IQR] percentage of adequate sedation scores was 90.5% [78 to 
100] in the control group versus 87.8% [79 to 100] in the Down syndrome group (P=0.33). 
Item descriptives and internal consistency
Table 2 lists the mean COMFORT-B item scores and SDs for both groups; the mean scores 
were derived from all scores of the first 7 days of the longest admission. There were signifi-
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cant differences for four items. However, the SDM between the two groups was low.  
The standardized Cronbach’s Ơ’s varied from 0.84 to 0.87 and all corrected item-total cor-
relations were above 0.54 (Table 2). 
Confirmatory factor analysis
Confirmatory factor analysis was applied on 347 scores in the Down syndrome group and 
2067 scores in the control group. The most plausible model included equal factor loadings, 
equal residual variances, unequal error variances and unequal factor means. In this model, 
the item ‘Calmness’ appeared to be correlated with ‘Respiratory response / crying’. ‘Facial 
expression’ was correlated with ‘Muscle tone’. The fit indices were satisfactory (Ƶò of 101 
with 19 degrees of freedom, Ƶò/df of 5.3, SRMR of 0.03 and a RMSEA of 0.06). The un-
standardized factor loadings varied from 0.36 for muscle tone to 0.86 for body movements 
both groups. The unstandardized and standardized loadings of the COMFORT-B items for 
the two groups are listed in Table 3. 
TABLE 3 Unstandardized and standardized factor loadings for the COMFORT-B scale
  Down Controls 
  syndrome scores  (2067 scores)
  (347 scores)
Alertness Unstandardized 1.00 1.00
 Standardized 0.74 0.78
Calmness Unstandardized 0.63 0.63
 Standardized 0.76 0.76
Physical movement Unstandardized 0.86 0.86
 Standardized 0.75 0.81
Facial tension Unstandardized 0.48 0.48
 Standardized 0.70 0.69
Muscle tone Unstandardized 0.36 0.36
 Standardized 0.54 0.57
Respiratory response / Crying a Unstandardized 0.66 0.66
 Standardized 0.68 0.63
a  These two items were combined in the confirmatory factor analysis. Respiratory response was scored in mechanically 
ventilated patients and crying in spontaneously breathing patients. 
Optimal clinical cut-off values 
For both groups the clinical cut-off COMFORT-B score of 17 presented with good sensitiv-
ity (82% in the Down syndrome group and 83% in the control group) and excellent specific-
ity (92% in the Down syndrome group and 91% in the control group). The positive predic-
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tive value was 0.32 in both groups. The negative predictive value was excellent (0.99) for 
both groups.
The AUC for the Down syndrome group did not statistically significantly differ from the 
AUC of the control group (P= 0.85), see Figure 1. 
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DISCUSSION
Psychometric properties of the COMFORT-B scale were comparable between 0-to 3-year 
old patients with and without Down syndrome. Confirmatory factor analysis revealed that 
a 1-factor model was sufficient to represent the six items of the COMFORT-B scale. The 
finding that more children in the Down syndrome group were mechanically ventilated and 
received morphine and midazolam can be explained by the fact this group included more 
surgical patients. 
The current study confirms the 1-factor structure of the COMFORT-B scale when applied in 
children with and without Down syndrome in the ICU setting. Previous studies have evalu-
ated the original COMFORT scale (eight items) in the pediatric ICU setting using explorato-
ry (4, 22) and confirmatory factor analysis(3). All three studies identified a 1-factor solution 
for the six behavioral items and one or more factors for the two physiological items blood 
pressure and heart rate. Omitting the items blood pressure and heart rate resulted in the 
six-item COMFORT-B scale, which is now often used(3, 4). However, in contrast to the pre-
vious studies, the items ‘Calmness’ and ‘Respiratory response / crying’ were intercorrelated 
in the present study, and so were ‘Facial expression’ and ‘Muscle tone’. These additional 
intercorrelations were required to reach an adequate fit of the model. Confirmatory factor 
analysis as applied in the present study has important advantages over exploratory factor 
analysis because it allows for statistical inference modeling. Exploratory factor analysis 
does not allow for this and gives no information about intercorrelations or significant dif-
ferences in factor loadings(23, 24). Hence, we recommend the use of confirmatory factor 
analysis for all future studies in this field.
The mean COMFORT-B scores did not differ significantly between the two groups. The 
prevalence of pain was low in both groups: COMFORT-B scores were 17 or higher in about 
7% of the assessments. NRSobs pain scores of 4 or higher (an indication for moderate to 
severe pain) were even more rare (5% of scores). The correlation coefficients between 
COMFORT-B and NRS pain scores were acceptable in both groups. The number of COM-
FORT-B scores was higher in the Down syndrome group because they were more often 
admitted after surgery. In practice, surgical patients are assessed more frequently. Other PI-
CUs have reported comparable prevalences of pain using the same assessment instruments 
as in the present study. One study by Johansson et al. in 40 PICU patients reported a median 
COMFORT-B score of 12 in the children who were adequately sedated(6). The NRSobs pain 
ratings in that study were 4 or higher in only 6% of the assessments. 
Comparing the mean item scores between the 1163 scores of the Down syndrome group 
and the 6276 scores of the control group, we observed some statistically significant differ-
ences. The item scores on the four items “Crying”, “Physical Activity”, “Facial Tension” and 
“Muscle Tone” were significantly different between the two groups. The standardized mean 
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differences (SMD) for these items ranged from -0.12 to 0.23; therefore we see these differ-
ences as clinically not relevant. Because the mean item score for “Crying” was lower, future 
studies using spectrographic analysis could evaluate the character of the cry of children 
with Down syndrome. Lind et al. observed that children with Down syndrome have a low-
pitched, hoarse cry(15). The COMFORT-B scale evaluates the intensity of the crying, not its 
characteristics. 
Children with Down syndrome are reported to have a weaker muscle tone(25). The mean 
item score for “Muscle Tone” was lower in the Down syndrome group, with a SMD of 0.21. 
The small magnitude of this difference may be explained by the fact that the COMFORT-B 
observer assesses muscle tone by lifting the child’s arm or leg, whereas the pediatrician 
applies an overall assessment of hypotonia. Another explanation may be that nurses will 
anticipate hypotonia when assessing muscle tone in children with Down syndrome. 
The optimal clinical cut-off value of the COMFORT-B scale for pain was 17 for both groups 
of patients with good sensitivity, specificity and negative predictive value. The positive pre-
dictive value was relatively low in both groups. This may be because distress without pain 
also results in a high COMFORT-B score. In our study, the NISS scores suggest that more 
than 80% of the children were adequately sedated. Children were treated according to the 
pain management protocol. More children with Down syndrome received morphine and 
midazolam, probably because of the higher rate of surgery in this group. The doses of mor-
phine and midazolam did not differ between the groups.  Reducing the incidence of pain is 
highly desirable and PICUs around the world strive for this, but this low incidence of pain 
may influence the psychometric evaluation of pain assessment scales. 
A possible limitation of this study is that background characteristics were collected from 
charts. Nevertheless, all pain assessment data were retrieved from the patient data man-
agement system (PDMS) in which these data are prospectively collected at set time points 
during a patient’s admission. The use of the PDMS assures a satisfactory level of quality and 
reliability of the data. The second limitation is that the sample size of the Down syndrome 
group was small. This is in line with other studies in this patient group and is because the 
incidence of Down syndrome in the Netherlands is 16 per 10,000 live births(26). In general, 
it is preferable to have a smaller discrepancy between group sizes.
Previous studies validated the COMFORT-B scale for the assessment of pain and distress in 
children admitted to the PICU. Nowadays, the COMFORT-B scale has gained wide accept-
ance in PICUs around the world. Because the COMFORT-B scale now proved valid for 0 to 
3 year old children with Down syndrome as well, there is no need to introduce yet another 
scale. The COMFORT-B scale may also serve as a validated outcome parameter in pharma-
codynamic studies in children with Down syndrome.
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A sort of battered kettle  
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ABSTRACT
Introduction
Pain is usually assessed by the interpretation of behavior, which can be subjective. There-
fore, there is an ongoing search for more objective methods. Performance of skin con-
ductance measurement as a pain assessment tool is variable, as some studies report low 
specificity and a low predictive value of the method. The aim of this pilot study was to test 
whether autoregulation of the skin temperature influences the skin conductance of pain-
free infants.
Methods
We included 11 infants, median (interquartile range (IQR)) age of 34 (13–76) d, who were 
admitted to the surgical high-care unit for monitoring after surgery. None was treated with 
opioids or sedatives, and observational pain scores were low.
Results
Skin conductance was highly correlated with skin temperature in all subjects. Moreover, 
a significant change in all other vital parameters was observed on comparing before- and 
after-peak data.
Discussion
These results indicate that sympathetic neural activity to maintain homeostasis (such as 
autoregulation of skin temperature) results in skin conductance peaks. Real-time evalua-
tion of the sympathetic nervous system would be valuable for pain assessment. However, 
the technique should be better defined to increase both sensitivity and specificity for the 
measurement of pain before use in daily practice can be advocated. 
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INTRODUCTION
Pain management and ideally pain prevention are corner stones of optimal postopera-
tive care. In verbal children and adults, self-report is the generally accepted gold standard 
for the assessment of pain. Self-report is impossible, however, in neonates and infants, 
intubated or sedated patients and intellectually disabled patients. In those cases, caregiv-
ers have to rely on observational pain assessment scales such as the COMFORT-behavior 
scale(1), the Numeric Rating Scale for pain, or physiological parameters such as heart rate 
or blood pressure(2). 
Still, researchers are in search for more objective methods. Recently studied methods 
include near-infrared spectroscopy(3), heart rate variability(4) and skin conductance 
measurement(5-7). The last is based on the following theory: Sweat glands are sympatheti-
cally innervated and will produce sweat, and thereby salt, which increases the electrical 
conductance of the skin. Pain is known to stimulate sympathetic nerve activity, but animal 
and human studies have shown that several other physiological responses have the same 
effect. The primary function of the eccrine sweat glands is to enable evaporative heat loss in 
the autoregulation of body temperature. The following receptors and simple maneuvers in-
fluence skin sympathetic nerve traffic: temperature receptors in the central nervous system 
and skin, arousal and stress, respiration, cardiopulmonary receptors, sleep, and pain(8). 
However, Rutter reports that palmar and plantar sweat glands respond more to emotional 
stimuli than to thermal stimuli(9). 
Measurement of skin conductance as a pain assessment tool has been studied during heel 
lancing(10), intraoperatively(11), directly postoperatively(12), during postoperative care(13, 
14) and during intensive care(15). Performances were variable, as some studies report good 
sensitivity (12) and others low specificity and a low predictive value(16). It could be possible 
that sympathetic nerve activity, other than caused by pain, influences skin conductance and 
therefore has impact on the performance of skin conductance measurement. 
Aim
The aim of this pilot study was to test whether autoregulation of the skin temperature influ-
ences the skin conductance of pain-free infants.
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METHODS
Design
We performed an observational pilot study in which we measured simultaneously the 
infants’ skin conductance and vital parameters such as skin temperature, respiratory rate, 
heart rate, peripheral oxygen saturation (SpO2) and Peripheral Flow Index (PFI). 
Subjects and Setting
The study protocol was approved by the local ethics review committee of the Erasmus 
University Medical Center (Rotterdam, the Netherlands). Written informed consent was 
obtained from all the parents. The pilot study was performed at the surgical high-care 
unit of Erasmus University Medical Center - Sophia Children’s Hospital between July and 
September 2008. 
Inclusion criteria were: Age up to and including 12 months, and being monitored in the 
surgical high-care unit. Exclusion criteria were: Mechanical ventilation, treatment with opi-
oids or sedatives in the 24 hours before the study, and a COMFORT-B score of 17 or higher 
(indicating moderate to severe pain or distress) before measurement.  
Measurements
The infants underwent routine medical examination and nursing care in the morning. Skin 
conductance electrodes (see below) were placed after nursing care, and data recording 
started 5 to 10 minutes later. Data were recorded for 60 minutes, thereafter the electrodes 
were removed.
Pain and distress assessment
On the test day, the nurse who provided the morning care assessed the infant’s distress 
and pain using the COMFORT-Behavior scale. The COMFORT-B scale is an observational 
assessment tool and includes 6 items; each item is rated with a score from 1 to 5. Adding all 
six items together provides a pain rating between 6 and 30. The COMFORT-B has been vali-
dated for pain and distress assessment in critically ill and postoperative children(1, 17, 18).
Skin conductance
Skin conductance was assessed using the Stress Detector (MedStorm, Oslo, Norway). The 
three pediatric skin electrodes (MedStorm) were attached to the heel of the neonate accord-
ing to the manufacturers’ recommendations. The software automatically defines peaks 
above the amplitude threshold of 0.02 microSiemens. The sample frequency of the Stress 
Detector is 65 Hz. The Stress Detector records the skin conductance in microSiemens and 
in terms of signal quality. The other parameters, such as number of fluctuations in skin 
conductance per second (NFSC) and area under the curve, are derived from the change of 
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skin conductance over time. The other parameters, such as number of fluctuations in skin 
conductance per second (NFSC) and area under the curve, are derived from the change of 
skin conductance over time. The NFSC was calculated over the entire measurement period 
(approximately one hour) as this would be more precise than considering a 15 or 30 sec-
onds time frame.
Vital parameters
Our surgical high-care unit uses the Philips Intellivue MP-30 monitor (Philips, Eindhoven, 
the Netherlands) for monitoring. The Oxisensor II neonatal probe (Covidien-Nellcor™, 
Boulder, USA) was attached to the sole of the foot to measure peripheral oxygen satura-
tion and to calculate the Peripheral Flow Index (PFI). Kendall Medi-Trace neonatal 3 lead 
ECG electrodes (Covidien-Nellcor™) were used to measure heart rate and respiratory rate. 
The skin temperature surface probe (Philips) was attached next to the skin conductance 
electrodes on the heel to measure the skin temperature. During the study, the monitor was 
connected to a laptop computer with TrendFace software (iexellence, Wildau, Germany) to 
record the vital parameters. Data were recorded with a sample frequency of 0.97 Hz.
Statistical analysis  
Data extraction
The Stress Detector stores the skin conductance data in a text file with a sample frequency 
of 65 Hz. The raw data as well as signal quality data were imported in MATLAB (Math-
Works, Natick, MA, USA), a high-level technical computing language and interactive 
environment for algorithm development, data visualization, data analysis and numeric 
computation. TrendFace software exported the vital parameter data into an Excel file with a 
sample frequency of 0.97 Hz (1.032s). We, therefore, used skin conductance values with the 
same sample frequency of 0.97 Hz. 
Data analysis in MATLAB
The Stress Detector software detects peaks and hills in the skin conductance data, but does 
not export this information. In MATLAB we therefore defined peaks and troughs accord-
ing to the definition used in the MedStorm software, i.e. the minimal amplitude of a peak 
is 0.02 microSiemens. The number of fluctuations in skin conductance per second (NFSC) 
per subject were compared between the Stress Detector and the MATLAB analysis to verify 
the similarity between the calculations. 
Because the absolute skin conductance values in microSiemens can be influenced by ac-
cumulation of sweat in the electrodes, Med-Storm advises the use the number fluctuations 
in skin conductance per second (NFSC) instead of the absolute skin conductance. A peak is 
a burst of sympathetic activity; however, not only caused by pain or distress. Mean values of 
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vital parameters measured during fifteen seconds before and after each peak were statisti-
cally compared using the t-test. 
Data analysis in SPSS
First, we analyzed patient characteristics using descriptive statistics. As the sample size is 
small in this pilot study, we report median and interquartile range values for the group. 
Second, we analyzed the skin conductance and vital parameter data per patient using 
descriptive statistics. Thereafter the mean values of the group were calculated. Also the 
Spearman rank order correlation coefficients between the skin conductance and vita  l 
parameters were calculated per patient. 
Third, the differences in vital parameter values before and after a peak were analyzed in 
SPSS 19 (Chicago, IL, USA). For each vital parameter, we calculated the percentage of values 
that significantly differed before and after a peak and applied the Friedman test to com-
pared these percentages between the different vital parameters(19). 
FIGURE 1 Percentages of significant differences before and after skin conductance peaks for the vital 
parameters. Median (horizontal line), 25th and 75th percentiles (box), and range (whiskers) of significant 
differences in vital parameters before and after a skin conductance peak. PFI = Peripheral Flow Index, 
SpO2 = peripheral oxygen saturation
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 RESULTS
Patient characteristics
We included 11 subjects with a median [interquartile range (IQR)] age of 34 [13 to 76] days. 
Six had had gastrointestinal surgery, three surgical closure of a congenital diaphragmatic 
hernia, one repair of esophageal atresia, and one a rigid bronchoscopy. Table 1 shows their 
baseline characteristics. Patients were studied at a median [IQR] of 11 [5 to 17] days after 
surgery. The median [IQR] COMFORT-behavior score prior to the study was 10 [9 to 10], 
indicating that none was in pain or distress. 
TABLE 1 Characteristics of the 11 subjects
Characteristic Median [IQR]
Sex (M/F) 5 / 6
Gestational Age, in weeks  36 [29 to 38]
Age, in days 34 [13 to 76]
Post-conceptional age, in days  275 [259 to 280]
Days after surgery 11 [5 to 17]
Duration of measurement in minutes 63 [61 to 65]
COMFORT-B score before measurement  10 [9 to 10]
Skin Conductance 
Number of peaks 36 [19 to 312]
Skin Conductance, in microSiemens  6.42 [3.13 to 9.21]
Number of Fluctuations 0.0098 [0.0047 to 0.0825]
in Skin Conductance per second
Vital parameters 
Heart rate, in beats/minute 154 [130 to 167]
Skin Temperature, in °C 32.19 [30.54 to 32.88]
Peripheral Flow Index 0.66 [0.37 to 1.20]
Peripheral oxygen saturation, in % 98.67 [97.65 to 99.50]
Respiratory rate, in breaths/minute 44.37 [37.39 to 60.85]
Descriptive results
Monitoring lasted a median [IQR] of 63 minutes [61 to 65] during which a median [IQR] 
number of 3576 [3099 to 3678] samples was obtained. The median [IQR] number of skin 
conductance peaks was 36 [19 to 312]. The median values of the vital parameters are shown 
in Table 1. 
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Significant differences before and after skin conductance peaks
The median percentages of statistically significant differences in vital parameters before 
and after a skin conductance peak are displayed in Figure 1. Percentages varied from a 
median [IQR] of 62 % [59 to 68] for heart rate to a median [IQR] of 88 % [82 to 94] for 
skin temperature (Friedman test: P = 0.003). In one subject, peripheral oxygen saturation 
changed significantly after all 18 peaks (see Figure 1). 
Correlations
In all 11 subjects, skin temperature (in ° Celsius) was statistically significantly correlated with 
the skin conductance value (in microSiemens; P <0.001). In eight subjects, this was a positive 
correlation: Median [IQR] Spearman’s rho correlation coefficient of 0.86 [0.78 to 0.94]. In 
the remaining three subjects, it was a negative correlation: Spearman’s Rho correlation coef-
ficient of -0.48, -0.49 and -0.99. Background characteristics (postnatal age, type of surgery, 
sex and environmental circumstances) and vital parameters of these three patients did not 
differ from those of the eight patients for whom a positive correlation was found. 
An example of the positive correlation between skin temperature and skin conductance 
for one subject is displayed in Figure 2; the Spearman’s Rho correlation coefficient for this 
subject was 0.92. 
FIGURE 2 Correlation between skin temperature and skin conductance for Subject 10. This figure is 
based on 2837 paired observations (skin conductance and skin temperature) in one subject during a 
measurement of 1 h. The Spearman’s rho correlation coefficient is 0.92 
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DISCUSSION
We found that in infants without evident pain, skin conductance was correlated with 
skin temperature. Using TrendFace and MATLAB software, we were able to analyze skin 
conductance and vital parameters in detail, focusing on the skin conductance peaks, which 
represent bursts of skin sympathetic nerve activity. Vital parameters before and after a peak 
mostly were significantly different. For skin temperature this was even the case in a median 
of 88% of the peaks. Percentages for all other four vital parameters were lower. In all 11 
infants, skin temperature was highly correlated with the skin conductance. However, this 
pilot study does not explain why there should be both positive and negative correlations 
since none of the background characteristics or vital parameters differed between patients 
for whom a negative correlation was found and those for whom a positive correlation was 
found. The possibility of coincidence cannot be excluded. Our results suggest that sympa-
thetic neural control of vital functions to maintain homeostasis (such as autoregulation of 
skin temperature) results in skin conductance peaks. 
Analysis of skin sympathetic nerve activity is not a new technique. In a review article on mi-
croneurographic recordings, Wallin et al. conclude that skin sympathetic nerves are mostly 
involved in thermoregulation(8). Other maneuvers that influence the sympathetic nerve 
activity are arousal, stress, respiration, sleep, cardiopulmonary receptors and pain. Four 
types of skin sympathetic nerves are distinguished vasoconstrictor, vasodilator, sudomotor 
and pilomotor. Sudomotor nerves are cholinergic and cause sweat secretion (measured as 
a peak in skin conductance) at increased activity, for example thermoregulation. Microneu-
rographic recordings from the sudomotor nerves simultaneously with skin conductance 
measurement are scarce. Macefield et al. made microneurographic recordings combined 
with skin conductance, electrocardiogram and skin blood flow(20). Sudomotor nerve activ-
ity appeared to be correlated with cardiac activity and skin conductance but not with skin 
blood flow. 
Studies that evaluated skin conductance as a means to measure (postoperative) pain report-
ed different degrees in clinical performance(12, 16). For example, Choo et al. found a weak 
correlation between skin conductance and numeric rating scale for pain (NRS-pain) in 90 
postoperative children, namely 0.21(13). They determined a cutoff value of 0.23 skin con-
ductance peaks per second for the detection of severe pain (NRS-pain 7 or higher) with a 
sensitivity of 56% and a specificity of 78%. The other study in children, by Hullett et al.(12), 
reports a better sensitivity of 90% but a lower specificity of 64%. Other relevant studies are 
listed in Table 2. Comparison between the studies is difficult, since cutoff points for the 
number of skin conductance peaks and gold standards differ between the studies. Com-
pared to skin conductance measurement, the COMFORT-behavioral scale performed better 
with a reported sensitivity of 83% and a specificity of 91%(21). Results from Loggia et al., 
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who compared skin conductance and visual analogue scale (VAS) scores in healthy adults, 
suggest that skin conductance is not a very reliable predictor of pain(22). The authors 
advise caution when using autonomic measures to infer pain. The reported poor sensitivity 
and specificity of skin conductance to measure (postoperative) pain could be a result of the 
correlation of skin conductance with for example autoregulation of the skin temperature, 
as confirmed in our study. 
TABLE 2 Studies that evaluated the performance of skin conductance as a  
measure of postoperative pain
 Ledowski (14) Ledowski (7) Hullett (12) Ledowski (16) Choo (13)
Study group 25 adults 75 adults 165 children 100 adults 90 children
Age 21 to 67 years 19 to 81 years 1 to 16 years 18 to 82 years 7 to 17 years
Cutoff value in skin 0.10 0.10 0.13 0.10 0.23
conductance peaks
per second
Gold standard NRS (by proxy) >3 NRS >3 VAS >3 NRS >3 NRS >5 NRS >6
Sensitivity 89% 89% 90% 50%  58% 56%
Specificity  74% 68% 64% 64%  61% 78%
NRS = Numeric Rating Scale, VAS = Visual Analog Scale
Limitations
None of the subjects had an arterial line for blood pressure monitoring. Therefore we were 
not able to evaluate the correlation between skin conductance and blood pressure. 
Implications
Preclinical and clinical studies in neonates, children and adults are needed to make skin 
conductance a clinically more useful measure for postoperative pain. Preclinical studies 
should use microneurography as the gold standard and measure skin conductance simulta-
neously. These studies should not only evaluate the influence of pain and other sympathetic 
activity on skin conductance, but also find certain rhythms, if any, in skin conductance 
peaks. The algorithms of the skin conductance monitor could then be made more specific 
for the measurement of pain by correcting for other sympathetic influences. 
The clinical studies then should validate the skin conductance monitor in different age 
groups such as neonates, children and adults for the measurement of (postoperative) 
pain(23). Furthermore, it could be difficult to compare pain-free and painful states in the 
same subjects and to assure stable circumstances. The clinical studies should therefore also 
integrate, for example, observational pain assessment and electroencephalography in a 
multimodal approach as applied by Slater et al.(24). This strategy could lead to a validated, 
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objective pain assessment tool that can be used in clinical practice and serve as a pharmaco-
dynamic parameter in pain research. 
Conclusions
In this pilot study we observed that, in a pain-free state, other sympathetic nerve activ-
ity, such as skin temperature autoregulation, also results in skin conductance peaks that 
are usually seen in pain states. Real-time evaluation of the sympathetic nervous system 
would be valuable for pain assessment. However, the technique should be better defined to 
increase both the sensitivity and specificity for the measurement of pain before use in daily 
practice can be advocated.
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PART 3
QUANTITATIVE  
SENSORY TESTING
kRUTGER KOPLAND
Hoe zal ik dit uitleggen, 
dit waarom
wat wij vinden niet is
wat wij zoeken?

PAIN SENSITIVITY OF CHILDREN WITH 
DOWN SYNDROME AND THEIR SIBLINGS: 
QUANTITATIVE SENSORY TESTING 
VERSUS PARENTAL REPORTS
Abraham J. Valkenburg, Monique van Dijk, Dick Tibboel
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ABSTRACT
Background
Children with Down syndrome are claimed to be less sensitive to pain. Previous studies 
showed that parents have difficulties in perceiving if their child is in pain and to identify the 
location of the pain. The aim is to compare thermal detection and pain thresholds between 
children with Down syndrome and their siblings, using qualitative and quantitative meth-
ods, as well as parental questionnaires on pain coping, pain behaviour and chronic pain.
Methods
Forty-two children with Down syndrome (mean age 12 years) and 24 siblings (mean age 
14 years) participated in this study. Tests included qualitative sensory tests, assessment of 
thermal pain and detection thresholds and parental questionnaires on developmental age, 
pain coping, pain behavior, chronic pain and the medical history. 
Results
The different sensory tests proved to be feasible in 33% to 88% of children in the Down 
syndrome group. Children with Down syndrome were less sensitive for the detection 
of cold and warmth than their siblings, but only when measured with the reaction time 
dependent method. Children with Down syndrome were more sensitive for heat pain. They 
also used less pain coping strategies than their siblings. Only 14% of the children with 
Down syndrome were able to adequately give self-report of pain versus 92% of the controls 
(P<0.001). Sixty-six percent of the children with Down syndrome were rated as less sensi-
tive to pain versus 10% of the controls (P<0.001).
Conclusion
Children with Down syndrome will remain dependent of pain assessment by proxy, since 
self-report is not adequate. Parents rate their children with Down syndrome as less sensi-
tive to pain, but this is not confirmed by quantitative sensory testing.
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INTRODUCTION
As early as 1887 John L. Down made the following observation about persons with what 
we now call Down syndrome: “common sensation is generally less acute than in ordi-
nary persons. Pain is borne with wonderful callousness.”(1). More than a century later, a 
study reported that around 30% of parents of children with Down syndrome had difficulty 
perceiving if their child is in pain and that 70% of the parents had difficulty identifying the 
location of the pain(2). These results were confirmed in a prospective study among a group 
of individuals with Down syndrome versus a control group. The individuals with Down 
syndrome had more problems to locate a painful stimulus and also reacted to the painful 
stimulus later than did the controls(3). Defrin et al. applied quantitative sensory testing 
to assess the heat pain sensitivity of 11 adults with Down syndrome and 14 controls and 
concluded that the individuals with Down syndrome were more sensitive to heat pain than 
controls (borderline significance; P=0.06)(4). 
Down syndrome is the primary cause of congenital intellectual disability worldwide. More 
than 80 different associated anomalies have been identified in children with Down syn-
drome, such as congenital heart defects, congenital duodenal obstruction, leukemia, hypo-
thyroidism, vision and hearing disorders(5, 6). Many children with Down syndrome suffer 
from such anomalies are therefore likely to experience pain from inevitable operations but 
also from, for example, orthopedic problems later on(7, 8). More knowledge on the pain 
sensitivity of children with Down syndrome and the pain coping strategies they use could 
lead to better, individualised pain management. 
The aim of the present study was to compare thermal detection and pain thresholds be-
tween children with Down syndrome and their siblings, using qualitative and quantitative 
methods, as well as parental questionnaires on pain coping, pain behaviour and chronic 
pain. 
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METHODS
Subjects and setting
This study has been approved by the local medical ethics committee of Erasmus University 
Medical Center – Sophia Children’s Hospital, Rotterdam, the Netherlands. 
Participants were recruited through the Zuid-Holland branch of the national parental or-
ganization for Down syndrome in the Netherlands. Around 80% of parents of children with 
Down syndrome are members of that organization. The Zuid-Holland area covers more 
than 20% of the Dutch population. Members with 8 to 18-year-old children received a letter 
from the organization informing them about the study and inviting them to participate. 
Those willing to participate were asked to complete a form with their contact details and 
return it in a prepaid envelope to the researcher (AJV). The researcher then contacted the 
parents to provide further information and to arrange a date for a home visit.
Parents of 42 children with Down syndrome gave written informed consent for the study, 
as well for 24 siblings without Down syndrome. Siblings of 12 years or older were asked to 
give written informed consent themselves for the study. 
Qualitative sensory testing
The child’s discriminative abilities for the perception of touch and sharpness were tested 
with the Neuropen (Owen Mumford Ltd., Oxford, UK). To test the perception of touch 
the monofilament is pressed to the skin (approximately a force of 10 gram); the sharp end 
of the device is calibrated to exert a force of 40 gram. To test the feasibility of testing the 
discriminative abilities with the Neuropen, the researcher demonstrated both ends of the 
Neuropen to the subject and asked the participant “does this feel blunt or sharp?”. If the 
subject could describe the difference between blunt and sharp, the researcher then asked 
the participant to close the eyes. The Neuropen was applied to the non-dominant arm of 
the participant (blunt – sharp – blunt – blunt – sharp). After each stimulus, the researcher 
asked “does this feel blunt or sharp?”. 
The child’s discriminative abilities for the perception of warmth and cold were tested with 
the Senselab Rolltemp (Somedic AB, Hörby, Sweden). The cold roller is 25 °C and the warm 
roller is 40 °C. To test the feasibility of testing the discriminative abilities with the Rolltemp, 
the researcher demonstrated both rollers to the participant and asked for each roller “does 
this feel warm or cold?”. If the subject could describe the difference between warmth and 
cold, the researcher then asked the participant to close the eyes. The rollers were applied 
five times to the non-dominant arm of the participant (warm – warm – cold – warm – cold). 
After each stimulus the researcher asked “does this feel warm of cold?”. 
Reaction time
The visual-motor reaction time for the dominant hand was measured with open-source 
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software (http://delphiforfun.org/Programs/Reaction_times.htm). The participant was 
asked to click the mouse as soon as the blue ball appeared on the white screen. The first 
sequence of 10 repetitions served to familiarize the participant with the test and to assess 
the feasibility. The second sequence of 10 repetitions served to measure the reaction time. 
The program calculated the mean of the 10 values.
Quantitative sensory testing
The mechanical perception threshold was tested with the Von Frey Aesthesiometer (So-
medic AB, Hörby, Sweden). The 20 nylon monofilaments each have another diameter. The 
force that is needed to buckle the hair ranges from 0.026 gram to 110 gram. The researcher 
first showed the Von Frey hairs and then asked the participant to close the eyes and to say 
“yes” as soon as the stimulus is perceived. The researcher applied the Von Frey hairs to the 
skin of the non-dominant arm, starting with the smallest hair. The test was regarded as 
feasible if the participant was able to keep the eyes closed and reacted verbally to the ap-
plication of the Von Frey hairs.
Skin temperature was measured at the thenar eminence of the non-dominant hand to en-
sure it was within the range of 27 to 37 degrees Celsius(9).
We anticipated that testing the thermal perception thresholds and pain thresholds would 
perhaps not be feasible in the children with Down syndrome. We therefore made a comic 
book to prepare the participants. The main character was a plush animal that we brought 
with us to the home visit. Her plush ‘tail’ was the thermode of the thermal sensory analyzer. 
The comic book was available online for parents and children; parents were asked to read 
the story with the child before the home visit. During the test, a hard copy of the book was 
used. Before the start of the test, the comic was read with the child and the plush animal 
was again introduced. Parents were asked to be present during the introduction and the 
test but to minimize interference with their child. Feasibility was defined by the following 
elements: the ability to indicate a change in the temperature of the thermode, the ability to 
retain attention for at least three successive stimuli, and the ability to distinguish between 
testing the detection threshold and the pain threshold (i.e. mere perception of the stimulus 
versus painfulness of the stimulus). 
Thermal thresholds were measured at the thenar eminence of the non-dominant hand, 
using the Thermal Sensory Analyzer-II (Medoc Ltd, Ramat Yishai, Israel) with the 30 by 
30 mm thermode. Baseline temperature for all measurements was 32 degrees Celsius, the 
minimum temperature was 0.0 °C and the maximum temperature was 50.0 °C. Detection 
thresholds were measured using both the method of limits (reaction time dependent) and 
the method of levels (reaction time independent). The standardized instructions were in 
accordance with other quantitative sensory testing studies in children(10-12). The only 
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adjustment was that the children were asked to release a button as soon as a stimulus was 
perceived since this is considered easier then pressing a button as in other studies. 
Six modalities were tested in the following order. 1) Detection threshold for cold (method 
of limits): Six repetitions, temperature decreased by 1.0 °C/s. Children were asked to release 
the button as soon as the cold stimulus was perceived. 2) Detection threshold for warmth 
(method of limits): Six repetitions, temperature increased by 1.0 °C/s. Children were asked 
to release the button as soon as the warm stimulus was perceived. 3) Pain threshold for 
cold (method of limits). Five repetitions, temperature decreased by 1.5 °C/s. Children were 
asked to release the button as soon as the stimulus was so cold it became painful. A note 
was made when the minimum temperature (0.0 °C) was reached. 4) Pain threshold for heat 
(method of limits): Five repetitions, temperature increased by 1.5 °C/s. Children were asked 
to release the button as soon as the stimulus was so hot it became painful. A note was made 
when the maximum temperature (50.0 °C) was reached. 5) Detection threshold for cold 
(method of levels): Children were asked per step if the cold stimulus was perceived, until 
the difference between two steps was less than 0.1 °C/s. The number of steps needed was 
recorded. 6) Detection threshold for warmth (method of levels): Children were asked per 
step if the warm stimulus was perceived, until the difference between two steps was less 
than 0.1 °C/s. The number of steps needed was recorded. 
Detection thresholds established by the method of limits were calculated as the mean value 
of the final four of the six measurements. The first two measurements served to assure that 
the child understood the test correctly. Pain thresholds established by the method of limits 
were calculated as the mean value of the final four of five measurements. The first meas-
urement served to assure that the child understood the test correctly. Detection thresholds 
established by the method of levels were measured once. If the minimum or maximum 
temperature is reached, the device records the minimum temperature (0.0 °C) / maximum 
temperature (50.0 °C) as the result. 
Questionnaires
Parents were asked to complete five questionnaires for the child with Down syndrome and 
the sibling (if applicable). The questionnaires could be completed either online (on a pass-
word protected website) or in writing.
1.  Questionnaire on the child’s medical history (medication prescriptions, surgical history, 
other medical issues), education and the family’s socioeconomic status (according to the 
standardized classification of occupations, provided by Statistics Netherlands, version 
2010). 
2.  The Vineland Adaptive Behavior Scale - Screener (Dutch version, PITS B.V., Leiden, the 
Netherlands)(13) asks parents to assess the child’s adaptive behavior. Adaptive behav-
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ior is defined as “the collection of conceptual, social and practical skills that have been 
learned by people in order to function in their everyday lives”. The questionnaire consists 
of 90 items in four domains: communication, daily living, socialization and motor skills 
(score range 0 to 180). Reference values for Dutch children with and without Down syn-
drome are available(14). 
3.  Self-developed questionnaire with qualitative and quantitative questions on pain and 
anxiety in medical and non-medical situations. Parents were asked to compare the pain 
behavior of their child with Down syndrome to children of the same age without Down 
syndrome. For example: Is your child with Down syndrome (less – equally – more) sensi-
tive for pain than children without Down syndrome? 
4.  The Pain Coping Questionnaire, is developed and validated by Reid et al.(15). Parents 
were asked to rate how often their child uses each of 39 pain coping strategies that 
represent 8 coping subscales: Information seeking, problem solving, seeking social 
support, positive self-statements, behavioural distraction, cognitive distraction, external-
izing, internalizing/catastrophizing. The questionnaire was translated into Dutch using 
forward-backward translation by two independent translators. 
5.  The Chronic Pain Questionnaire, is developed and validated by Perquin et al.(16). This 
questionnaire asks for the incidence of pain in the past 3 months and additional in-
formation about the pain (location, frequency, duration and intensity). A pain episode 
with duration of 3 months or longer is defined as chronic pain. The original language is 
Dutch.
Statistical analysis
Summary statistics of continuous variables are presented as median [interquartile range] 
and as percentage for ordinal and categorical variables. Data were compared between the 
children with and without Down syndrome using the Mann-Whitney test for continuous, 
non-normal data and the chi-square test (or Fisher exact test in case of low predicted cell 
counts) for nominal data. Binary logistic regression analysis was performed with the fea-
sibilities of the different tests as outcome variables and chronological age, developmental 
age and socioeconomic status as predictor variables. P values (two-sided) of less than 0.05 
are considered statistical significantly. Data were analysed by SPSS software, version 19.1 
(IBM, Armonk, NY, USA). 
Chapter 8
144
 RESULTS
Background
Background characteristics are presented in Table 1. Children with Down syndrome under-
went more often cardiac surgery and were more often treated for hypothyroidism. 
TABLE 1 Background Characteristics 
 Down syndrome (n= 42) Controls (n= 24) P value a
                            Median [IQR] or number (%) 
Sex, n(%) male 21 (50%) 16 (67%) 0.19
Age in years  11.9 [10.6 to 14.7] 13.8 [11.5 to 17.3] 0.06
Reaction time in seconds 0.84 (0.35) 0.38 (0.06) <0.001
Number of surgical interventions 2 [1 to 3] 0 [0 to 1] <0.001
Surgery for congenital heart defect 14 (34%) 0 (0%) 0.002
Hypothyreoidism  9 (22%) 0 (0%) 0.02
Socioeconomic status   
Low 7 (17%) 4 (17%) 
Middle  13 (32%) 6 (26%) 0.87
High 21 (51%) 13 (57%) 
Vineland Adaptive Behavior Scale   
Communication 32 [24 to 38] 52 [50 to 52] <0.001
Daily skills 31 [26 to 36] 44 [42 to 45] <0.001
Social 33 [28 to 35] 45 [42 to 46] <0.001
Motor 32 [27 to 35] 36 [36 to 36] <0.001
Total 123 [108 to 141] 175 [169 to 177] <0.001
% of maximum score 68 [60 to 78] 97 [94 to 98] <0.001
Developmental age in years 4.6 [4.1 to 5.3]  
a P value from Mann Whitney U test or Fisher Exact test   IQR= Interquartile Range
Feasibility
All qualitative and quantitative sensory tests were feasible in 100% of the controls. 
The feasibility in the children with Down syndrome ranged from 88% for the Rolltemp 
test and the Von Frey hair test to 33% for the detection thresholds for warmth (method 
of levels) (see Figure 1). Logistic regression analysis revealed that chronologic age was a 
significant covariable for the feasibility of the warm detection threshold as well as for cold 
and heat pain threshold testing (P=0.02, P=0.04 and P=0.02 respectively), i.e. the tests were 
more often feasible in older children than in younger children. The feasibility of the tests 
was not predicted by developmental age or socioeconomic status. 
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FIGURE 1 Feasibility rates of sensory tests in children with Down syndrome. The striped sections of the 
bars represent percentages of children in whom testing was feasible; numbers in the bars are the num-
bers of children. Not all tests were applied to every subject.
Qualitative sensory tests
Twenty-one (70%) of the children with Down syndrome made one or more mistakes with 
the Neuropen test (distinguishing sharp and blunt) versus 8 (35%) of the controls (P=0.01). 
Ten (32%) of the children with Down syndrome made one or more mistakes with the 
Rolltemp test (distinguishing warmth and cold) versus none of the controls (P=0.003). 
Quantitative sensory tests
The mechanical detection threshold determined with the Von Frey hairs was 0.026 gram 
(the fi rst hair) in 21 (91%) of the control group versus in 16 (53%) of the Down syndrome 
group (P=0.003). 
The reaction time of the children with Down syndrome was signifi cantly longer than that of 
the controls (P<0.001), see Table 1.
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The results for the detection thresholds and pain thresholds are displayed in Table 2. 
Detection thresholds for cold and warmth (method of limits) were significantly higher in 
the Down syndrome group compared to the control group (P=0.001 and P<0.001 respec-
tively). However, when measured with the method of levels, the detection thresholds for 
warmth and cold were not statistically significant between both groups. This difference 
between the method of limits and method of levels for the Down syndrome group could 
be explained by the longer reaction time of the children with Down syndrome. The detec-
tion threshold for warmth measured with the method of limits (a reaction time dependent 
method) is statistically significantly correlated with the reaction time (0.59; 95% CI 0.25 to 
0.80; P=0.002), but the detection threshold for warmth measured with the method of levels 
(a reaction time independent method) is not statistically significantly correlated with the 
reaction time (0.19; 95%CI -0.40 to 0.67; P=0.54). Pain thresholds in the Down syndrome 
group were lower than those in controls; the heat pain thresholds were statistically signifi-
cantly lower (P=0.03) and the cold pain threshold were borderline statistically significantly 
lower (P=0.06). There was a trend that more controls perceived no heat or cold pain before 
reaching 50 °C or 0 °C, respectively, than did children with Down syndrome, however this 
was not statistically significantly different (P=0.10 and P=0.09 respectively). 
TABLE 2 Quantitative sensory testing 
 Down Controls (n=21) P value
 syndrome (n=41)
Detection threshold cold (MLI) 26.4 (3.7) 30.5 (0.6) 0.001
Detection threshold warmth (MLI) 37.1 (2.0) 34.1 (1.1) <0.001
Pain threshold cold (MLI) 13.5 (7.8) 7.2 (7.0) 0.06
Threshold not reached 1 (8%) 4 (36%) 0.09
Pain threshold heat (MLI) 44.7 (3.0) 47.0 (3.4) 0.03
Threshold not reached 3 (15%) 8 (38%) 0.10
Detection threshold cold (MLE) 29.4 (3.0) 30.6 (1.1) 0.23
Detection threshold warmth (MLE) 34.6 (2.8) 33.4 (0.9) 0.11
MLI = Method of Limits , MLE = Method of Levels
Questionnaires
The questionnaires were completed for 41 (98%) of the children with Down syndrome and 
22 (92%) of the controls. 
Of the children with Down syndrome, 36 (85%) were able to verbalize pain versus 20 (95%) 
of the controls (P=0.65). However, only 6 (14%) of the children with Down syndrome were 
able to verbalize, localize and tell the intensity of the pain according to their parents, versus 
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22 (92%) of the controls (P<0.001).
Sixty-six percent of the children with Down syndrome were rated as less sensitive to pain 
versus 10% of the controls (P<0.001). Children with Down syndrome were seen as more 
anxious in a medical situation than controls, especially during venepuncture (73% versus 
14%; P<0.001), see Table 3. Incidence of an episode of pain in the last three months was 
comparable between both groups, as well as the incidence of chronic pain (duration > 3 
months) (See Table 3)
TABLE 3 Pain behaviour and chronic pain 
 Down syndrome (n=41) Controls (n=22) P value
Chronic Pain Questionnaire   
Episode of pain in last 3 months 15 (37%) 9 (41%) 0.74
Duration of pain > 3 months 3 (7%) 1 (4%) 0.74
Anxiety in medical situations   
Visiting a doctor 10 (24%) 0 (0%) 0.01
Visiting a dentist 13 (32%) 3 (14%) 0.12
Undergoing a vaccination 24 (59%) 2 (9%) <0.001
Undergoing a venepuncture 30 (73%) 3 (14%) <0.001
Difficulties to assess if 32 (78%) 4 (19%) <0.001
your child is in pain?
Pain sensitivity, compared to other children
Less sensitive 27 (66%) 2 (10%) 
Equally sensitive 11 (27%) 17 (85%) <0.001
More sensitive 3 (7%) 1 (5%) 
Difficulties to console my child, in comparison with other children
Less difficult 7 (17%) 2 (10%)   
Equally difficult  30 (73%) 17 (85%) 0.71
More difficult 4 (10%) 1 (5%) 
Difficulties to explain the episode of pain, compared to other children
Less difficult 2 (5%) 3 (15%) 
Equally difficult 16 (39%) 16 (80%) <0.001
More difficult 23 (56%) 1 (5%) 
Abilities to locate the pain, compared to other children
Less able to 21 (52%) 1 (5%)   
Equally able to 19 (46%) 16 (80%) <0.001
More able to  1 (2%) 3 (15%) 
Abilities to verbalize the intensity of the pain, compared to other children
Less able to 32 (78%) 1 (5%)   
Equally able to 8 (20%) 17 (85%) <0.001
More able to 1 (2%) 2 (10%) 
Missing data: n=1 with Down syndrome; n=2 controls
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Pain coping
The results of the pain coping questionnaire are displayed in Table 4. The children with 
Down syndrome were rated significantly lower than controls on the subscales information 
seeking, problem solving, seeking social support and positive self-statements. 
For the Down syndrome group, the use of information seeking, problem solving and seek-
ing social support coping strategies was significantly correlated with their developmental 
age (respectively 0.56, 95% CI 0.30 to 0.74, (P<0.001, 0.50, 95%CI 0.23 to 0.70, (P=0.002) 
and 0.44, 95%CI 0.15 to 0.66, (P=0.004)). 
TABLE 4 Pain Coping 
 Down syndrome (n=41) Controls (n=22) P value
Information seeking 1.8 [1.0 to 2.3] 3.1 [2.4 to 3.8] <0.001
Problem solving 1.5 [1.0 to 2.5] 3.3 [2.5 to 3.7] <0.001
Seeking social support 2.4 [1.6 to 3.2] 3.0 [2.6 to 3.6] 0.009
Positive self-statements 1.0 [1.0 to 2.4] 2.7 [2.2 to 3.6] <0.001
Behavioural distraction 3.0 [2.0 to 3.2] 3.0 [2.4 to 3.6] 0.30
Cognitive distraction 2.8 [1.6 to 3.5] 3.0 [2.6 to 3.2] 0.45
Externalizing 1.4 [1.0 to 1.8] 1.2 [1.0 to 1.8] 0.91
Internalizing / catastrophizing 1.4 [1.0 to 1.9] 1.5 [1.0 to 2.2] 0.38
Cronbach’s alpha 0.68 0.76 
Cronbach’s alpha (standardized) 0.67 0.73
Missing data: n=1 with Down syndrome; n=2 controls
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DISCUSSION
Summary
Qualitative sensory testing is feasible in the majority of children with Down syndrome, 
whereas quantitative sensory testing is more difficult and therefore less feasible in chil-
dren with Down syndrome. The results show that it takes longer for children with Down 
syndrome to detect a warm or cold stimulus and that there is a trend for lower heat and cold 
pain thresholds, compared to siblings without Down syndrome. Two-third of the parents 
reported that their child with Down syndrome is less sensitive to pain and that the child 
uses fewer pain coping strategies than do the siblings. 
Feasibility
The different qualitative and quantitative sensory tests were feasible in only 33% to 88% 
of the children with Down syndrome. De Graaf et al. found that measuring warm and 
cold detection thresholds was feasible in 81% of 5-year-old children(11). Testing the pain 
thresholds with quantitative sensory testing is generally feasible in children of 7 years and 
older(17). Defrin et al. did not report any results on the feasibility of quantitative sensory 
testing in intellectually disabled adults(4). Feasibility of the more complicated quantitative 
sensory testing tests (such as pain thresholds and detection thresholds according to the 
method of levels) was limited in the children with Down syndrome and was significantly 
lower in the children with a lower chronological age but not in children with a lower devel-
opmental age. The limited variability in the developmental age of children with Down syn-
drome could explain why it is not found as a covariate for the feasibility, since the interquar-
tile range for developmental age was 1.2 years versus 4.1 years for the chronological age. 
The limited feasibility of the different tests is an important finding, but it makes it difficult 
to draw overall conclusions on the pain sensitivity of children with Down syndrome. 
Sensory testing
Children with Down syndrome were well able to distinguish between a warm and a cold 
stimulus. Distinguishing between sharp and blunt was more difficult, seeing that 70% 
made one or more mistakes. 
Quantitative sensory testing is more complex, since the intensity of the stimulus increases 
during the test. Children with Down syndrome responded slower to a hot or cold stimulus 
(detection threshold), probably due to delayed peripheral conduction of the stimulus and 
delayed cerebral processing, since previous studies found that the sensory nerve conduc-
tion velocities of children with Down syndrome are prolonged(18) and the inter-hemispher-
ic transmission time of adults with Down syndrome is longer than in controls(19).
With regard to the hot and cold pain thresholds; children with Down syndrome are more 
sensitive for heat pain and there is a trend that they are more sensitive to cold pain. Defrin 
et al. also found that adults with Down syndrome are more sensitive for heat pain, but this 
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did not reach statistical significance(4). The reaction time of the subjects in their study 
based on the difference in pain thresholds obtained with the method of limits (reaction 
time dependent) and the method of levels (reaction time independent) was prolonged and 
the authors therefore recommended the method of levels in intellectually disabled subjects. 
Our findings support this recommendation, since the visuomotor reaction time was signifi-
cantly correlated (r 0.59) with the detection threshold for warmth measured with the meth-
od of limits, but not when measured with the method of levels. The method of levels would 
therefore be preferable over the method of limits, but the feasibility of the method of levels 
was poor in the children with Down syndrome compared to the feasibility of the method of 
limits. A small-scale study found that pain thresholds in children were stable over short re-
test intervals, but that thresholds significantly decreased over longer retest intervals (mean 
interval of 16 months)(20). Future quantitative sensory studies should therefore assess the 
detection and pain thresholds over time to verify stability of the thresholds. 
Quantitative sensory testing versus proxy (parental) report 
Although the quantitative sensory testing results suggest that children with Down syn-
drome are more sensitive to heat and cold pain, their parents reported in 66% of the cases 
that their child was less sensitive to pain. What could be the reason for this discrepancy? 
Parents see their child daily, whereas we tested the thermal detection and pain thresholds 
only on one occasion and the pain thresholds only in a subset of the children. In addition, 
Edwards et al. showed that there is no correlation between self-report of pain sensitivity 
and results of pain threshold testing in adults(21). We assume that parents will rate their 
child as less sensitive based on occasions when the child did not respond to an obvious 
painful stimulus or event in the way the parents expected. The lesser ability of children with 
Down syndrome to rate the intensity of the pain or to localize the pain supports this idea. 
The verbal and non-verbal pain expressions of children with Down syndrome are probably 
different from what we expect. Parents see this as less sensitive to pain, but this perception 
is not confirmed by quantitative sensory testing. 
Pain coping
The children with Down syndrome used fewer pain coping strategies than did their 
siblings. The four less often used coping strategies all belong to the high-order factor 
approach (attempts to deal with pain and emotional distress when in pain)(15). The use 
of coping strategies of the two other high-order factors (problem- and emotion-focussed 
avoidance) was comparable between the children with Down syndrome and their siblings. 
Burkitt et al. found that pain coping of intellectually disabled children and adults is highly 
dependent of their cognitive age, as was confirmed in the present study(22). Caregivers 
should be aware that children with Down syndrome do not make many attempts to deal 
with the pain, but use primarily distraction coping styles. 
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Self-report
LaChapelle et al. found that 65% of intellectually disabled adults was able to provide self-
report of pain(23). Adequate self-report of pain requires the ability to quantify the pain and 
localize the pain(24, 25). Although 85% of the children with Down syndrome in the present 
study could verbalize the pain, no more than 20% was able to quantify the pain and only 
46% was able to localize the pain. The abilities of children with Down syndrome to provide 
an adequate self-report for pain are rather limited, so that they will have to rely on caregiv-
ers for their pain assessment.  
Limitations
We tested more children with Down syndrome than siblings, since not all children with 
Down syndrome had a sibling who met the inclusion criteria. By recruiting the subjects 
through the parental organization for Down syndrome in the Netherlands, we hoped to 
reach a more representative population than by recruiting children seen in the outpatient 
clinics of our hospital. However, this strategy could also have resulted in a selection bias, 
since parents who did not participate often motivated this by pointing out that their child 
had many medical problems. Furthermore, around 80% of parents of children with Down 
syndrome in the Netherlands are members of the organization, so this could have resulted 
in a potential selection bias as well. 
Implications
From a clinical point of view, it will be important to investigate the pain expression of 
children and adults with Down syndrome after surgery and to find appropriate assessment 
tools for chronic pain. Even if the individual can verbalize pain, it will still be necessary for 
caregivers to apply observational pain assessment tools. Caregivers should anticipate that 
children with Down syndrome do use problem and emotion avoidance pain coping styles, 
and they should support the use of those coping styles with (developmental) age appropri-
ate distraction methods. 
From a research point of view, the poor feasibility of currently used quantitative sensory 
tests necessitates the use of other methods to quantify the pain behaviour of children with 
Down syndrome. Functional Magnetic Resonance Imaging (fMRI)(26) or electroencepha-
lography (EEG)(27) could help elucidate the cerebral processing of sensory and painful 
stimuli in children with Down syndrome. Another quantitative sensory testing modality, 
diffuse noxious inhibitory control (DNIC), could give insight into the inhibitory potential of 
individuals with Down, but this test may be too complex to be feasible(28). 
Conclusions
Only a minority of children with Down syndrome is able to use adequate self-report of pain 
according to their parents. This skill is probably required for quantitative sensory testing 
as well, since the feasibility of the tests was poor. In accordance with previous studies in 
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adults with Down syndrome, we found that children with Down syndrome were less sensi-
tive for the detection of cold and warmth than their siblings, but they were more sensitive 
for heat pain than their siblings. 
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ABSTRACT
Short-term and long-term effects of neonatal pain and its analgesic treatment have been 
topics of translational research over the years. The present study aimed to identify possible 
long-term effects of continuous morphine infusion on thermal pain sensitivity, incidence of 
chronic pain and neurological functioning. Eighty-nine of the 150 participants of a neona-
tal RCT on continuous morphine infusion versus placebo during mechanical ventilation 
underwent quantitative sensory testing and neurological examination at the age of 8 or 
9 years. Forty-three children from the morphine group and 46 children from the placebo 
group participated. Thermal detection and pain thresholds were compared to data of 139 
historical controls. Multivariate analyses revealed no statistically significant differences 
in thermal detection thresholds and pain thresholds between the morphine and placebo 
group. More children in the morphine group experienced an episode of pain in the three 
months before the follow-up visit compared to the placebo group, but the incidence of 
chronic pain (>3 months) was comparable. Neurological examination was normal in the 
majority of the children; mild deviations in coordination and balance were present in 7/9 
(78%) of the morphine group versus 5/16 (31%) of the placebo group (P=0.04). We found 
in the present study that neonatal continuous morphine infusion (10 mcg/kg/hr) has no 
adverse effects on thermal detection and pain thresholds or overall neurological function-
ing eight to nine years later.
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INTRODUCTION
Providing adequate and evidence-based analgesia and sedation to newborns receiving 
intensive care is an ongoing challenge; one has to account for developmental changes in 
drug pharmacokinetics and pharmacodynamics as well as in the human nervous system(1, 
2). The short-term and long-term effects of neonatal pain and its analgesic treatment have 
become topics of translational research. The repeated painful procedures in intensive care 
can lead to short-term hyperalgesia(3). Long-term follow-up of the extremely preterm born 
showed a generalized decrease of thermal sensitivity, probably due to tissue injury and 
modulation of nociceptor pathways(4). Opioids have both beneficial and adverse short-
term effects. Morphine is an effective analgesic agent for newborns’ postoperative pain but 
not acute procedural pain(5-8). However, continuous morphine infusion does not lower the 
risk of poor neurological outcome after intensive care(7). Animal studies have shown nega-
tive long-term effects of neonatal morphine on cognitive functioning and proliferation of 
damaged astrocytes(9-11). Participants of two RCTs on neonatal morphine administration 
were studied again five years after the original RCT(7, 8). The one, a small-scale follow-
up of the NEOPAIN trial, showed that children who had received morphine (n=14) had a 
smaller head circumference, weighed less, and had more social problems than children 
who had received placebo (n=5)(12). The other, performed in our institution, showed that 
children who had received morphine (n=49) performed more poorly on one subtest of the 
intelligence scale than did the children who had received placebo (n=41); other neurobe-
havioral outcomes and the incidences of chronic pain were comparable between the two 
groups(13). This unique cohort is being followed and at the age of 8 years, participants 
were old enough for quantitative sensory testing(14). 
Morphine is used world wide for opioid analgesia in neonates, infants and children. 
In the present study we aimed to identify any adverse effects of continuous morphine infu-
sion on thermal detection thresholds and pain thresholds, incidence of chronic pain, and 
neurological functioning at 8 to 9 years of age. 
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METHODS
Original study
Between 2000 and 2002, 150 neonates who received mechanical ventilation in two level III 
neonatal intensive care units participated in a multi-center randomized controlled trial. 
Seventy-three neonates were randomly assigned to the continuous morphine group (load-
ing dose of 100 mcg/kg followed by infusion of 10 mcg/kg/hr) and 77 to the placebo group 
(normal saline). If pain or distress was noted, children in both groups received open-label 
morphine bolus of 50 mcg/kg and, if indicated, open-label morphine infusion (5-10 mcg/
kg/hr) as rescue medication. Open-label morphine was administered to 27% of the children 
in the morphine group versus 40% of the placebo group (P=0.10). Further details, includ-
ing background characteristics of the participants, can be found in the original article(7). 
Follow-up study (8 to 9 year)
The institutional ethics review boards of the two study sites (Erasmus University Medical 
Center - Sophia Children's Hospital, Rotterdam, the Netherlands and Isala Clinics, Zwolle, 
the Netherlands) approved the study plan. Parents of the 132 survivors were informed of the 
study and were asked for written informed consent. Seventeen participants from the mor-
phine group were lost to follow-up and 5 parents refused informed consent for the follow-up 
study. Sixteen patients of the placebo group were lost to follow-up and 5 parents refused 
informed consent for the follow-up study. The remaining 89 children and their parents were 
then invited for a follow-up visit in their hospital (either Rotterdam or Zwolle)(See Figure 1). 
Parents were asked to complete several questionnaires (see below) before the visit. The 
visit consisted of three parts: Quantitative sensory testing by a trained researcher, medi-
cal examination by a pediatrician and neuropsychological testing by a psychologist. These 
health professionals were blind to the participants’ study condition (continuous morphine 
infusion versus placebo) in the original RCT. 
Quantitative sensory testing
Participants underwent quantitative sensory testing in a quiet hospital room, with a stable 
room temperature (20 to 22 degrees Celsius). Parents were present in the room and were 
instructed ‘not to interfere during the test’. Reaction time was measured using the baseline 
speed task for the dominant hand (Amsterdam Neuropsychological Tasks, Version 3.1, 
Boom test publishers, Amsterdam, the Netherlands). This computerized visual-motor task 
includes 32 repetitions. Skin temperature was measured at the thenar eminence of the non-
dominant hand to confirm it was within the range of 27 to 37 degrees Celsius(15).
Thermal thresholds were measured at the thenar eminence of the non-dominant hand, 
using the Thermal Sensory Analyzer-II (Medoc Ltd, Ramat Yishai, Israel) with the 30 by 
30 mm thermode. Baseline temperature for all measurements was 32 degrees Celsius, 
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the minimum temperature was 0.0 °C and the maximum temperature was 50.0 °C. Detec-
tion thresholds were measured using both the method of limits (reaction time dependent) 
and the method of levels (reaction time independent). The standardized instructions were 
in accordance with other quantitative sensory testing studies in children(14, 16, 17). Six 
modalities were tested in the following order. 1) Detection threshold for cold (method of 
limits): Six repetitions, temperature decreased by 1.0 °C/s. Children were asked to press 
the button as soon as the cold stimulus was perceived. 2) Detection threshold for warmth 
(method of limits): Six repetitions, temperature increased by 1.0 °C/s. Children were asked 
to press the button as soon as the warm stimulus was perceived. 3) Pain threshold for cold 
(method of limits). Five repetitions, temperature decreased by 1.5 °C/s. Children were asked 
to press the button as soon as the stimulus was so cold it became painful. A note was made 
when the minimum temperature (0.0 °C) was reached. 4) Pain threshold for heat (method 
of limits): Five repetitions, temperature increased by 1.5 °C/s. Children were asked to press 
the button as soon as the stimulus was so hot it became painful. A note was made when the 
maximum temperature (50.0 °C) was reached. 5) Detection threshold for cold (method of 
levels): Children were asked per step if the cold stimulus was perceived, until the differ-
ence between two steps was less than 0.1 °C/s. The number of steps needed was recorded. 
6) Detection threshold for warmth (method of levels): Children were asked per step if the 
warm stimulus was perceived, until the difference between two steps was less than 0.1 °C/s. 
The number of steps needed was recorded. 
Detection thresholds established by the method of limits were calculated as the mean value 
of the final four of the six measurements. The first two measurements were used to assure 
that the child understood the test correctly. Pain thresholds established by the method of 
limits were calculated as the mean value of the final four of five measurements. The first 
measurement was used to assure that the child understood the test correctly. Detection 
thresholds established by the method of levels were measured once. In case the participant 
did not establish a pain threshold before the minimum or maximum temperature was 
reached, the device recorded the minimum temperature (0.0 °C) / maximum temperature 
(50.0 °C) as the result. 
Reference data quantitative sensory testing (historical controls)
Reference values for quantitative sensory testing in 139 children between 7 and 11 years 
have been collected by our group.(http://repub.eur.nl/res/pub/8210/Early%20Pain.pdf ). 
Subjects (ages 7 through 11 years) were recruited at two elementary schools in the reference 
area of the Erasmus University Medical Center – Sophia Children’s Hospital, Rotterdam, 
the Netherlands. The local ethics committee and the Dutch Central Committee on Research 
involving Human Subjects approved the study. Parents provided written informed consent 
for the study. Exclusion criteria were a history of surgery or admission to a neonatal inten-
sive care unit. 
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The cold/warm detection and cold/heat pain thresholds were obtained using the method of 
limits. Instructions and methods were the same as in the present study. The only difference 
was that the lower limit for the cold pain threshold was -10 °C, where nowadays 0.0°C is the 
lower limit.  
All 139 subjects were tested between July 2004 and August 2005. Eighty-one (58%) of them 
were male. The median [IQR] age was 8 [7 to 9] years. 
Questionnaires
The participants’ parents completed the Vineland Adaptive Behavior Scale - Screener 
(Dutch version, PITS B.V., Leiden, the Netherlands)(18); the four domains of this scale are 
communication, daily living, socialization and motor skills. Parents also completed the 
Chronic Pain Questionnaire (Dutch version)(19); this questionnaire asks for the incidence 
of pain in the 3 months before the visit and additional information about the pain (location, 
frequency, duration and intensity). 
Medical examination
All children were examined by a pediatrician and were, if indicated, referred for further 
diagnosis or treatment. Weight, height and head circumference were measured and plot-
ted against sex-matched reference values for the Netherlands (4th nation-wide growth 
study 1997). The neurological examination was based on the Touwen assessment of minor 
neurological dysfunctions.(20) We assessed 41 items in 5 domains (posture/muscle tone, 
reflexes, involuntary movements, coordination/balance and cranial nerve dysfunctions). 
Minor neurological dysfunctions were defined as the presence of 2 or more deviant items in 
at least one domain. 
Neuropsychological testing
A trained psychologist tested the children’s intelligence quotient (IQ) with the Wechsler 
Intelligence Scale for Children - III (Dutch version). 
Statistical analysis
Summary statistics of continuous variables are presented as median [interquartile range] 
and as percentage for ordinal and categorical variables. Data were compared between the 
continuous morphine and the placebo group using the Mann-Whitney test for continuous, 
non-normal data and the chi-square test (or Fisher exact test in case of low predicted cell 
counts) for nominal data. The quantitative sensory testing data is compared to reference 
values of 139 historical controls using analysis of variance with post-hoc Bonferroni correc-
tion for multiple comparisons. 
For the multivariate analysis of the quantitative sensory testing data, we built step-wise 
robust regression models for each of the six modalities, using robust regression procedure 
with MM estimation(21). We applied this method for the very reason that the outcome vari-
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ables were non-normally distributed. Tukey bisquare estimator was the weight function. In 
the fi rst model, we added the treatment condition (continuous morphine versus placebo) 
and the amount of additional morphine in the fi rst 28 days after birth as covariables. In the 
second model, we added sex and study site (Rotterdam versus Zwolle) as additional covari-
ables. In the third model, we added the intelligence quotient as additional covariable. For 
the model on the cold pain threshold we added fl oor (pain threshold was not reached at 
minimum) and for the heat pain threshold ceiling (pain threshold was not reached at maxi-
mum) as covariable in all three models. For each model, we present the unstandardized 
regression estimates, including the 95% confi dence intervals and P values (chi-square test). 
Logistic regression analyses were applied with prevalence of pain and chronic pain as 
dichotomous outcome variables and the treatment condition (continuous morphine versus 
placebo) and the amount of additional morphine in the fi rst 28 days after birth as predictor 
variables.
P values (two-sided) of less than 0.05 are considered statistical signifi cantly. Data were ana-
lyzed by SPSS software, version 19.1 (IBM, Armonk, NY, USA) and SAS, version 9.2 (SAS, 
Cary, NC, USA). 
FIGURE 1 Flowchart based on the CONSORT fl owchart
Participated in neonatal study 
(N=150) 
18 neonatal non-survivors 
Analyzed (n=43) 
 
 Follow up visit + questionnaires 
(n=39) 
 Questionnaires (n=4) 
Invited for follow-up (8 year) 
(n=132) 
Morphine group (n=65) Placebo group (n=67) 
Excluded (n=22) 
t Lost to follow-up (n=17) 
t No informed consent (n=5) 
Excluded (n=21) 
t Lost to follow-up (n=16) 
t No informed consent(n=5) 
Analyzed (n=46) 
 
 Follow up visit + questionnaires 
(n=41) 
 Questionnaires (n=5)  
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RESULTS
Background characteristics
Of the 132 survivors, 43 children from the morphine group and 46 children from the pla-
cebo group participated in this follow-up study (See Figure 1). Their mean age was now 8.9 
years. Background characteristics were comparable between the two groups (see Table 1). 
Mean IQ was 101 (SD 18) for the placebo group versus 99 (SD 19) for the morphine group (P 
= 0.63). 
TABLE 1 Background Characteristics (distinguished by group) 
 Placebo group (n= 46) Morphine group (n=43) P value a
                                  Median [IQR] or number (%) 
Sex, n(%) male 28 (61) 28 (65) 0.83 
Birth characteristics    
Gestational age in weeks 31 (28 to 32) 30 (29 to 32) 0.39
        Birthweight in grams 1520 (995 to 2145) 1400 (1024 to 1788) 0.70
Age in years  8.9 [8.7 to 9.3] 8.9 [8.8 to 9.1] 0.54
Height in cm 137 [131 to 140] 135 [131 to 140] 0.42
SDS height for age b 0.02 [-0.7 to 1.1] -0.04 [-0.5 to 0.7] 0.72
Weight in kg 29.2 [26.5 to 32.8] 27.9 [24.6 to 31.6] 0.29
SDS weight for age b 0.05 [-0.6 to 0.7] 0.01 [-1.3 to 0.8] 0.53
Head circumference in cm 52 [51 to 53] 52 [51 to 54] 0.90
SDS head circumference for age b -0.20 [-0.8 to 0.7] -0.03 [-1.0 to 0.6] 0.92
IQ c  101 (18) 99 (19) 0.63
Developmental age in months d 72 [67 to 77] 73 [69 to 77] 0.41
Reaction time in ms e 391 [354 to 442] 390 [331 to 442] 0.82
Test location Rotterdam, n(%) 25 (54) 25 (58) 0.83
a Mann-Whitney test for continuous variables and Fisher exact test for categorical variables
b According to reference values (the Netherlands 1997)
c Intelligence Quotient (Wechsler Intelligence Scale for Children), mean (SD), P value from t test
d Vineland Adaptive Behavior Scale
e Amsterdam Neuropsychological Tasks 
IQR = Interquartile Range ; cm = centimeter ; kg = kilogram ; ms = milliseconds  
Quantitative sensory testing
Quantitative Sensory Testing (QST) was performed in 41(89%) of the placebo group and 
in 37(86%) of the morphine group. Nine children did not attend the follow-up visit (but 
completed the questionnaires) and the equipment was not available in the remaining 2 oc-
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casions. QST was feasible in all subjects with regard to understanding the instructions and 
completing the test. 
Univariate analysis showed that these children (both morphine and placebo group) were 
more sensitive for the detection of cold (method of limits), compared to the historical con-
trols (P=0.002 and P=0.005 respectively). The children in the morphine group were more 
sensitive for the detection of cold than the children in the placebo group (method of levels, 
P=0.045) (see Table 2).
Ten (24%) of the children in the placebo group did not establish a pain threshold for cold 
before the minimum temperature (0.0 °C) was reached, versus 9 (25%) of the morphine 
group (P=0.82). Ten (24%) of the children in the placebo group did not establish a pain 
threshold for heat before the maximum temperature (50.0 °C) was reached, versus 8 (22%) 
of the children in the morphine group (P=0.95). 
TABLE 2 Results of quantitative sensory testing, distinguished by group
 Placebo Morphine Historical P value a
 group(n= 41) group(n= 37) controls (n=139)
                Mean (standard deviation) or number (%)  
Method of Limits   
Cold detection threshold in °C  29.6 (2.4) 29.9 (1.4) 28.1 (3.1) <0.001 c
Warm detection threshold in °C 34.8 (1.4)  34.5 (1.4) 34.7 (2.2) 0.70
Cold pain threshold in °C 11.8 (8.4) 12.3 (8.9) 8.5 (9.7) 0.06
Threshold not reached b 10 (24%) 9 (25%)  0.82
Heat pain threshold in °C 45.0 (3.5) 44.9 (4.3) 44.8 (4.7) 0.97
Threshold not reached b 10 (24%) 8 (22%)  0.95
Method of Levels    
Cold detection threshold in °C 30.7 (1.2) 31.1 (0.7)  0.045
Number of stimuli 11 (3) 10 (2)  0.32
Warm detection threshold in °C 33.3 (1.1) 33.2 (1.1)  0.74
Number of stimuli 11 (4) 10 (2)  0.15
a    ANOVA test for the comparison between the three groups, t-test for continuous variables and Fisher exact test for 
categorical variables
b   Patients in whom 1 or more times the pain threshold was not reached (the child did not press the button before the 
temperature of the thermode reached its minimum/maximum (0.0 °C and 50.0 °C respectively)
c  Post-hoc Bonferroni correction: Placebo group versus Controls P=0.005 and Morphine group versus Controls P=0.002 
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TABLE 3 Regression estimates of intervention, with and without adjustment for different 
covariables: Detection thresholds (method of limits) 
 Estimate 95% CI limits P value
DETECTION TRESHOLD FOR COLD
1  Intercept 30.13 29.85 to 30.41 <0.0001
  Treatment condition a 0.21 -0.18 to 0.60 0.29
  Additional morphine b 0.00 -0.0002 to 0.0002 0.81
2 Intercept 30.21 29.79 to 30.63 <0.0001
   Treatment condition a 0.22 -0.19 to 0.62 0.29
   Additional morphine b 0.00 -0.0002 to 0.0003 0.85
   Sex -0.096 -0.51 to 0.32 0.65
   Study site -0.047 -0.46 to 0.37 0.82
3 Intercept 28.95 27.80 to 20.09 <0.0001
   Treatment condition a 0.25 -0.15 to 0.64 0.22
   Additional morphine b 0.0001 -0.0002 to 0.0003 0.57
   Sex -0.15 -0.56 to 0.26  0.48
   Study site -0.012 -0.42 to 0.39 0.95
   IQ c 0.012 0.0016 to 0.0228 0.024
DETECTION THRESHOLD FOR WARMTH
1  Intercept 34.58 34.11 to 35.04 <0.0001
   Treatment condition a -0.35 -0.98 to 0.29 0.29
   Additional morphine b 0.00 -0.0003 to 0.0004 0.87
2  Intercept 34.18 33.50 to 34.86 <0.0001
   Treatment condition a -0.37 -1.006 to 0.26 0.25
   Additional morphine b 0.00 -0.0003 to 0.0004 0.82
   Sex 0.33 -0.33 to 0.99 0.33
   Study site 0.37 -0.27 to 1.01 0.26
3  Intercept 36.51 34.76 to 38.25 <0.0001
   Treatment condition b -0.50 -1.09 to 0.10 0.10
   Additional morphine c 0.00 -0.0004 to 0.0003 0.88
   Sex 0.39 -0.23 to 1.01 0.21
   Study site 0.44 -0.16 to 1.04 0.15
   IQ c -0.023 -0.039 to -0.0069 0.005
a Morphine group versus placebo group
b Additional morphine in first 28 days 
c Intelligence Quotient (Wechsler Intelligence Scale for Children)
CI = Confidence Interval
169
a Morphine group versus placebo group  b Additional morphine in first 28 days  c Pain threshold was not reached in one 
of more occasions  d Intelligence Quotient (Wechsler Intelligence Scale for Children)  CI = Confidence Interval
TABLE 4 Regression estimates of intervention, with and without adjustment for different 
covariables: Pain thresholds (method of limits) 
 Estimate 95% CI limits P value
PAIN TRESHOLD FOR COLD
1  Intercept 14.26 11.75 to 16.76 <0.0001
Treatment condition a 1.67 -1.58 to 4.93 0.31
Additional morphine b -0.0013 -0.0032 to 0.0007 0.22
Floor  c -4.49 -5.73 to -3.25 <0.0001
2  Intercept 16.35 13.31 to 19.40 <0.0001
Treatment condition a 2.21 -0.66 to 5.08 0.13
Additional morphine  b -0.0014 -0.0032 to 0.0004 0.12
Sex 0.65 -2.34 to 3.65 0.70
Study site -5.38 -8.30 to -2.46 0.0003
Floor c -4.20 -5.31 to -3.09 <0.0001
3  Intercept 15.27 6.98 to 23.56 0.0003
Treatment condition a 2.23 -0.67 to 5.13 0.13
Additional morphine b -0.0014 -0.0032 to 0.0004 0.14
Sex 0.52 -2.53 to 3.57 0.74
Study site -5.42 -8.37 to -2.47 0.0003
IQ d 0.012 -0.067 to 0.090 0.77
Floor c -4.19 -5.31 to -3.07 <0.0001
PAIN TRESHOLD FOR HEAT
1  Intercept 44.01 42.93 to 45.10 <0.0001
Treatment condition a 0.42 -1.05 to 1.88 0.58
Additional morphine b -0.0004 -0.0031 to 0.0005 0.40
Ceiling c 1.74 1.21 to 2.27 <0.0001
2  Intercept 44.02 42.48 to 45.57 <0.0001
Treatment condition a 0.34 -1.13 to 1.81 0.65
Additional morphine b -0.0005 -0.0014 to 0.0004 0.31
Sex -0.61 -2.21 to 0.90 0.43
Study site 0.86 -0.64 to 2.36 0.26
Ceiling c 1.67 1.13 to 2.20 <0.0001
3  Intercept 45.50 41.07 to 49.93  <0.0001
Treatment condition a 0.36 -1.10 to 1.82 0.63
Additional morphine b -0.0005 -0.0014 to 0.0004 0.27
Sex -0.55  -2.05 to 0.96 0.48
Study site 0.92 -0.57 to 2.42 0.23
IQ d -0.015 -0.056 to 0.026 0.47
Ceiling c 1.61 1.07 to 2.16 <0.0001
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TABLE 5 Regression estimates of intervention, with and without adjustment for different 
covariables: Detection thresholds (method of levels) 
 Estimate 95% CI limits P value
DETECTION TRESHOLD FOR COLD
1  Intercept 31.04 30.78 to 31.30 <0.0001
Treatment condition a 0.21 -0.14 to 0.56 0.25
Additional morphine b -0.0001 -0.0003 to 0.0001 0.22
2  Intercept 31.05 30.66 to 31.44 <0.0001
Treatment condition a 0.23 -0.14 to 0.59 0.23
Additional morphine b -0.0002 -0.0004 to 0.0001 0.17
Sex -0.14 -0.52 to 0.24 0.47
Study site 0.12 -0.25 to 0.50 0.53
3  Intercept 30.74 29.66 to 31.82 <0.0001
Treatment condition a 0.24 -0.13 to 0.61 0.20
Additional morphine b -0.0002 -0.0004 to 0.0001 0.18
Sex -0.16 -0.54 to 0.23 0.43
Study site 0.13 -0.24 to 0.51 0.49
IQ c 0.0030 -0.0069 to 0.013 0.55
DETECTION TRESHOLD FOR WARMTH
1  Intercept 32.98 32.73 to 33.23 <0.0001
Treatment condition a -0.079 -0.42 to 0.26 0.65
Additional morphine b 0.0001 -0.0001 to 0.0003 0.27
2  Intercept 32.96 32.57 to 33.34 <0.0001
Treatment condition a  -0.090 -0.43 to 0.25 0.61
Additional morphine b 0.0001 -0.0001 to 0.0003 0.17
Sex 0.17 -0.18 to 0.53 0.34
Study site -0.14 -0.50 to 0.21 0.43
3  Intercept 33.95 32.99 to 34.92 <0.0001
Treatment condition a -0.13 -0.46 to 0.19 0.42
Additional morphine b 0.0001 -0.0001 to 0.0003 0.23
Sex 0.22 -0.12 to 0.56 0.20
Study site -0.14 -0.48 to 0.19 0.39
IQ c -0.0098 -0.019 to -0.0010 0.029
a Morphine group versus placebo group
b Additional morphine in first 28 days 
c Intelligence Quotient (Wechsler Intelligence Scale for Children)
CI = Confidence Interval
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Regression estimates for the six QST modalities are presented in Tables 3 to 5. Neither 
treatment modality (morphine group versus placebo) nor the amount of additional mor-
phine in the fi rst 28 days was a statistically signifi cant predictor in any of the models. For 
the cold and warmth detection thresholds (method of limits), IQ was a statistically signifi -
cant predictor (P=0.024 and P=0.005 respectively). The higher the IQ, the more sensitive 
the children were for the detection of cold and warmth, see Table 3. Children who reached 
the minimum (0.0 °C) or maximum (50.0 °C) at one or more occasions, had statistically sig-
nifi cantly higher mean pain thresholds. Children seen in the hospital in Zwolle (n=39) had 
statistically signifi cant lower mean cold pain thresholds (P=0.0003), but we did not see an 
effect from the study site on the heat pain thresholds (P=0.26).(Table 4) For the warm de-
tection thresholds (method of levels), IQ was a statistically signifi cant covariable (P=0.029). 
Chronic pain
Nine (20%) of the children in the placebo group versus 18 (43%) children in the morphine 
group experienced an episode of pain in the three months before the study visit, as reported 
by the parents in the Chronic Pain Questionnaire. This prevalence was entered in the logis-
tic regression analysis as dichotomous outcome variable and treatment modality (morphine 
FIGURE 2 Prevalence of chronic pain, based on Chronic Pain Questionnaire, by group
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versus placebo group) was a significant predictor (P=0.02), but the amount of additional 
morphine in the first 28 days was not (P=0.98). 
Abdominal pain was the most common type of pain; it was present in 4 (44%) of the chil-
dren in the placebo group versus in 10 (56%) of the children in the morphine group with 
pain (P=0.70). The second most common type of pain was headache; it was present in 6 
(67%) of the children in the placebo group versus in 6 (33%) of the children in the mor-
phine group with pain (P=0.13). Six (67%) children in the placebo group suffered from pain 
at more than one body site, versus 8 (44%) of the children in the morphine group with pain 
(P=0.42) The pain was chronic (duration longer than 3 months) in 4 (9%) children in the 
placebo group versus 5 (12%) in the morphine group (P=0.42), see Figure 2. There was a 
weak but significant correlation between a reported episode of pain in the last three months 
at the follow-up visit at 5 years versus a reported episode or pain at 8 to 9 years of age (64 
subjects, r=0.32, P=0.01).
Neurological examination:
Two children in the placebo group and two children in the morphine group were severe in-
tellectually and developmentally disabled, and did therefore not attend the follow-up visit. 
Neurological examination was performed in 37 children of the morphine group and 41 of 
the placebo group, see Table 6. The neurological examination was normal in 28 (76%) of 
the children in the morphine and in 25 (61%) of the children in the control group (P=0.14).
In the children with minor neurological dysfunctions, mild deviations in coordination and 
muscle tone were more common in the morphine group (7/9 (78%)) than in the placebo 
group (5/16 (22%)) (P=0.04).
The presence of minor neurological dysfunctions at 8-9 years of age was not related to the 
presence of intraventricular hemorrhages in the neonatal period (P=0.26). 
TABLE 6 Minor Neurological Dysfunctions (distinguished by group) 
 Placebo Morphine P value a
 group (n=41) group (n=38)
Minor Neurological Dysfunctions 16/41 (39%) 9/38 (24%) 0.14
Mild deviations in posture/muscle tone 6/16 (38%) 2/9 (22%) 0.66
Mild deviations in reflexes 4/16 (25%) 1/9 (11%) 0.62
Presence of involuntary movements 0/16 (0%) 0/9 (0%) 1.00
Mild deviations in coordination/balance 5/16 (31%) 7/9 (78%) 0.04
Mild deviations in cranial nerve function 1/16 (6%) 0/9 (0%) 1.00
a Fisher exact test
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DISCUSSION
A cohort of children who as neonates participated in a RCT on continuous morphine infu-
sion versus placebo for mechanical ventilation was seen at the age of 8-9 years. Univariate 
analysis revealed that children in the morphine group were more sensitive for the detection 
of cold (according to the method of levels). However, this was not confirmed in the multi-
variate analysis. The treatment condition (morphine versus placebo) was not a significant 
covariable in any of the 6 quantitative sensory testing modalities. The multivariate analysis 
did show correlations between IQ and the detection thresholds, both with the reaction time 
dependent method of limits and the reaction time independent method of levels. However, 
all correlations were weak (see Table 3 and Table 5) and clinically not significant. 
The children in both the placebo and the morphine group were more sensitive for the 
detection of cold (method of limits), compared to the reference data (1.5°C and 1.8°C, re-
spectively). This might be due to methodological variations; cold detection threshold test-
ing was the first test for the controls, so they might have needed to adapt to a test situation 
and setting, whereas the children in the present study already did several other tests before 
the quantitative sensory testing. Analysis of the other three method of limits modalities 
revealed no differences between the morphine or placebo group on the one hand and the 
reference data on the other hand.
Numbers of children who did not establish a pain threshold before reaching the minimum or 
maximum temperature were comparable between the morphine and placebo group. Blank-
enburg et al. provided an overview of QST studies in children that revealed a wide variation 
of pain thresholds, probably due to methodological variations (e.g. test site and instructions 
to participants)(16). The 95% confidence intervals in that study suggest that some children 
reached the minimum or maximum as well(16). Our multivariate analyses showed that the 
floor/ceiling effect should be added as a covariable when analyzing QST data. 
In two other follow-up studies(4, 22), the lower limit of the thermal sensory analyzer was 
set at 10.0 °C, instead of the generally accepted 0.0 °C. International and multidisciplinary 
guidelines on quantitative sensory testing in children are needed to improve reproducibility 
of testing and reduce methodological variations(23). 
  
Long-term effects of surgery and morphine
Hermann et al. reported long-term hypoalgesia for heat pain in both preterm and term 
born 9 to 14-year-old children who had received neonatal intensive care(24). The preterm 
neonates in that study underwent a mean number of 172 invasive procedures in the first 
week of life; however, no more than 53% of them received analgesics.
The hypoalgesia in former extremely preterm born 11-year-olds, reported by Walker et al., 
was most marked in those who had undergone neonatal surgery(4). In contrast, another 
study on long-term effects of neonatal surgery (all neonates received opioids postopera-
tively) showed no differences in the cold and warmth detection thresholds between the 
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neonatal surgery group and the control group at the age of 9 to 12 years(22). 
Combining the previous data with the results of present study, we hypothesize that that 
neonatal injury or surgery is likely to have more pronounced long-term effects on pain 
processing than neonatal morphine treatment itself.
Chronic pain
In both groups in the present study, prevalence of pain in the three months before the 
follow-up visit was lower than Dutch reference values (i.e. 58% for boys versus 75% for the 
girls respectively)(19). Overall, the prevalence of a pain episode in the last three months 
did not significantly differ between boys and girls. The prevalence of chronic pain was 
comparable between the two groups and lower than the reference values (i.e. 11% for boys 
versus 13% for girls)(19). Noteworthily, the prevalence of chronic pain in both groups had 
dropped since the 5-year follow-up visit, i.e. from 14% to 9% in the placebo group and from 
15% to 12% in the morphine group(13). 
Neurological functioning
The majority of the children had a normal neurological examination. The prevalence of mi-
nor neurological dysfunctions (i.e. 39% of the placebo group versus 24% of the morphine 
group) is comparable to the prevalence in a reference cohort of term born children (i.e. 
50% prevalence of minor neurological dysfunctions)(20). Mild deviations in coordination / 
balance control – a minor neurological dysfunction that could indicate cerebellar dysfunc-
tion – were more common in the morphine group of the present study (P=0.04). Research 
in rodents suggests that morphine treatment has a negative effect on the development of 
cerebellar neurons(25). A study in human preterm born found that they were more at risk 
for cerebellar injuries during the neonatal period than term born and that at adolescent 
age their cerebellum volume was smaller than that in term born adolescents(26). Minor 
cerebellar dysfunction could therefore be related to the preterm birth, but we cannot rule 
out an adverse effect from the higher morphine doses on cerebellar functioning. 
The pilot follow-up study of the NEOPAIN trial found an overall lower prevalence of neuro-
logical soft signs (i.e. 20% in the placebo group (n=5) versus 14% in the morphine group 
(n=14)); however, the researchers did not detail which neurological soft signs (comparable 
to minor neurological dysfunctions) were assessed(12). In that study, the children in the 
morphine group had 7% smaller head circumference and 4% less bodyweight than children 
in the placebo group. Although several children in our study were prematurely born or born 
small for gestational age, most children in both groups now had normal height, weight and 
head circumference for their age. The difference in height between the two groups found at 
the age of five was not longer apparent. The preterm neonates in the NEOPAIN trial received 
higher doses of morphine, up to 30 mcg/kg/hr of morphine(8, 12). At neonatal age, the chil-
dren in the morphine group of our study received 10 mcg/kg/hr of morphine; in the case of 
pain or distress children in both groups received open-label morphine as rescue medication. 
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Limitations 
There are various other quantitative sensory testing modalities, such as mechanical or 
current detection and pain thresholds(27). Because 8-to 9-year old children are expected to 
have a short attention span, we decided to assess only thermal detection and pain thresh-
olds. 
Given the range of variation in data on pain thresholds in other studies(16) and the fact 
that the study site (Zwolle versus Rotterdam) was a significant covariable for the cold pain 
thresholds in the present study, we suggest that the determination of pain thresholds is 
sensitive to variations in instructions and methodology. However, this does not influence 
the comparison between the morphine and the placebo group in the present study. At both 
study sites the children received the same instructions, however, we did not investigate the 
inter-tester reliability for giving the instructions. 
Reference data were available only for the four tests according to the Method of Limits, 
and not for the tests according to the Method of Levels. The reference data were collected 
in a set-up in which the minimum temperature of the thermal sensory analyzer was -10.0 
degrees Celsius, compared to 0.0 degrees Celsius in the present study; this hampered the 
comparison of the cold pain thresholds between the control group and the present study.
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CONCLUSION
We found in the present study that neonatal continuous morphine infusion (10 mcg/kg/
hr) had no adverse effects on thermal detection and pain thresholds or overall neurological 
functioning eight to nine years later. Univariate analysis showed differences in the cold de-
tection thresholds, however, this was not confirmed in the multivariate analysis. Children 
who had received continuous morphine as neonates experienced more episodes of pain in 
the three months before the study visit, but the prevalence of chronic pain was comparable 
between the morphine and the placebo group. 
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Je kijkt en je kijkt en je 
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naar wat je ziet,  
maar wat je ziet
is het enige antwoord
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ABSTRACT
Background
Reports conflict on optimal postoperative analgesic treatment in children with intellectual 
disability. We retrospectively compared postoperative analgesia consumption between 
neonates with Down’s syndrome and neonates without Down’s syndrome in relation to 
anaesthesia requirements and pain scores. 
Methods
We analysed hypnotic and analgesic drugs administration, pain scores (COMFORT-Behav-
iour scale) and duration of mechanical ventilation during the first 48 hours after surgical 
repair of congenital duodenal obstruction in neonates between 1999 and 2011. Data of 15 
children with Down’s syndrome were compared with data of 30 children without Down’s 
syndrome. 
Results
General anaesthesia requirements did not differ. Median [IQR] maintenance dose of 
morphine during the first 24 hours postoperatively was 9.5 [7.8 to 10.1] µg kg-1 hr-1 in the 
Down’s syndrome group versus 7.7 [5.0 to 10.0] µg kg-1 hr-1 in the control group (P=0.46). 
Also morphine doses at postoperative day 2 and COMFORT-B scores at day 1 did not 
significantly differ between the two groups. COMFORT-B scores at day two were lower in 
children with Down’s syndrome (P=0.04). Duration of postoperative mechanical ventilation 
did statistically not differ between the two groups (P=0.89). 
Conclusions
In this study, neonates with and without Down’s syndrome received adequate postoperative 
analgesia, as judged from comparable analgesic consumption and pain scores. We recom-
mend prospective studies in children of different age groups with Down’s syndrome and 
in other groups of intellectually disabled children to provide further investigation of the 
hypothesis that intellectual disability predisposes to different analgesic requirements. 
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Research on systematic pain assessment and adequate analgesic therapy in children and 
neonates is on the rise(1). It is not clear whether the “standard” dosing regimens are appli-
cable to intellectually disabled children(2). The evidence nevertheless points at differences 
in analgesia for intellectually disabled children. Fewer children with intellectually disability 
were assessed for pain after spinal fusion surgery and they received smaller doses of opi-
oids(3). On the other hand, Gakhal et al. found that children with Down’s syndrome were 
more likely to receive morphine on day 3 after cardiac surgery than were controls(4). 
Most studies in children with intellectual disability are limited by the sample heterogeneity 
in terms of aetiologies and intellectual disability levels. The reported incidence of congeni-
tal duodenal obstruction in children with Down’s syndrome is 369 per 10 000 live births, 
far exceeding that in children without Down’s syndrome, from 1.16 to 3.06 per 10 000 live 
births(5). This makes repair of duodenal obstruction eminently suitable for comparison of 
anaesthesia, analgesia and pain scores between a well-defined group of future intellectually 
disabled neonates and a group of neonates with a lesser risk of future intellectual disability. 
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METHODS
Participants and setting
After approval of the local ethics review board, we identified all patients who underwent 
surgical repair of congenital duodenal obstruction between March 1999 and February 
2011 in Erasmus University Medical Centre - Sophia Children’s Hospital, Rotterdam, the 
Netherlands, and reviewed their medical records. The Erasmus MC Department of Paedi-
atric Surgery and ICU serves as the only level III facility for those patients in a referral area 
comprising about 4 million inhabitants and 35 000 newborns/year. 
Eligible subjects were those who underwent surgical repair of congenital duodenal ob-
struction within the first 28 postnatal days. Exclusion criteria were: sedation or analgesic 
treatment during the 24 hours before surgery, other surgical interventions at the same time 
or within 48 hours after primary surgery for duodenal obstruction or no digital record avail-
able.
Anaesthesia management
Anaesthesia management is not standardized in our centre and has changed over the years, 
reflecting new developments. Management of neonates with Down’s syndrome gener-
ally does not differ from neonates without Down’s syndrome, although anaesthetists may 
anticipate on possible airway management difficulties in neonates with Down’s syndrome. 
Atracurium was the preferred neuromuscular blocking agent until around 2008, when it 
was replaced with cisatracurium. Until 2008, most patients received barbiturates (thio-
penthal or pentothal) as the hypnotic agent, which was then replaced with propofol. After 
2008, a single shot caudal block was used more frequently as anaesthetists became familiar 
with this technique. Evidence of specific anaesthesia for surgical repair of congenital duo-
denal obstruction is missing.  
Postoperative pain protocol
A postoperative pain protocol is in place since 1999, see Supplementary figure S1 at the 
end of this chapter. The first step was regular pain assessment by an intensive care nurse; 
at least every two hours during the first postoperative days and then every eight hours. 
The nurse used both the COMFORT-Behaviour (COMFORT-B) scale and the Numeric 
Rating Scale (NRS) for pain(6-8). The COMFORT-B scale includes 6 items, each rated 
from 1 to 5. Adding the ratings for all six items provides a pain rating between 6 and 
30. The COMFORT-B scale has been validated for the use in children with and without 
Down’s syndrome(8, 9). The NRS score for pain is a validated tool that asks a proxy (the 
nurse) to rate pain intensity (0= no pain at all and 10 = worst imaginable pain). The NRS 
expresses the observer’s expert rating of the patient’s level of pain, taking the patients’ 
circumstances (disease-related, treatment related, and environmental and patient specific) 
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into account(10). The NRS assessments – part of the pain management protocol since 
1999 – serve to differentiate between pain and distress. The second step of the protocol is 
analgesic therapy. Already at the end of surgery, neonates receive a loading dose of 100 µg 
kg-1 morphine, followed by a maintenance dose of 10 µg kg-1 hr-1. The protocol-associated 
decision-tree suggests that score combinations of COMFORT-B ≥ 17 and NRS ≥ 4 indicate 
moderate to severe pain, warranting opioid analgesia. Otherwise, maintenance doses of 
morphine are gradually decreased on the guidance of COMFORT-B and NRS scores. The 
pain management protocol makes no difference between children with or without Down’s 
syndrome. The sedation algorithm has been described previously(11).
In the study period, four children with Down’s syndrome and four without had been 
included in a randomized controlled trial about the potential morphine-sparing effects of 
rectal acetaminophen to continuous morphine infusions(12). No differences in outcomes 
between the two treatment modes were seen; therefore, those neonates were not excluded 
from our study. 
Measurements
The following demographic characteristics were recorded: Sex, gestational age at birth, 
postnatal age at day of surgery, weight at day of surgery, presence of trisomy 21 and diagno-
sis of associated congenital abnormalities (in particular, cardiac anomalies). We recorded 
amounts of anaesthetics, neuromuscular blocking agents, and analgesics (intravenous or 
caudal) given intraoperatively. From the surgeons’ report, we retrieved the cause of duo-
denal obstruction (duodenal atresia, duodenal web or annular pancreas), duration of the 
surgery, and whether a central venous catheter had been placed. Furthermore, we recorded 
all hypnotics and analgesics administered during the first 48 hours postoperatively and 
the duration of postoperative mechanical ventilation. Prospectively collected COMFORT-
B scores and NRS ratings were retrieved from in the Patient Data Management System 
(PDMS). Postoperative day 1 is defined as 0 to 24 hours after surgery and postoperative day 
2 as 24 to 48 hours after surgery. 
Statistical analysis
Data were analysed using SPSS version 19.0 (IBM, Chicago, IL). The chi-square test (or 
Fisher exact test in the case of low predicted cell counts) was used to compare nominal data 
for the neonates with and without Down’s syndrome. Continuous data are presented as 
median [interquartile range] and the two groups were compared using the Mann-Whitney 
U test. Duration of morphine use is presented as mean (SD) and the two groups were com-
pared using the t test. All reported P values are two-sided, and P values of less than 0.05 are 
considered to indicate statistical significance.
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FIGURE 1 Flowchart for the 107 children assessed for eligibility 
Assessed for eligibility 
(n=107) 
Included (n=15) 
 
 Duodenal atresia (n=5) 
 Duodenal webbing (n=8) 
 Annular pancreas (n=2) 
Patients with Down’s syndrome 
(n=36) 
Patients without Down’s syndrome 
(n=71) 
Excluded (n=21) 
t Postnatal age >28 days (n=8) 
t Postoperative caudal analgesia (n=2) 
t No digital record (n=9) 
t Additional surgical interventions (n=2) 
Excluded (n=41) 
t Postnatal age >28 days (n=14) 
t Postoperative caudal analgesia (n=2) 
t No digital record (n=16) 
t Additional surgical interventions (n=8) 
t Analgesics <24 hr before surgery (n=1) 
Included (n=30) 
 
 Duodenal atresia (n=19) 
 Duodenal webbing (n=4) 
 Annular pancreas (n=7) 
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RESULTS
From 1999 to 2011, one hundred and seven children underwent surgical repair of congeni-
tal duodenal obstruction in our hospital. Figure 1 gives a flowchart showing that 45 were 
included in this study; that is 15 with Down’s syndrome (Down’s syndrome group) and 30 
without (control group). The excluded neonates are listed in Figure 1. 
Background characteristics of both groups are listed in Table 1. During surgery, a central 
venous catheter was placed in 7 of the patients with Down’s syndrome versus 12 of the con-
trols (P=0.67). Children with Down’s syndrome had more often a congenital heart disease 
(P=0.001), notably an atrioventricular septal defect. The causes of the congenital duodenal 
obstruction were comparable between the two groups (see Figure 1). 
TABLE 1 Characteristics of the 45 subjects, by study group
Characteristic Down’s syndrome Controls (n = 30) P value
 (n = 15)
        Median[IQR] a or Proportion 
Male / Female, n 12 / 3  9 / 21 0.002 b
Gestational age, weeks 37 [36 to 40] 36 [33 to 38] 0.021 c
Presence of congenital heart disease, n(%) 8 (53) 2 (7) 0.001 d
Age at surgery, days 3 [1 to 10] 2 [1 to 4] 0.30 c
Weight at surgery (kg) 2.8 [2.5 to 3.0] 2.2 [1.7 to 2.6] 0.005 c
Duration of surgery (min) 187 [149 to 201] 167 [144 to 208] 0.78 c
Postoperative ventilation, n (%)  12 (80) 25 (83) 1.00 d
Duration of postoperative 32 [16 to 46] 27 [18 to 46] 0.89 c
ventilation (hours)
a IQR = Interquartile range 
b Chi-square test
c Mann-Whitney U test
d Fisher Exact test
General anaesthesia
General anaesthesia was induced intravenously in 14 (93%) of the children with Down’s 
syndrome, of whom 3 received a rapid sequence induction, while 24 (80%) of the controls 
were induced intravenously, of whom twelve received a rapid sequence induction (P=1.00). 
The hypnotic agents administered during general anaesthesia are listed in Table 2. Five of 
the children with Down’s syndrome received a bolus of midazolam prior to transport to the 
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ICU versus one in the control group (P=0.01). 
Fentanyl was administered to 14 (93%) of the children with Down’s syndrome versus 26 
(87%) of the children without Down’s syndrome. The median [IQR] dose was 6.7 [5 to 10] 
µg kg-1 for the Down’s syndrome group versus 6.7 [4 to 10] µg kg-1 for the control group 
(P=0.69). The others (1 with and 4 without Down’s syndrome) received sufentanil. Three 
of the patients with Down’s syndrome versus 6 of the controls received single-shot caudal 
analgesia during surgery (P=1.00). Seven of these patients received 1 to 7 mL ropivacaine 
0.2%; the other two patients 4 and 7 mL bupivacaine 0.25%.  
Paracetamol was administered intraoperatively as a loading dose in six (40%) of the pa-
tients with Down’s syndrome versus 13 (43%) of the controls (P=0.38). 
Postoperative intensive care treatment
Except one neonate in the control group, all patients received morphine after operation 
(see Table 3). Continuous morphine administration was discontinued within the first 24 
hours in 8 (53%) of the neonates with Down’s syndrome versus in 13 (43%) of the controls 
(P = 0.53). Mean (SD) total duration of morphine use was 28.2 (15.6) hours in the Down’s 
syndrome group versus 31.9 (16.8) hours in the control group (P=0.48). 
Paracetamol was administered after operation in 12 (80%) of the patients with Down’s syn-
drome versus 16 (53%) of the controls (P=0.08). Two patients with Down’s syndrome and 
three controls received midazolam after operation (P=1.00; Table 3). 
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TABLE 2 Intra-operative analgesics, hypnotics and neuromuscular blocking agents, by 
group 
 Down’s syndrome (n = 15) Controls (n = 30) P value
Type of induction   
Intravenous, n (%) 11 (73) 12 (40)  
Rapid Sequence Induction, n (%) 3 (20) 12 (40) 0.06 a
Inhalational, n (%) 1 (7) 6 (20) 
Hypnotics   
Barbiturates, n (%) 12 (80) 18 (60) 0.18 b
Median [IQR] dose, mg/kg 4.7 [3.6 to 5.1] 4.6 [4.3 to 5.6] 0.63 c
Propofol, n (%) 3 (20) 6 (20) 1.00 a
Median [IQR] dose, mg/kg 3.9 [3.6 to 3.9] 3.5 [2.4 to 7.3] 1.00 c
Sevoflurane, n (%) 5 (33) 5 (15) 0.20 b
Isoflurane, n (%) 4 (27) 13 (43) 0.28 b
Midazolam, n (%) 5 (33) 1 (3) 0.01 a
Median [IQR] dose mcg/kg 118 [55 to 419] 91  0.67 c
Neuromuscular blocking agents   
Succinylcholine, n (%) 3 (20) 13 (43) 0.12 b
Median [IQR] dose, mg/kg 1.9 [1.4 to 1.9] 1.9 [1.6 to 2.2] 0.90 c
Atracurium, n (%) 10 (67) 11 (37) 0.06 b
Median [IQR] dose, mg/kg 1.0 [0.5 to 1.3] 1.1 [0.8 to 1.4] 0.39 c
Cisatracurium, n (%) 4 (27) 14 (47) 0.20 b
Median [IQR] dose, mcg/kg 197 [155 to 228] 170 [121 to 279] 0.80 c
Analgesics   
Fentanyl, n (%) 14 (93) 26 (87) 0.65 a
Median [IQR] dose, mcg/kg 6.7 [5.0 to 10.1] 6.7 [4.0 to 9.9] 0.69 c
Sufentanil, n (%) 1 (7) 4 (13) 0.65 a
Median [IQR] dose, mcg/kg 0.4 0.4 [0.3 to 0.6] 0.80 c
Caudal block, n (%) 3 (20) 6 (20) 1.00 a
Paracetamol, n (%) 6 (40) 13 (43) 0.83 b
Median [IQR] dose, mg/kg 22 [8 to 28] 25 [8 to 35] 0.58 c
a Fisher exact test 
b Chi-square test
c Mann-Whitney test 
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TABLE 3 Postoperative administration of analgesics and sedatives, by group 
 Down’s syndrome  Controls  P value
Morphine   
Number of patients (%) 15 (100) 29 (97) 1.00 a
Loading dose, mcg/kg 100 [87 to 107] 107 [96 to 136] 0.09 b
Maintenance dose 9.5 [7.8 to 10.1] 7.7 [5.0 to 10.0] 0.46 b
day 1, mcg/kg/hr
Maintenance dose 7.0 [5.0 to 8.6] 5.0 [5.0 to 6.3] 0.47 b
day 2, mcg/kg/hr
Paracetamol   
Number of patients (%) 12 (80) 16 (53) 0.08 c
Median [IQR] cumulative 46 [29 to 78] 67 [45 to 88] 0.21 b
dose day 1, in mg/kg
Median [IQR] cumulative 72 [44 to 82] 59 [28 to 77] 0.61 b
dose day 2, in mg/kg
Midazolam   
Number of patients (%) 2 (13) 3 (10) 1.00 a
Cumulative dose day 398 [107 to 398] 703 [200 to 703] 0.40 b
1 and 2, mcg/kg
a Fisher exact test 
b Mann-Whitney U test
c Chi-square test  
Postoperative pain scores
Over the first two postoperative days, 429 COMFORT-B and 431 NRS scores had been 
recorded (See Table 4). The median [IQR] COMFORT-B score after arrival at the ICU was 
9 [8 to 11] in children with Down’s syndrome versus 10 [8 to 11] in controls (P=0.36). The 
median [IQR] COMFORT-B score at day two was 10 [9 to 11] in children with Down’s syn-
drome versus 11 [10 to 12] in controls (P=0.04). Almost all NRS scores were 3 or lower (low 
or no pain): 97% in the Down’s syndrome group versus 96% in the control group (P=0.43). 
Scores were even 0 (no pain) in 110 (66%) observations in the Down’s syndrome group 
versus 217 (74%) in the control group (P=0.06). The combined scores suggested moderate 
to severe pain (NRS score of ≥ 4 combined with a COMFORT-B score of ≥17) only once in 
no more than two patients with Down’s syndrome and three controls. 
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TABLE 4 Postoperative COMFORT-B and NRSa scores, by group 
 Down’s  Controls (n = 28) b P value      
 syndrome (n = 15 ) 
                               Median[IQR] 
Median number of scores per patient 
Day 1 6 [3 to 8] 4 [3 to 8] 0.30
Day 2 4 [3 to 6] 3 [3 to 7] 0.59
Median scores per patient   
COMFORT-B day 1 10 [9 to 11] 10 [9 to 11] 0.52
COMFORT-B day 2 10 [9 to 11] 11 [10 to 12] 0.04
Percentage of NRS a scores of 0, i.e. no pain, per patient    
Day 1 86 [59 to 100] 75 [52 to 100] 0.65
Day 2 100 [59 to 100] 100 [69 to 100] 0.63
a Numeric Rating Scale
b Two patients without Down’s syndrome were not assessed due to a short stay on the PICU
c Mann-Whitney U test
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DISCUSSION
Our analysis did not reveal any substantial differences in anaesthesia and analgesia for con-
genital duodenal obstruction repair between neonates with and without Down’s syndrome, 
nor in pain scores. Even the duration of mechanical ventilation was not longer - as often 
expected - in the neonates with Down’s syndrome. Neonates with Down’s syndrome had 
a higher gestational age; this could explain their higher weight at surgery. However, it is 
unlikely that this influenced anaesthetic or postoperative management because medication 
was calculated per kilogram body weight. Congenital heart disease was more frequent in 
neonates with Down’s syndrome, which is consistent with findings from previous stud-
ies(5, 13, 14). Children with Down’s syndrome received more often a bolus midazolam 
before transport to the ICU. COMFORT-B scores at day two were lower in children with 
Down’s syndrome than in children without Down’s syndrome, but the difference is clini-
cally not significant. 
The question arises whether our findings tally with those of previous studies? Table 5 pro-
vides an overview of previous studies (3, 4, 15, 16) and the present study. Valid comparison, 
however, is hampered by the different age groups and the heterogeneity of diagnoses and 
surgical procedures in the previous studies. Two reported that the intellectually disabled 
children received less intraoperative analgesia than the others. One reported more postop-
erative analgesia and one less postoperative analgesia in the intellectually disabled children. 
In addition, a questionnaire among physicians revealed that 89% agreed with the statement 
that intellectually disabled children receive sub therapeutic doses of analgesics(17). Two of 
the previous studies also evaluated pain scores. One observed lower pain scores in the intel-
lectually disabled children but lacked statistical testing(3). In the other, pain scores had 
been documented in only one-third of the children with cerebral palsy and these did not dif-
fer from those of the children without cerebral palsy(16). In view of the above, the question 
remains whether potential differences in pain experience(18, 19), pain expression, or both 
of intellectually disabled children influence analgesic requirements (what they need) or 
pain management (what they get) in these children. The COMFORT-B scale has been vali-
dated by our group for the use in 0-to 3-year old children with Down’s syndrome as well(9). 
Therefore, we have reason to believe that at this age the pain expression of children with 
Down’s syndrome is similar to other children. It does remain possible that neonates with 
Down’s syndrome experience pain differently. Adults with Down’s syndrome are reported 
to be more sensitive for heat pain(20). Since several pain-related genes (ADAMTS5, GRIK1, 
S100B, RUNX1, KCNE1, KCNJ6) are located on chromosome 21(21), it will be important to 
study the effect of the trisomy 21 on pain experience as well as the pharmacokinetics and 
pharmacodynamics of analgesics(2). 
In the present study, the ICU’s postoperative pain protocol provided for adequate treatment 
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of potential pain and distress, as demonstrated by generally low COMFORT-B and NRS 
scores in all children. Results from a recent study by our group suggest that, independent 
of the presence of Down’s syndrome, neonates, in particular those younger than 10 days, 
have impaired pharmacokinetic capacity to metabolise morphine. This study provided new 
dosing recommendations based on a population pharmacokinetic model of intravenous 
morphine in children up to the age of three years old. Simulations showed that a different 
dosing regimen would result in a more narrow range of morphine and metabolite concen-
trations(22). This new dosing recommendation for morphine entails a 50% dose reduction 
in children younger than 10 days old. Since most of the children in our study were younger 
than 10 days, the administered doses may therefore have been to the upside. As such, it 
might be speculated that the neonates in our analysis may have been pain-free with even 
less analgesia. A new pharmacodynamics study is needed to validate these new dosing 
recommendations; specifically also in intellectually disabled children.
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TABLE 5 Comparison of the available evidence
a Analgesic doses compared to the control group. 
b The difference between the two groups has not been tested in the study by Malviya et al. 
c Pain scores were available in only 31% of the study group. 
Pain 
scores in 
the study 
group
Not available
rb
Not available
= c
=
Study 
design
Retro-
spective 
case-control 
study
Retrospec-
tive cross-
sectional 
study
Prospec-
tive cohort 
study
Retrospec-
tive cross-
sectional 
study
Retrospec-
tive cross-
sectional 
study
Study group 
16 children 
with Down’s 
syndrome 
(mean age: 5 
years)
19 intellectu-
ally disabled 
children 
(mean age: 11 
years)
152 intellectu-
ally disabled 
children 
(mean age: 10 
years)
71 children 
with cerebral 
palsy (29 
intellectu-
ally disabled) 
(mean age: 
11 years)
15 children 
with Down’s 
syndrome 
(median age: 
3 days)
Control 
group
16 children 
without 
Down’s syn-
drome (mean 
age: 
5 years)
23 children 
without intel-
lectual dis-
ability (mean 
age: 
11 years)
148 children 
without intel-
lectual disabil-
ity (mean age: 
8 years)
77 children 
without 
cerebral palsy 
(mean age: 
11 years)
30 children 
without Down’ 
syndrome 
(median age: 2 
days)
Type of 
surgery
Cardiac 
surgery
Spinal 
fusion 
surgery
Various
Orthopedic 
surgery
Congenital 
duodenal 
obstruction 
repair
Intraop-
erative an-
algesia of 
the study 
group a
Not available
=
r
r
=
Postopera-
tive anal-
gesia of 
the study 
group a
q
r
=
=
=
Gakhal 
1998
Malviya 
2001
Koh 
2004
Long 
2009
Present study 
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Study limitations
Judging from the insignificant differences found between the two groups, the study could 
have been underpowered. For two important outcome parameters we determined the sam-
ple size required to result in a statistically significant difference (Ơ of 0.05 and ơ of 0.80). 
First, the maintenance dose of morphine on day 1 was higher in children with Down’s 
syndrome; 76 patients in each group would be required to make this difference statistically 
significant. Second, 260 patients in each group would be required to make the difference 
in COMFORT-B scores at day 1 statistically significant. Given the incidence of congenital 
duodenal obstruction of 1.16 – 3.06 per 10 000 live births(5), such a study would be chal-
lenging, but may be usefully informed by the current work. 
Complications and unexpected events were not registered during most years of our study 
period. Therefore we are not able to present reliable data regarding complications or unex-
pected events.
Conclusions
In this study, both neonates with and without Down’s syndrome received adequate post-
operative analgesia, as judged from comparable analgesic consumption and pain scores. 
The pain scores were low and this finding suggests that these neonates, independent of the 
presence of Down’s syndrome, might have been pain-free with less analgesia. 
Since evidence is still scarce and contradictory, we recommend prospective multicentre 
studies evaluating postoperative pain management in different age groups of children with 
Down’s syndrome and in other groups of intellectually disabled children. These studies 
should preferably use a randomized controlled study design comparing different analgesic 
regimens. In this way, conclusive evidence on the premise that intellectual disability predis-
poses to different analgesic requirements can be obtained.
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SUPPLEMENTARY FIGURE S1: Postoperative Analgesia Protocol (Paediatric Intensive Care Unit; Eras-
mus University Medical Centre – Sophia Children’s Hospital)
201
Chapter 10
 
REFERENCES
1. Berde CB, et al. Anesthesia and analgesia during and after surgery in neonates. Clin Ther. 2005;27(6):900-21.
2.  Valkenburg AJ, et al. Pain management in intellectually disabled children: Assessment, treatment, and translational 
research. Dev Disabil Res Rev. 2010;16(3):248-57.
3.  Malviya S, et al. Pain management in children with and without cognitive impairment following spine fusion surgery. 
Paediatr Anaesth. 2001;11(4):453-8.
4.  Gakhal B, et al. Comparison of morphine requirements for sedation in Down's syndrome and non-Down's patients 
following paediatric cardiac surgery. Paediatr Anaesth. 1998;8(3):229-33.
5.  Cleves MA, et al. Congenital defects among liveborn infants with Down syndrome. Birth Defects Res A Clin Mol 
Teratol. 2007;79(9):657-63.
6.  van Dijk M, et al. The COMFORT Behavior Scale. Am J Nurs. 2005;105(1):33-6.
7.  van Dijk M, et al. The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 
3-year-old infants. Pain. 2000;84(2-3):367-77.
8.  Ambuel B, et al. Assessing distress in pediatric intensive care environments: the COMFORT scale. J Pediatr Psychol. 
1992;17(1):95-109.
9.  Valkenburg AJ, et al. The COMFORT-behavior scale is usefull to assess pain and distress in 0- to 3- year old children 
with Down syndrome. Pain. 2011;152:2059 - 64.
10.  van Dijk M, et al. Observational visual analog scale in pediatric pain assessment: useful tool or good riddance? Clin J 
Pain. 2002;18(5):310-6.
11.  Ista E, et al. Implementation of standard sedation management in paediatric intensive care: effective and feasible? J 
Clin Nurs. 2009;18(17):2511-20.
12.  van der Marel CD, et al. Rectal acetaminophen does not reduce morphine consumption after major surgery in young 
infants. Br J Anaesth. 2007;98(3):372-9.
13.  Dalla Vecchia LK, et al. Intestinal atresia and stenosis: a 25-year experience with 277 cases. Arch Surg. 
1998;133(5):490-7.
14.  Singh MV, et al. Does Down syndrome affect the outcome of congenital duodenal obstruction? Pediatr Surg Int. 
2004;20(8):586-9.
15.  Koh JL, et al. Analgesia following surgery in children with & without cognitive impairment. Pain.2004;111(3):239-44.
16.  Long LS, et al. Intraoperative opioid dosing in children with and without cerebral palsy. Paediatr Anaesth. 
2009;19(5):513-20.
17.  Malviya S, et al. Difficult pain assessment and lack of clinician knowledge are ongoing barriers to effective pain 
management in children with cognitive impairment. Acute Pain. 2005;7:27-32.
18.  Lind J, et al. Spectographic analysis of vocal response to pain stimuli in infants with Down's syndrome. Dev Med 
Child Neurol. 1970;12(4):478-86.
19.  Hennequin M, et al. Pain expression and stimulus localisation in individuals with Down's syndrome. Lancet. 
2000;356(9245):1882-7.
20.  Defrin R, et al. A quantitative somatosensory testing of pain threshold in individuals with mental retardation. Pain. 
2004;108(1-2):58-66.
21.  Lacroix-Fralish ML, et al. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout 
studies. Pain. 2007;131(1-2):3.e1-4.
22.  Knibbe CA, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin 
Pharmacokinet. 2009;48(6):371-85.
kRUTGER KOPLAND
Zo andersom is alles, 
misschien.
Ik zal dit uitleggen.

PHARMACODYNAMICS AND 
PHARMACOKINETICS OF MORPHINE 
AFTER CARDIAC SURGERY IN CHILDREN 
WITH AND WITHOUT DOWN SYNDROME
Abraham J. Valkenburg, Monique van Dijk, Elke H.J. Krekels, Brendan O’Hare, William Casey, 
Ron A.A. Mathôt, Catherijne A.J. Knibbe, Dick Tibboel, Cormac Breatnach 
Chapter 11
206
ABSTRACT
Background
Approximately 40 to 60% of children with Down syndrome have a congenital heart defect 
and many therefore undergo major surgery and postoperative intensive care management 
at a young age. Children with Down syndrome are described as being more agitated and 
“difficult to sedate” after surgery. The aim of this study was to compare the pharmacody-
namics and pharmacokinetics of intravenous morphine after cardiac surgery in two groups 
of children – those with and without Down syndrome.
Methods
All children received standardized general anaesthesia for cardiac surgery; all received a 
loading dose of morphine (100 mcg/kg) after cardiopulmonary bypass; thereafter a mor-
phine infusion was commenced at 40 mcg/kg/hr. During intensive care, nurses regularly 
assessed pain and discomfort with validated observational instruments (COMFORT-B scale 
and Numeric Rating Scale  (NRS) for pain). These scores guided analgesic and sedative 
treatment. Pain scores and analgesia and sedation requirements were recorded. Blood sam-
ples were obtained for pharmacokinetic analysis at preset time intervals. 
Results
Eighteen children with Down syndrome and sixteen controls underwent cardiac surgery 
with cardiopulmonary bypass. Median COMFORT-B and NRS scores were not statistically 
significantly different between the two groups. Median morphine infusion rate during first 
24hr after surgery was 31.7 [IQR 22.8 to 37.0] mcg/kg/hr in the Down’s syndrome group 
versus 31.8 [IQR 25.7 to 36.2] mcg/kg/hr in the control group (P=1.00). Morphine require-
ments during the following days as well as need for additional sedation were comparable 
between the two groups. 
Population pharmacokinetic analysis revealed no statistically significant differences in any 
of the pharmacokinetic parameters of morphine between the children with and without 
Down syndrome. 
Conclusion
Based on pharmacodynamic and pharmacokinetic analysis, there is no evidence to adjust 
morphine dosing after cardiac surgery in children with Down syndrome compared to chil-
dren without Down syndrome. 
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 INTRODUCTION
Approximately 40 to 60% of children with Down syndrome have a congenital heart defect 
and many will therefore undergo major surgery and require postoperative intensive care 
management(1). Children with Down syndrome are described as being more agitated and 
“difficult to sedate” after surgery(2). Walker acknowledged that the provision of analgesia 
may be influenced by perceptions about a patient’s sensitivity to pain or response to analge-
sia(3). 
The results from retrospective chart review studies on analgesia/sedation requirements of 
children with Down syndrome do not provide a consensus view: Gakhal et al. found that 
children with Down syndrome are more likely to require morphine at day 3 after cardiac 
surgery than are children without Down syndrome. The children with Down syndrome 
were also more likely to receive additional sedatives and muscle relaxants than those with-
out(4). On the other hand, a more recent study in 15 neonates with and 30 without Down 
syndrome who had undergone surgical repair of congenital duodenal obstruction revealed 
no statistically significant differences in postoperative analgesic or sedative requirements, 
or pain scores, between the two groups(5). 
Worldwide, morphine is the first line analgesic and sedative agent in children after cardiac 
surgery(6, 7). Recent advances have improved the feasibility of pharmacokinetic studies in 
infants and children, since both the required blood sample volume and number of samples 
required for analysis has decreased substantially(8). Validated population pharmacokinetic 
models have been applied to describe the pharmacokinetics of morphine in various groups 
of critically ill and postoperative neonates, infants and children(9, 10).
Pharmacokinetic analysis of other drugs such as paracetamol(11), theophylline(12) and 
methotrexate(13) have revealed altered metabolism and lower clearance in children and 
adults with Down syndrome. However, knowing the pharmacokinetics of a drug alone 
is not enough: information on the effect of a drug, the pharmacodynamics, is invalu-
able as well(14). Combining the pharmacokinetics of morphine with pharmacodynamic 
endpoints, i.e. pain/distress assessments and dosing requirements, in children with and 
without Down syndrome will provide information on the degree of variability between chil-
dren with and without Down syndrome. Armed with this information our ability to assess if 
dosing adjustments are required will be enhanced.
Therefore the aim of this study was to compare the pharmacodynamics and pharmacoki-
netics of intravenous morphine after cardiac surgery in two groups of children – those with 
and without Down syndrome. 
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METHODS
Subjects and setting
This observational, prospective case-control study was conducted at the Department of An-
aesthesia and Intensive Care Medicine of Our Lady’s Children’s Hospital, Dublin, between 
January and May 2012.
The study protocol was approved by the local ethics committee. Written parental informed 
consent for the study was obtained preoperatively. 
The inclusion criteria for the Down syndrome group were: a confirmed diagnosis of Tri-
somy 21, age 3 to 36 months and cardiac surgery with cardiopulmonary bypass for atrial 
septal defect (ASD), ventricular septal defect (VSD), atrioventricular septal defect (AVSD), 
or Tetralogy of Fallot (TOF) repair. The inclusion criteria for the control group were: age 
3 to 36 months and cardiac surgery with cardiopulmonary bypass for ASD, VSD, AVSD or 
TOF repair. The exclusion criteria for both groups were: epilepsy, cerebral palsy or birth 
asphyxia, history of cardiothoracic surgery through sternotomy, preoperative mechanical 
ventilation, preoperative treatment with morphine or midazolam and extracorporeal mem-
brane oxygenation (ECMO) treatment after cardiopulmonary bypass. 
General anaesthesia
Children received a standardized general anaesthesia regimen without premedication. After 
IV access was secured, anaesthesia was induced with intravenous midazolam (optional; 100 
to 200 mcg/kg), ketamine (1 to 3 mg/kg), pancuronium (100 to 150 mcg/kg) and fenta-
nyl (up to 10 mcg/kg). The anaesthetist had the option to use propofol (1 to 4 mg/kg) for 
induction of anaesthesia instead of midazolam and ketamine. Anaesthesia was maintained 
with sevoflurane (0.75 to 2.5% fraction inspired) in an air/oxygen mixture. Arterial and 
central venous access was secured thereafter. Prior to incision and sternotomy, a further 
fentanyl bolus was given. The range for the total dose of fentanyl used up to the start of 
cardiopulmonary bypass was 10 to 25 mcg/kg. During cardiopulmonary bypass, general 
anaesthesia was maintained with remifentanil (0.25 to 0.50 mcg/kg/min) and isoflurane 
(0.5 to 1.0% fraction inspired), both delivered through the bypass circuit. After coming off 
bypass, anaesthesia was maintained with sevoflurane (0.75 to 2.5 % fraction inspired). All 
patients underwent modified ultrafiltration after cardiopulmonary bypass for 10 minutes. 
Afterwards the morphine loading dose (100 mcg/kg) was administered and the morphine 
infusion was commenced at 40 mcg/kg/hr. 
Postoperative intensive care management
All patients received standardized postoperative pain and distress management accord-
ing to the following departmental guidelines, based on pain and distress assessments (see 
below for clinical cutoff values). Morphine infusion was continued at 40 mcg/kg/hr during 
intensive care. Three doses of IV paracetamol were prescribed (7.5 mg/kg for children <10 
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kg and 15 mg/kg for children >10 kg). Morphine boli (20 to 40 mcg/kg) were prescribed as 
needed (PRN). 
For rescue sedation, midazolam boli (50 to 100 mcg/kg) were prescribed as needed (PRN) 
with escalation to a midazolam infusion (1 to 2.5 mcg/kg/min) if a requirement for further 
sedation persisted. The second-line sedative agent was enteral chloral hydrate (25 to 50 mg/
kg every six hours). 
When, based on COMFORT-B and NRS scores, continuous morphine infusion was weaned 
to 12 mcg/kg/hr or less and patients were ready for discharge to the ward, they were com-
menced on oral morphine (double the total daily IV dose; divided in six-hourly doses). 
Two hours after the first dose of oral morphine, the intravenous morphine infusion was 
switched off. 
Pain and distress were assessed at least every two hours after return to the intensive care 
unit with the COMFORT-B scale and the NRS for pain. Both instruments are validated for 
children (0 to 3 years) with and without Down syndrome admitted to an intensive care 
unit(15, 16). The COMFORT-B scale is a pain and distress assessment instrument that asks 
observers to consider the intensity of six behavioral manifestations: Alertness, Calmness, 
Respiratory response (for mechanically ventilated children) or Crying (for spontaneously 
breathing children), Body movements, Facial tension and Muscle tone. For each of these 
items, five descriptions, rated from 1 to 5, are provided, reflecting an increasing intensity of 
the behavior in question. Summating the ratings of the six behavioral manifestations leads 
to a score ranging from 6 to 30. The NRS for pain (0=no pain at all and 10= worst imagina-
ble pain) expresses the observer’s informed opinion of the patient’s level of pain – taking 
disease-related, treatment related, environmental and patient-specific circumstances into 
account. 
All nurses follow a 2-hour COMFORT-B training program when they start to work in our 
unit. The program includes 10 assessments of different patients, with a qualified nurse 
(trained to teach pain and distress assessment) performing the same assessments. Agree-
ment is assessed from the linearly weighted Cohen k calculated from these 10-paired as-
sessments. Median [IQR] linearly weighted kappa values were excellent; 0.92 [0.88 to 0.96] 
for 147 nurses. 
Clinical cutoff scores for the COMFORT-B and NRS pain have been determined(17). The 
decision tree suggests that score combinations of COMFORT-B >16 and NRS > 3 indicate 
moderate to severe pain, warranting additional opioid analgesia. Otherwise, maintenance 
doses of morphine are gradually decreased on the guidance of COMFORT-B and NRS 
scores. 
Measurements
Data collection for the study commenced on arrival of the patient in the operating theatre. 
Measurements included patient demographics, dose and time of anaesthetic agents admin-
istered, details of the cardiac surgery performed, duration of mechanical ventilation and 
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duration of intensive care admission. The following risk assessment scales were applied: 
Risk Adjustment for Surgery for Congenital Heart Disease (RACHS-1)(18) on admission 
(score range 1 to 6 where 6 is the highest risk category), Paediatric Index of Mortality 
(PIM2) (probability of death in %)(19) on admission and daily Paediatric Logistic Organ 
Dysfunction scores (probability of death in %) (PELOD-II)(20). Postoperative administra-
tion of morphine and other analgesic and sedative agents were recorded. Arterial blood 
samples for pharmacokinetic analysis were taken at preset time points (see below). COM-
FORT-B and NRS scores were noted. The end of the data collection period was marked by 
one of the following events: a switch from intravenous to oral morphine, discharge to the 
ward, a procedure requiring general anaesthesia and reintubation for any reason other than 
oversedation. 
Samples for pharmacokinetic analysis
Arterial blood samples (1.0 mL) for determination of morphine plasma concentrations 
were taken at the following time intervals: immediately prior to morphine loading dose 
(t=0), t=10, t=30 to 60 minutes, t=4 hours, t=8 hours, t=16 hours, t=24 hours; in addition 
daily at 8.00 am and once just before the end of the study. Blood samples were centrifuged 
and plasma was stored at  -80°C. 
Analytical method
Morphine, morphine-3-glucoronide and morphine-6-glucoronide concentrations were 
analyzed using LC-MS/MS in the positive ionisation mode on a Shimadzu LC-30 (Nishino-
kyo-Kuwabaracho, Japan) system coupled to an AB SCIEX 5500 QTRAP mass spectrometer 
(Framingham, MA, US). 75 µl acetonitril/methanol 84:16 (v/v%) containing the internal 
standard morphine-d3, morphine-3-glucoronide-d3 and morphine-6-glucoronide-d3 was 
added to 10 µl of patient’s plasma to precipitate proteins. Samples were vortexed, stored at 
-20°C for 30 minutes, vortexed again and centrifuged. For the determination of morphine, 
morphine-3-glucoronide and morphine-6-glucoronide 3 µl was injected onto a Thermo 
Scientific Hypersil Gold HILIC (50 x 2.1 mm, 1.9 µm) column. A stepwise chromatographic 
gradient was applied using acetonitril and water with a constant 5% addition of 1% am-
monium formate / 2% formic acid in water. The flow was 600 µl/min for the HILIC method, 
column-oven temperature was 40°C. Morphine, morphine-3-glucoronide and morphine-
6-glucoronide were measured as [M+H]+, using the mass transition of 286.1/165.1, 
462.2/286.2 and 462.2/286.2 respectively. The method was validated over a range of 2 to 
500 ng/mL.  The accuracies ranged from 93.5% to 105.5%, the intra-day precisions were 
below 9.6% and the inter-day precisions were below 12.9%.
Population pharmacokinetic analysis
Morphine concentrations were modeled with the nonlinear mixed-effects modeling soft-
ware NONMEM VI (ICON, Ellicott City, MD, US), with the First-Order Conditional Estimate 
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(FOCE) method for fitting and with PLTtools (PLTsoft, San Francisco, CA, USA) for the 
visualization of the data. The model was developed in the following steps: 1) choice of the 
structural model, 2) choice of the error model, 3) covariate analysis, and 4) internal valida-
tion of the model.
A decrease in objective function of more than 3.8 points between different (sub) models 
was considered to be statistically significant: this correlates with a P value of <0.05 assum-
ing a Ƶ2 distribution. In addition, the following plots were used for diagnostic purposes: A) 
observed versus individually predicted, B) observed versus population predicted, C) time 
versus weighted residuals, D) population predictions versus weighted residuals. Further-
more, the 95% confidence interval of the parameter estimates, the correlation matrix and 
visual improvement of the diagnostic plots served to evaluate the model.
The following covariates were analysed: bodyweight, age, sex, and Down syndrome. Con-
tinuous covariates were tested in linear or exponential equations; categorical covariates 
were tested by estimating separate parameter values for each category. Potential covari-
ates were separately incorporated into the model and considered statistically significant 
(P<0.05) if the objective function decreased 7.9 points or more and the 95% confidence 
interval of the additional parameter did not include zero. When more than one significant 
covariate for the simple model was found, the covariate-adjusted model with the largest 
decrease in objection function was chosen as a basis to sequentially explore the influence of 
additional covariates with the use of the same criteria.
The model was internally validated according to a recently developed framework for the 
evaluation of paediatric population models(10), by the following steps: Initially, the condi-
tion number was assessed by taking the ratio of the largest and smallest Eigenvalue of the 
covariance matrix in the NONMEM output, 2) a bootstrap analysis with 100 resampled 
datasets was performed, 3) population predicted versus observed plots were made strati-
fied by weight, age, sex and Down syndrome, 4) Ʀ-shrinkage was determined according to 
Karlsson and Savic(21) and was accepted if less than 20%, 5) NPDE-analysis was performed 
on the basis of 1000 simulated profiles(22), and 6) individual and population parameter 
estimates for the distribution volumes were plotted versus bodyweight to visually assess 
whether the obtained covariate relationship described the trend in individual parameter 
values accurately.
Morphine-3-glucoronide and morphine-6-glucoronide concentrations were not included in 
this NONMEM model.  
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Statistical analysis
Data were analysed using SPSS version 20.0 (IBM, Chicago, IL, USA). Nominal data were 
compared using the Chi-square test (or Fisher’s exact test in the case of low predicted cell 
counts). Continuous data are presented as median [interquartile range] and the two groups 
were compared with the Mann-Whitney-U-test. Mean (SD) morphine, morphine-3-gluc-
oronide and morphine-6-glucoronide concentrations are calculated per subject. The mean 
(SD) values are then presented per group and compared with the t test. Risk factors for a 
COMFORT-B score of <11 (indicating oversedation) were determined with logistic regres-
sion analysis(23). All P values are two-sided and a value of <0.05 is considered as statisti-
cally signifi cant. 
FIGURE 1 Flowchart recruited patients. 
Eligible subjects (n=41) 
No informed consent (n=2) 
Missed due to logistics (n=5) 
Recruited subjects (n=34) 
Down syndrome group (n=18) Control group (n=16) 
Postoperative data available (n=18) 
Pharmacokinetic samples available (n=17) 
Postoperative data available (n=14) 
Pharmacokinetic samples available (n=14) 
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RESULTS
Background
Eighteen subjects with Down syndrome and sixteen without Down syndrome were included 
in the study between January and May 2012 (see flow chart in Figure 1). There were no sta-
tistically significant differences between the demographic characteristics of the two groups 
(see Table 1). 
Medical history taking revealed that one child with Down syndrome group had under-
gone surgical repair of congenital duodenal obstruction and that two children with Down 
syndrome had undergone correction of aortic coarctation combined with pulmonary artery 
banding (both through lateral thoracotomy). 
Of the children with Down syndrome, 11 (61%) received diuretics preoperatively versus 5 
(31%) of the controls (P=0.08). Three controls and 1 child with Down syndrome received 
an ACE-inhibitor preoperatively. Two controls and 1 child with Down syndrome received 
a beta-blocker preoperatively. Two children with Down syndrome received levothyroxine 
preoperatively for hypothyroidism versus none in the control group. Parents of one subject 
with Down syndrome did not give consent for the pharmacokinetic samples, see Figure 1. 
General anaesthesia and surgery
Details of the general anaesthesia and surgery are presented in Table 1 for both groups. 
Since more children with Down syndrome underwent repair of an AVSD, the RACHS-1 
score is higher for the Down syndrome group (see Table 1). Cardiopulmonary bypass times 
and aortic cross-clamp times were comparable between both groups. More children in the 
control group were cooled to 28°C than in the Down syndrome group (P=0.03), since more 
children in the control group underwent Tetralogy of Fallot repair. None of the children 
received muscle relaxants after cardiopulmonary bypass.
One patient in the control group could not be weaned from cardiopulmonary bypass and 
was commenced on ECMO; thereafter this patient was excluded from the study. One other 
child in the control group was excluded from the study before admission to the intensive 
care unit, due to inadvertent disconnection of the IV line for an unknown period during 
transport from theatre to the intensive care unit. 
Chapter 11
214
TABLE 1 Background characteristics, by group
 Down syndrome (n=18) Controls (n=16) P value
                                  Median [IQR] or n (%) 
Male, n(%)  5 (28%) 8 (50%) 0.18
Gestational age, in weeks 39 [37 to 40] 40 [39 to 41] 0.08
Age at surgery, in days 175 [130 to 270] 180 [124 to 234] 0.55
Weight at surgery, in kg 5.9 [4.9 to 7.7] 6.6 [5.5 to 7.3] 0.67
Height at surgery, in cm 64 [58 to 66] 67 [61 to 68] 0.24
Procedure   
ASD 1 (6%) 0 (0%) 
VSD 3 (17%) 5 (31%) 
AVSD 13 (72%) 1 (6%) 
TOF 0 (0%) 10 (63%) 
AVSD+TOF 1 (6%) 0 (0%) 
ASA classification 3 18 (100%) 16 (100%) 1.00
RACHS-1 score   
2 4 (22%) 15 (94%) <0.001
3 14 (78%) 1 (6%) 
Cardiopulmonary bypass time, in min  114 [83 to 132] 115 [96 to 139] 0.80
Aortic cross-clamp time, in min 76 [55 to 99] 74 [47 to 106] 1.00
Target temperature  
intraoperative cooling 
34 °C 1 (6%) 0 (0%) 
32 °C 16 (89%) 10 (63%) 0.03
28 °C 1 (6%) 6 (38%) 
Sedative agent for induction
of general anaesthesia   
Ketamine 15 (83%) 15 (94%)  
Midazolam 7 (39%) 10 (63%) 0.17
Propofol 3 (17%) 1 (6%) 
Cumulative fentanyl dose, in mcg/kg  12 [10 to 16] 12 [10 to 17] 0.80
Cumulative remifentanil dose, in mcg/kg 28 [20 to 49] 37 [32 to 49] 0.24
Pain/distress assessment
Median COMFORT-B and NRS ratings were comparable between both groups (Table 2). 
The median [IQR] number of pain and distress assessments per subject was not statistically 
different between both groups, 14[10 to 18] for the Down syndrome group and 18[10 to 
24 for the control group (P=0.40). Univariate analysis revealed that 54 (18%) of the scores 
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in the Down syndrome group indicate oversedation (COMFORT-B <11) at any time point, 
versus 18 (7%) of the scores in the control group (P<0.001). This was confirmed in a logistic 
regression analysis: Children with Down syndrome were more at risk for oversedation [OR 
= 3.0(95% CI:1.7 to 5.3)] and children in both groups were more at risk for oversedation in 
the first 3 hours after surgery [OR =7.4(95% CI:4.0 to 13.4)]. However, there was no statis-
tically significant interaction effect between those two covariables. 
TABLE 2 COMFORT-B and NRS scores during the study period, by group
 Down syndrome (298 scores) Controls (264 scores) P value
COMFORT-B, median [IQR] 13 [12 to 16] 14 [12 to 16] 0.56
COMFORT-B >16, n(%) 71 (24%) 60 (23%) 0.76
NRS, median [IQR] 2 [0 to 3] 2 [0 to 2] 0.11
NRS >3, n(%) 39 (13%) 34 (13%) 0.94
COMFORT-B >16 and NRS >3, n (%) 23 (8%) 17 (6%) 0.56
Oversedation (COMFORT <11), n(%) 54 (18%) 18 (7%) <0.001
Undersedation (COMFORT >22), n(%) 7 (2%) 3 (1%) 0.35
Morphine
The mean infusion rates during the first 24 hours as well as the second 24 hours were com-
parable between both groups (see Table 3). 
Of the children with Down syndrome, 4 (22%) received intravenous morphine at day 3 (48 
to 72 hours) versus 5 (36%) of the controls (P=0.45); morphine infusion was discontinued 
or switched to oral morphine in the others. 
One child in the control group was switched to an oxycodone infusion after 20 hours of 
continuous morphine infusion, due to relentless pruritus, a side effect of morphine. 
TABLE 3 Postoperative administration of intravenous morphine, by group
 Down syndrome (n=18) Controls (n=14) P value
DAY 1 (0 to 24 hr)
Mean infusion rate in mcg/kg/hr 31.7 [22.8 to 37.0] 31.8 [25.7 to 36.2] 1.00
Number bolus  3 [1 to 5] 4 [3 to 4] 0.49
DAY 2 (24 to 48 hr)  
N(%) on IV Morphine 13 (72%) 12 (86%) 0.43
Mean infusion rate in mcg/kg/hr 16.8 [10.7 to 24.6] 16.1 [12.0 to 19.9] 0.81
Number bolus 0 [0 to 1] 0 [0 to 2] 0.69
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Sedation
The median time before rescue sedation was required - 10 [4 to 15] hours in the Down 
syndrome group versus 6 [4 to 13] hours in the control group - was not statistically signifi-
cantly different (P=0.51). The number of midazolam boli and the number of children that 
required a midazolam infusion was comparable between both groups (Table 4).
TABLE 4 Postoperative sedation requirements, by group
 Down syndrome (n=18) Controls (n=14) P value
Time to start of rescue sedation, in hours 10 [4 to 15] 6 [4 to 13] 0.51
Mean number midazolam boli 3 [0 to 11] 5 [2 to 7] 0.67
Midazolam infusion, n (%) 7 (39%) 7 (50%) 0.53
Mean number chloral hydrate boli 0 [0 to 3] 0 [0 to 2] 0.64
Mean number morphine / 7 [3 to 18] 10 [7 to 17] 0.49
midazolam / chloral hydrate boli
Pharmacokinetics of morphine
A total of 333 plasma samples from 17 subjects with Down syndrome and 14 controls were 
available for the pharmacokinetic analysis. The median [IQR] number of samples was 11 
[9 to 13] for the Down syndrome group versus 12 [10 to 13] for the control group (P=0.71). 
Mean (SD) morphine, morphine-3-glucoronide and morphine-6-glucoronide concentra-
tions per subject, stratified by group, are presented in Table 5.
TABLE 5 Mean (SD) morphine, morphine-3-glucoronide and morphine-6-glucoronide 
plasma concentrations per subject, by group
 Down syndrome (n=17) Controls (n=14) P value
Morphine in ng/mL 38 (17) 42 (15) 0.58
Morphine-3-glucoronide in ng/mL 220 (98) 280 (141) 0.17
Morphine-6-glucoronide in ng/mL 35 (16) 40 (25) 0.49
The time-course of morphine concentrations was best described with a two-compartment 
model, with log-normally distributed inter-individual variability in the volume of the central 
compartment and the total morphine clearance. A proportional error model was used for 
the residual variability. In the covariate analysis, bodyweight proved to be a significant pre-
dictor of the inter-individual variability in the distribution volume in a linear relationship. 
Including bodyweight as a covariate in a linear relationship on the distribution volume of 
the peripheral compartment further improved the model fit. No other significant covariate 
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relationships could be identified. The bootstrap analysis showed that except for the periph-
eral distribution volume, the bootstrap parameter values were within 10% of the parameter 
values obtained in the original model fit. Table 6 shows the population parameter estimates 
for the final model. The observed versus predicted morphine concentrations, stratified by 
Down syndrome, are plotted in Figure 2. 
TABLE 6 Parameter estimates of the population pharmacokinetic model
 Original value (CV%) Mean bootstrap value (Ƌ from original in %)
Structural parameter
V1, L/kg 5.49 (11%) 5.49 (0%)
V2, L/kg 30.4 (34%) 41.5 (37%)
Q, ml/min 54.9 (18%) 56.3 (3%)
CL, ml/min 82.2 (12%) 80.3 (-2%)
Interindividual variability 
Ʒ2 V1 0.22 (26%)  0.22 (0%)
Ʒ2 CL 0.32 (48%)  0.35 (9%)
Residual variability 
Ʊ2 Morphine concentrations 36.6%  36.8% (0.5%)
CV = coefficient of variation; V1 = Central volume of distribution; V2 = Peripheral volume of distribution; CL = total 
clearance; Q= intercompartemental clearance
Individual parameter estimations for the central volume of distribution, peripheral volume 
of distribution and clearance are displayed in Figure 3, stratified by group. Although the 
range of the estimations is wider for the Down syndrome group, there were no statistically 
significant differences between both groups.
Standard paediatric model evaluation and validation steps showed that the condition 
number of the final model was 32, which is well under threshold for over-parameterisation 
of 1000. The results from the NPDE-analysis (See Figure 4) show that the model slightly 
overpredicts the variability in the population; however this overprediction is constant over 
time and over the predicted morphine concentration range.
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FIGURE 2 Observed versus predicted morphine concentrations, stratified by group. Down syndrome = 
filled circles; Controls = open circles
FIGURE 3 Individual post-hoc parameter estimations, stratified by group. CL = total clearance; V1 = Cen-
tral volume of distribution; V2 = Peripheral volume of distribution. Down syndrome: No = 0; Yes = 1
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FIGURE 4 Normalized prediction distribution error (NPDE) plots. The histogram (left panel) shows the 
NPDE distribution for morphine (solid line is the normal distribution). NPDE versus time is displayed in 
the middle panel and NPDE versus predicted concentrations is displayed in the right panel. 
Intensive care management
The PIM-2 and PRISM-II scores were not statistically different between the two groups. 
Duration of intensive care admission as well as duration of mechanical ventilation was 
comparable between both groups (see Table 7). Three children were reintubated (after 
which data collection was ended); two controls (due to sepsis and pulmonary hypertension) 
and one child with Down syndrome (due to post-extubation stridor). Following study com-
pletion, 5 (28%) of the children with Down syndrome remained mechanically ventilated in 
the intensive care unit (due to sepsis, obstructive sleep apnea, possible seizures, pulmonary 
hypertension and reoperation for pacemaker insertion) as did one (6%) control (for pulmo-
nary hypertension) (P=0.13). 
TABLE 7 Intensive care management, by group
 Down syndrome (n=18) Controls (n=16) P value
PIM2 score (%) 2 [2 to 3] 2 [1 to 3] 0.99
PRISM-II score Day 1 (%) 0.55 [0.1 to 1.3] 1.3 [0.1 to 1.4] 0.54
PRISM-II score Day 2 (%) 1 [0.1 to 1.3] 0.1 [0 to 0.9] 0.14
Duration of mechanical ventilation, in hours 23 [17 to 29] 28 [19 to 50] 0.48
Reintubation, n(%) 1 (6%) 2 (13%) 0.59
Study period, in hours 40 [24 to 55] 46 [30 to 64] 0.57
Duration intensive care admission, in days 3.9 [2.1 to 7.8] 4.0 [2.2 to 6.2] 0.93
PIM = Paediatric Index of Mortality PELOD = Paediatric Logistic Organ Dysfunction
Time Predicted concentrationsNPDE
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 DISCUSSION
This study showed that children with Down syndrome have comparable analgesia and 
sedation requirements after cardiac surgery, compared to controls. Pain and distress as-
sessment showed no statistically significantly differences between the two groups, other 
than the finding that children with Down syndrome are more at risk for oversedation. No 
differences were observed in the volume of distribution and clearance of morphine between 
children with and without Down syndrome. Duration of mechanical ventilation and dura-
tion of intensive care admission were comparable between both groups. 
Morphine dosing
To our knowledge, there is no evidence that establishes the optimal morphine infusion rate 
after cardiac surgery in children. After a loading dose, 40 mcg/kg/hr is a commonly used 
rate to start with, after which the dose will be titrated based upon effect and pain scores. 
We did not expect a prolonged effect from residual anaesthetic agents during intensive 
care, since the anaesthetic agents during cardiopulmonary bypass were short-acting (i.e. 
remifentanil and isoflurane) and after bypass morphine (100 mcg/kg loading dose followed 
by an infusion of 40 mcg/kg/hr) and sevoflurane. The mean morphine infusion rate over 
the first 24 hours after surgery was 32 mcg/kg/hr in both groups.
Gakhal et al. compared the analgesia and sedation requirements of 16 children with Down 
syndrome and 16 controls after cardiac surgery(4). The mean infusion rate for the first 24 
hours after surgery was somewhat lower (26 mcg/kg/hr for the Down syndrome group and 
24 mcg/kg/hr for the controls) than in the present study. The authors report that prescribing 
patterns differed between the physicians and do not mention availability of observational 
pain/distress assessment or departmental guidelines in their study. These lower infusion 
rates in the study by Gakhal et al. could account for the higher use of muscle relaxants and 
sedative agents reported. The children were also older than in the present study (mean age of 
4 years for the Down syndrome group and 5 years for the control group), probably because at 
that time congenital heart defects were corrected at a later age than in the current era. 
The comparable morphine requirements between children with and without Down syn-
drome in the present study confirm the laboratory findings by Martinez-Cue et al.; they 
found that the dose response curve for morphine analgesia is comparable between the 
animal model for Down syndrome (Ts65Dn mice) and control littermates(24). 
Pain/distress assessment
The incidence of a high COMFORT-B score combined with a high NRS for pain was low 
in both groups (8% of the scores in the Down syndrome group versus 6% in the control 
group). Children in both groups were more at risk for oversedation (a low COMFORT-B 
score) in the first three hours after surgery; and children with Down syndrome were slightly 
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more at risk for oversedation. The oversedation in the first three hours after cardiac surgery 
could be partly attributed to the morphine. However, such oversedation might contribute 
to hypotension. The median COMFORT-B scores were still comparable between the two 
groups (13 in the Down syndrome group versus 14 in the control group, P=0.56), so the 
clinical significance of the oversedation in children with Down syndrome may be limited. 
In a previous study by our group, COMFORT-B and NRS for pain scores were also com-
parable between the children with and without Down syndrome that were admitted to the 
intensive care unit after surgical repair of congenital duodenal atresia(5). However, median 
COMFORT-B scores and NRS for pain scores were lower than in the present study; this 
maybe due to the difference in age groups (neonates versus infants/children) and the use of 
regional anaesthesia in 20% of the children in both groups in that study. 
In another study on pain and distress assessment in children postoperatively admitted to 
the intensive care unit (primarily after cardiac surgery), COMFORT-B scores were generally 
lower (median of 12) and the NRS for pain was >3 in 6% of the scores compared to 13% in 
the present study. However, the majority of the children in that study received a high dose 
midazolam infusion; this may explain the lower scores(25). 
Sedation
Although morphine was the primary analgesic agent (with sedative properties), most chil-
dren in both groups received rescue sedation at some point, probably to facilitate mechani-
cal ventilation. The time before rescue sedation was required was shorter in the controls 
than in the Down syndrome group, but this did not reach statistical significance. Addition-
ally, the number of boli of midazolam, or chloral hydrate, or the number of children requir-
ing a midazolam infusion was not statistically significantly different between both groups. 
This is not in line with previous reports on higher sedative requirements in children with 
Down syndrome(2, 4).
Pharmacokinetics
The main finding of the pharmacokinetic analysis was that Down syndrome is not a signifi-
cant covariate for the volume of distribution or total clearance of morphine. Therefore there 
is no need for dose adjustments in children with Down syndrome on the basis of pharma-
cokinetic considerations. 
Our group previously developed a population pharmacokinetic model in 248 children aged 
0-to 3-year-old who received morphine after major non-cardiac surgery or to facilitate me-
chanical ventilation(26). In the current model, the estimation of both central and peripheral 
volume of distribution was larger compared to the estimations from the previous model 
in infants and children after non-cardiac surgery. Altered pharmacokinetics of morphine 
after cardiopulmonary bypass has been described before(6, 27, 28). After cardiopulmo-
nary bypass, it takes some time to restore homeostasis; systemic inflammatory response, 
haemodilution, low cardiac output as well as impaired hepatic and renal function are com-
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mon findings in children after cardiac surgery(29). 
Furthermore, body weight was not a significant covariate for the morphine clearance in this 
study, whereas it was in previous studies(26). The small range in bodyweight in the present 
study could explain this. The population clearance estimated in the present study was only 
slightly smaller compared to the predictions in children after non-cardiac surgery. These 
aspects will have to be addressed in further analysis of morphine clearance post cardiac 
surgery.
Future directions
All children in the present study were below the age of three. The (postoperative) analgesic 
and sedative requirements of older children and adults with Down syndrome should be 
carefully investigated in a prospective study. On the other hand, perceptions of caregivers 
with regard to pain sensitivity and response to sedation of children with Down syndrome 
require more attention, since they could influence the provision of analgesia and sedation(3). 
For both children with and without Down syndrome the next step could be to compare 
different strengths of intravenous morphine in a randomized, double blind controlled trial, 
in order to find the optimal dose of morphine after cardiac surgery. So far dosing recom-
mendations are based on institutional based guidelines only, not supported by studies of 
high quality.
Limitations
Anaesthetists titrated the sevoflurane concentration to effect but we could not present the 
end-tidal sevoflurane concentrations because these were not recorded. We did not take 
plasma samples for pharmacokinetic analysis after discontinuation of the intravenous 
morphine, since patients were switched to oral morphine. The pharmacokinetic model was 
based on morphine concentrations only; the next step will be to incorporate the metabo-
lites (morphine-3- and morphine-6-glucoronide) into the model as well.
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CONCLUSIONS
Based on pharmacodynamics and pharmacokinetic analysis, there is no evidence to adjust 
morphine dosing after cardiac surgery in children with Down syndrome compared to chil-
dren without Down syndrome.  
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DISCUSSION
kRUTGER KOPLAND
Ik zeg niet dat het erg is
ik zeg alleen wat ik dacht 
te zien.

GENERAL DISCUSSION
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“I don’t mind pain as long as it doesn’t hurt”  
Oscar Wilde (1854 – November 30th, 1900) 
Like anyone else, Oscar Wilde must have known what pain is; as a poet he knew how to 
put it in words. This quote perfectly hints at the presence of different layers of pain and the 
personal nature of pain. The different layers of pain were explained in a model, nearly 100 
years after Oscar Wilde, by neurosurgeon John D. Loeser, see Figure 1. The model consists 
of nested circles identifying four components of pain(1).   
FIGURE 1 The four different layers of pain, adapted from Loeser (1). 
Loeser defined the different components as follows: “Nociception is the detection of tissue 
damage by specialized transducers connected to A delta and C fibres. Pain is the perception 
of a noxious stimulus that begins in the dorsal horn and involves the entire spinal cord and 
brain. Suffering is the consequence of a physical or psychological threat to the integrity of 
the human being. Pain behaviors are the things a person says, does, or does not do that you 
and I would interpret as reflecting tissue damage.”(2).
Around the same time, Loeser was member of a committee of the International Association 
for the Study of Pain (IASP) that formulated the following definition of pain in 1979: “Pain 
is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage.”(3).
Chapter 12
233
This definition still stands today. Anand and Craig addressed already in 1996 the limitations 
of this definition, as it is not applicable to persons incapable of self-report: For example 
infants, young children and intellectually disabled children and adults(4). In the note that 
comes with the definition, IASP therefore later added: “The inability to communicate ver-
bally does not negate the possibility that an individual is experiencing pain and is in need of 
appropriate pain-relieving treatment.”
The group that may not able to communicate pain verbally is not in particular a small 
minority; it includes children below the age of 4, intellectually disabled children and adults, 
and elderly with cognitive impairment or dementia. What do we know about the Dutch 
situation? The Netherlands has a population of 17 million people; this includes according 
to Statistics Netherlands approximately 720 000 children below the age of 4, 115 000 intel-
lectually disabled children and adults and 230 000 demented elderly. In other words, more 
than a million people in the Netherlands could have great difficulty in expressing pain in a 
way caregivers will recognize it. Over the next decades, the number of demented elderly is 
likely to increase substantially due to the aging population in the Netherlands(5). 
You may ask yourself, why study pain assessment in intellectually disabled children if we 
still do not have a measure for pain beyond doubt in other patient groups who are not able 
to reliably report their pain? And on what basis do you treat the pain then? 
Over the years much effort was spent on developing good observational pain assessment 
instruments that now have been implemented in pain management algorithms. These 
instruments include several specific tools for intellectually disabled children (see Chapter 2 
for an overview). Still, these children are often excluded from pain research because of their 
inability to self-report pain, the variability in intellectually disability, unknown and poten-
tial altered pharmacokinetics of analgesics, and use of co-medication. Seeing that they are 
at high risk for pain, there is every reason to study pain assessment and its management in 
intellectually disabled children. 
In this chapter I will discuss the three different parts of this thesis - pain assessment, quan-
titative sensory testing, and pain management. The emphasis then shifts to pain process-
ing of children with Down syndrome, since most studies were carried out in children with 
Down syndrome. I give with recommendations for clinical pain management and pain 
research in children. I will conclude with a comparison of the components of pain that are 
affected in intellectually disabled children and neonates admitted to the intensive care unit.
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PAIN ASSESSMENT
The ability to accurately measure pain is the foundation for successful clinical pain man-
agement(6). Observational pain assessment, usually performed by nurses, is the silver 
standard in children up to 4 years of age, sedated or mechanically ventilated patients, and 
intellectually disabled children. Physicians however, tend to prefer physiological param-
eters for pain and distress assessment(7). Pain increases the heart rate and blood pressure 
through the connections from the spinoreticular tract to the brainstem and then further 
on to the sympathetic and parasympathic efferent pathways. The sensitivity and specific-
ity of heart rate and blood pressure monitoring for the measurement of pain are not high 
enough; however in many occasions, for example during general anesthesia or in intu-
bated patients, heart rate and blood pressure monitoring is the only available measure of 
pain. This is why bedside monitors based on “objective surrogate” measures for pain and 
distress have been developed – such as Bispectral index(8) and skin conductance(9). In this 
thesis we evaluated one observational pain assessment tool, the COMFORT-B scale, and 
two objective surrogate measures, the Bispectral index and skin conductance. 
COMFORT-B scale
The COMFORT scale has gained popularity in many hospitals since its introduction in 
1992(10). The intensive care nurses of the two children’s hospitals where the studies 
described in this thesis were conducted, were well trained to use this scale, given the high 
interrater reliability (Chapters 6, 7, 10 and 11). They each perform approximately 1000 
assessments annually. Although the scale already showed good psychometric proper-
ties, validation is an ongoing process. Two items, crying and muscle tone were thought 
to be rated differently in children with Down syndrome, compared to other children(11, 
12); the validity of the COMFORT-B scale in children with Down syndrome was therefore 
questioned. In this thesis we showed that the COMFORT-B scale was also valid in children 
with Down syndrome and that the clinical cut-off values did not need to be adjusted. The 
observational pain and distress assessment with COMFORT-B scale might then be the best 
available option; it has its limitations as well. First, because the observation period is as 
long as 2 minutes, it is not a good measure for short-lasting procedural pain. A study by 
our group showed that a shorter observation period of 30 seconds increased the risk for 
underscoring pain(13). Second, next to the COMFORT-B scale, nurses apply the Numeric 
Rating Scale (NRS), in order to be able to differentiate between pain and distress. This rat-
ing (0=no pain at all and 10= worst imaginable pain) expresses the nurse’s informed opin-
ion of the patient’s level of pain  – taking disease-related, treatment-related, environmental 
and patient-specific circumstances into account. Nevertheless there is a certain measure of 
subjectivity involved here, as the influence of the nurse’s personal perception of pain can-
not be ruled out. A study on how observers translate the various circumstances into a rating 
from 0 to 10 would provide welcome information on the validity of this rating. Third, the 
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COMFORT-B scale is only applied 3 to 10 times a day. It will therefore not recognize sudden 
changes in a child’s behaviour as a continuous measure would. Fourth, caregivers will have 
to apply other observational pain assessment tools for other groups of intellectually disa-
bled children (see Chapter 2 for an overview). However, these scales have been validated 
only in children aged 4 years and older whereas the COMFORT-B has been validated in 0- to 
3-year-old children. 
Surrogate physiological parameters
Since they do not require self-report, devices that measure physiological reactions to pain-
ful or stressful stimuli are potentially helpful for pain and distress assessment in intellectu-
ally disabled children and non-verbal patients. The sensitivity and specificity of changes 
in blood pressure and heart rate are low, since these changes can also be side-effects from 
general anesthetic agents, effects from comorbidities such as cardiovascular diseases, or 
from the surgical procedure itself. Furthermore, inotropic and vasoactive drugs that pro-
vide hemodynamic support are often titrated based on the blood pressure and heart rate. In 
those occasions blood pressure and heart rate monitoring for the assessment of pain and 
distress may be less reliable. 
Physiological parameters are regarded as objective, but objective does not automatically 
means valid. For example, the algorithm of the BIS monitor is derived from adult data; the 
validity of that algorithm in infants (age 0 to 12 months) is questionable since their elec-
troencephalogram (EEG) has not matured yet(14, 15). Furthermore, the Bispectral index is 
based on only two frontal EEG channels. Epileptic activity and anticonvulsant drugs alter 
the EEG as well(16). Epilepsy is a common comorbidity in intellectually disabled children; 
prevalences of up to 75% have been reported(17). Sixty percent of the intellectually disa-
bled children in the study on Bispectral index monitoring suffered from epilepsy and were 
therefore treated with anticonvulsants; this could be an explanation for the lower Bispectral 
index values in intellectually disabled children compared to controls(Chapters 4 and 5). 
Further evaluation of the EEG and the BIS algorithm is required, before the BIS can be used 
in infants and intellectually disabled children. To investigate the effect of anticonvulsants 
on depth of anesthesia, a prospective study is needed in which depth of anesthesia is meas-
ured in four study groups – based on intellectual disability and use of anticonvulsant drugs 
– receiving the same standardized anesthetic regimen. Until then, BIS monitoring cannot 
be recommended for assessing the depth of anaesthesia in intellectually disabled children.  
Another example of a supposedly objective measure of pain and distress is skin conduct-
ance monitoring. Comparison of this methodology to other measures in various age groups 
and various settings proved it has to low sensitivity and specificity for measuring pain(9, 
18). For instance, we observed that autoregulation of the body temperature during a rest 
phase results in skin conductance peaks of similar magnitude as in pain (Chapter 7). In or-
der to make skin conductance measurement more useful, preclinical studies should apply 
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microneurography of both nociceptive C fibres and sympathetic nerve fibres(19) as the gold 
standard, and measure skin conductance simultaneously. Comparing pain and pain-free 
recordings would then enable us to single out the influences of pain and other sympathetic 
activity on skin conductance. Next, the algorithms of the skin conductance monitor could 
be refined for the measurement of pain by correcting for other sympathetic influences. For 
now, the sensitivity and specificity of the COMFORT-B scale for pain assessment exceed 
those of skin conductance monitoring.
Researchers and clinicians keep searching for more objective measures of pain and 
distress. In order to move forward, the industry, academic researchers and clinicians 
should make an effort to develop and validate an useful and reliable bedside monitor. We 
must leave the time of small-scale observational studies aimed at promoting the use of 
poorly validated and expensive monitors behind us. The proposed monitor would ideally 
be a combination of EEG monitoring and hemodynamic monitoring. Two recent studies 
showed the additional value of advanced statistical methods and combining different con-
tinuous recordings. Fabrizi et al. recognized patterns in EEG recordings that discriminated 
between nociception and other tactile stimulation, using advanced statistical analysis of the 
data with a principal component analysis(20). Treister et al. found that combining hemody-
namic parameters such as heart rate variability and skin conductance discriminated better 
between pain and no pain than the single parameter approach(21). Multimodal assessment 
of pain has not been studied in intellectually disabled children and adults, although these 
are the ones who would certainly benefit from more advanced pain assessment methods.  
Self-report 
Self-report is regarded as the gold standard for the measurement of pain in (non-sedated) 
children aged 4 years and older and in adults(22). However, only a minority (12%) of the 
children with Down syndrome of 8 year and older were able to provide adequate self-report 
according to their parents - based on verbalizing, localizing and rating the intensity of the 
pain(Chapter 8). The Faces Pain Scale-revised is suitable for self-report in children aged 4 
years and older; however chronological age was the only relevant predictor for the ability to 
use this tool(23). We did not investigate if this scale can help the children with Down syn-
drome to rate the intensity of their pain. Is it fair to classify them as inadequate to provide 
self-report? There will be few children with Down syndrome that can provide adequate self-
report. But overestimating their abilities can have bigger consequences, possibly resulting 
in under- or overrating their pain.
It is likely that other intellectually disabled children will not be able to adequately report 
their pain and that they therefore will remain dependent on pain assessment by proxy. 
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QUANTITATIVE SENSORY TESTING
Quantitative sensory testing systematically documents alterations and reorganization in 
nervous system function and, in particular, the nociceptive system(24). It is one of the 
methodologies fit to diagnose sensory abnormalities in patients with neuropathic pain(25). 
QST gave researchers the opportunity to evaluate sensory processing in a standardized way; 
it was picked up to investigate pain sensitivity in intellectually disabled children and adults.
Quantitative sensory testing in intellectually disabled individuals
The suggestion that intellectually disabled children and adults are less sensitive for 
pain(26, 27) is not confirmed by quantitative sensory testing; the results show they are even 
more sensitive for heat pain, see Table 1. However, their intellectual disability and pro-
longed reaction time make quantitative sensory testing less feasible. The study in Chapter 
10 showed that self-report for pain in children with Down syndrome is not adequate, and 
in retrospect this is a requirement for quantitative sensory testing. Also, the studies did not 
investigate the reproducibility of the sensory testing in the intellectually disabled subjects 
leaving the issue of test-retest reliability unresolved. Reliability of thermal detection and 
pain thresholds in adults varied considerably between studies as well(28). The value of 
quantitative sensory testing remains questionable in intellectually disabled children. This 
could be resolved if the tests could be performed without depending on the subject’s self-
report for pain, using continuous monitoring of more objective parameters such as in the 
study by Treister et al.(21) or preferably with the proposed monitor described above.
TABLE 1 Overview QST studies in intellectually disabled individuals
 Hennequin (24) Defrin(29) This thesis (Chapter 8)
Chapter 12
Study group
Control group
QST modality
Cold
Warmth
Reaction time
Other findings
Methodological 
considerations
26 individuals with 
Down syndrome
75 controls
Longer latencies for 
cold pain
Not assessed
Not assessed
More difficulties with 
localization of stimulus 
No conventional QST 
methods
14 adults with unspecified intel-
lectual disability
11 adults with Down syndrome
14 adult controls
Not assessed
More sensitive for heat pain (MLE)
Prolonged
No data on feasibility of QST
42 children with Down syndrome 
24 siblings
Less sensitive for detection of cold 
(MLI)
Less sensitive for detection of  
warmth (MLI)
More sensitive for heat pain
Prolonged
Less sensitive for detection of  
pressure
QST feasible in only minority of  
children with Down syndrome
MLI = Method of Limits    MLE = Method of Levels
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Quantitative sensory testing and long-term effects of neonatal morphine / surgery
Morphine is worldwide used for opioid analgesia in (preterm) infants, for example after 
surgery for congenital anomalies. Given the adverse effects of morphine and neonatal tis-
sue damage in rodents, it is important to investigate those effects in humans as well(30); 
for example by applying quantitative sensory testing to evaluate thermal detection and pain 
thresholds. 
Quantitative sensory testing was feasible in the former preterm and term born neonates at 
8 to 16 years of age. However, differences in instructions and sensory testing methods (tem-
perature settings and for example methods of levels versus methods of limits) hampers test 
standardization and comparison of study findings(31). In addition, the long-term adverse 
effects of neonatal pain and morphine treatment vary widely between the various studies 
reported in Table 2. It would therefore be desirable to develop international QST guidelines 
and testing protocols and perform a meta-analysis of both the data of study groups and 
control groups. 
The study in Chapter 9 provided input for the translational research continuum on the 
development of functional nociceptive circuits in early life. Previous research in rodent 
models gave new insights in the development of neuronal circuits and neuroplasticity 
of the fetal and neonatal brain(32). Ruda et al. found that neonatal peripheral injury in 
a rodent model (evoked with complete Freund’s adjuvant) gave long-term alterations of 
sensory processing and altered nociceptive neuronal circuits(33). It has been argued that 
a rodent model with repetitive needle pricking better represents the nerve injury in neo-
nates during intensive care admission than does the model with high doses of intraplantar 
hind paw injections of inflammatory substances such as complete Freund’s adjuvant(34). 
Neonatal rodents showed impaired learning and enhanced hippocampal gliosis (prolifera-
tion of damaged astrocytes) after morphine administration(35-38). Extreme prematurity 
(gestational age of <28 weeks) combined with neonatal surgery in humans was associated 
with more pronounced long-term effects on sensory processing than was admission to the 
NICU for mechanical ventilation and continuous morphine administration (See Table 2). 
Major limitations of previous studies are the small sample size and absence of prospective 
data on administered analgesic and sedative agents in the neonatal period.
Analysis of the electroencephalogram (EEG) during heel lancing in neonates suggests that 
specific neural circuits for nociceptive processing undergo critical developmental changes 
until a postconceptional age of 35 to 37 weeks(20). 
Therefore the influences of neonatal pain and analgesia on human neurodevelopment and 
neuroplasticity need closer investigation. More importantly, researchers should be ex-
tremely wary of classifying a relationship between administration of anesthetic or analgesic 
agents and long-term adverse effects as causative(39). They should also judge whether the 
relationship is strong enough to be clinically relevant. Otherwise we might expect a lot of 
media attention and risk upsetting parents and caregivers of infants and neonates who 
require surgery or intensive care treatment. 
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TABLE 2 QST and long-term effects of neonatal pain and morphine administration on 
thermal detection and pain thresholds
Chapter 12
Study group
 
Opioid  
analgesia
Surgery
Control group
Age
QST modality
Cold
 
Warmth
Other findings
Hermann(40) 
19 former preterm 
NICU patients
20 former term 
NICU patients
Yes, in 18 (46%)
No
20 controls
9 to 14 years
Not assessed
Both study groups 
were less sensi-
tive for heat pain
Schmelzle- 
Lubiecki(41) 
9 former neonatal 
cardiac surgical 
patients
Yes
Yes
9 controls
9 to 12 years
No differences 
in cold detection 
thresholds
No differences in 
warmth detection 
thresholds
Study group was 
less sensitive for 
thermal detection 
at thoracic scar 
area
Walker(42)
 
43 former ex-
tremely preterm 
NICU patients
No information 
provided
Yes, 12 (28%)
44 controls
11 years
Study group less 
sensitive for detec-
tion of cold and 
cold pain
Study group less 
sensitive for detec-
tion of warmth and 
heat pain
Findings more 
pronounced in 
neonates that had 
surgery
Hohmeister(43) 
9 former preterm 
NICU patients
9 former term 
NICU patients
No information 
provided
No
9 controls
11 to 16 years
Not assessed
No differences in 
warmth detection 
or pain thresholds
Higher fMRI activa-
tions in former 
preterm NICU 
patients
This thesis (Chap-
ter 9)
43 in continuous 
morphine group
46 in placebo 
group 
(both preterm 
and term NICU 
patients)
Yes
No
139 controls
8 to 9 years  
(study group)
7 to 11 years (con-
trol group)
Study group more 
sensitive for detec-
tion of cold; No 
differences in cold 
pain thresholds
No differences in 
warmth detec-
tion or heat pain 
thresholds
In multivariate 
analysis no differ-
ences in thermal 
detection and pain 
thresholds between 
continuous mor-
phine and placebo 
group 
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PAIN MANAGEMENT
In previous studies intellectually disabled children received lower amounts of intraopera-
tive analgesia than controls(44, 45). Are their analgesic requirements different or is there 
another explanation? As a possible reason, the provision of analgesia may be influenced by 
physicians’ perceptions about the patient’s sensibility to pain or response to analgesia(46). 
We studied the analgesic and sedative requirements of children with Down syndrome 
initially retrospectively and then prospectively (Chapter 10 and 11). Before the start of those 
studies, many clinicians assured that children with Down syndrome were more difficult 
to sedate. In the prospective study, the same standardized anesthetic and postoperative 
regimen was applied to both the children with and without Down syndrome. Anesthesiolo-
gists titrated the dose of anesthethic agents based on specific clinical endpoints (i.e. blood 
pressure, heart rate or observational pain assessments), not on the presence or absence of 
intellectual disability. Furthermore, all patients received standardized postoperative pain 
and distress management, based on COMFORT-B and NRS scores. The incidence of mod-
erate to severe pain was comparable between both groups: 8% of the assessments in the 
Down syndrome group versus 6% of the assessments in the control group. No differences 
in intraoperative analgesic or sedative requirements were found between the two groups. 
In addition, the analysis of morphine pharmacokinetics gave no reason for different dosing 
recommendations in children with Down syndrome. 
To our knowledge, there is no evidence that establishes the optimal morphine infusion rate 
after cardiac surgery in children. A next investigation should compare different doses of 
intravenous morphine in a randomized, double blind controlled trial using the incidence 
of pain, rescue medication requirements, and side-effects as outcome measures. As 43% 
of the children in the retrospective study in Chapter 10 and all children in the prospective 
study in Chapter 11 received paracetamol next to opioid analgesia, further investigations on 
multimodal postoperative analgesia in children are needed.  
Extrapolation to other groups
The study in Chapter 11 addressed the pharmacodynamics and pharmacokinetics of 
morphine after cardiac surgery in children with Down syndrome. Can the results be 
extrapolated to other groups of intellectually disabled children, for example those undergo-
ing spinal fusion correction or other orthopedic procedures? It is not easy to answer this 
question, seeing the differences in age groups, heterogeneity in the etiology of the intellec-
tual disability, in the surgical procedures, and in co-medication. Prospective studies on the 
analgesic and sedation requirements of intellectually disabled children as well as pharma-
cokinetics of analgesic and sedative agents are needed to optimize the pain management 
for these children. 
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Optimal pharmacotherapy 
Recent advances have improved the feasibility of pharmacokinetic studies in infants and 
children, since both the required blood sample volume and number of samples required 
for analysis have decreased substantially(47). Data from population pharmacokinetic and 
pharmacodynamic studies can be used for simulations. These simulations then can form 
the basis for the design of proof of principal studies, preferably randomized controlled 
trials(48). This approach has successfully been applied to for the development of evidence-
based pharmacotherapy in (critically ill) neonates, infants and children without intellectual 
disability – e.g. for midazolam, morphine, propofol and paracetamol(49). 
But is it feasible to study the pharmacokinetics and pharmacodynamics for every group of 
intellectually disabled children and for every analgesic or sedative agent? Systematic and 
careful monitoring of pharmacodynamic effects could be a starting point (50), preferably 
with a more advanced bedside monitor as described above. Analysis of the pharmacokinet-
ics would be justified when we could expect an effect size of differences in the pharmacody-
namics between two groups as well as potential sources for pharmacokinetic variability. 
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PAIN PROCESSING IN CHILDREN WITH DOWN SYNDROME
This thesis started quoting John Langdon Down’s observations that individuals with Down 
syndrome bear pain with wonderful callousness. Parents and caregivers still perceive 
children with Down syndrome to be less sensitive to pain (Chapter 3 and 8). It is a logical 
evaluation based on these children’s pain: each parent gave examples of situations where 
their child did not report an injury and where they had difficulties in perceiving their child’s 
pain. But medical professionals, too, tell anecdotes on the decreased pain sensitivity and 
how difficult to sedate children with Down syndrome are - topics that have been prospec-
tively studied in this thesis. We did not exactly find what we expected based on these anec-
dotes: Children with Down syndrome are not less sensitive to pain (Chapter 8) and are not 
more difficult to sedate than children without Down syndrome (Chapter 10 and 11). I think 
we are dealing with confirmation bias here; clinicians will clearly remember individuals 
with Down syndrome in whom sedation was not easy or who appeared to be less sensitive 
to pain. They will not remember the children with Down syndrome who responded ‘nor-
mally’. This notion, however, represents the wide variability between children with Down 
syndrome. We should try to avoid preconceptions and bias and focus on assessing pain in 
children who do not express pain as we would expect. What do the studies in this thesis tell 
about pain processing in children with Down syndrome? 
Nociception
Nociception seems to be intact in children with Down syndrome. Nociception is the neural 
process of encoding noxious stimuli and pain sensation is not necessarily implied. Apply-
ing the qualitative sensory tests most children with Down syndrome were able to distin-
guish a sharp and blunt stimulus; applying the quantitative sensory tests to assess the pain 
thresholds revealed that they are even more sensitive for pain. The studies in children with 
Down syndrome after congenital duodenal atresia repair and cardiac surgery showed that 
nociception seems to be intact, judging from the fact that the pain and distress ratings as 
well as analgesic or sedative requirements did not differ between children with and without 
Down syndrome. 
From nociception to pain behaviour
The higher processing of the nociceptive stimuli - from nociception to experiencing and ex-
pressing pain - seems to be affected in children with Down syndrome. Children with Down 
syndrome had difficulties with localizing pain and with rating the intensity of pain; in other 
words, their ability for self-report of pain is rather limited. Furthermore, they used fewer 
pain coping strategies than children without Down syndrome. This is likely to have a big 
impact on the pain experience and pain expression of children with Down syndrome and 
will therefore explain the observations by their parents and John Langdon Down. Children 
with Down syndrome may express pain differently than caregivers expect. Adequate pain 
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expression – preferably using self-report – requires higher cognitive skills that probably are 
affected by an intellectual disability. Furthermore, it is likely that the pain expression will be 
less adequate if a child is anxious or distressed. Pain is known to be a subjective experience, 
but rating pain expression of others as adequate or not is perhaps even more subjective.
Other methods of evaluating pain processing
In this thesis we evaluated pain processing using qualitative and quantitative sensory 
tests, predominantly with the thermal sensory analyser. There are other potential relevant 
methods available that we did not apply, such as the cold pressor task, magnetic resonance 
imaging (MRI) and nerve conduction velocity measurement:
The cold pressor task asks the child to submerse their hand in cold water (with a constant 
temperature, for example 10 degrees Celsius) until it becomes painful(51). The thermal 
sensory analyser, on the other hand, is based on increasing the intensity of the stimulus. 
The limited feasibility of the thermal sensory analyser in children with Down syndrome was 
certainly an issue. It is worthwhile to study whether the cold pressor task would be more 
feasible. 
Structural magnetic resonance imaging (MRI) of the brain in children and adults with 
Down syndrome showed smaller brain volumes; in particular the volume of the hippocam-
pus and the amygdala(52, 53). Since these MRI scans give no information on the function 
of these brain areas, it is hard to determine how these findings contribute to our knowledge 
on pain processing in children with Down syndrome.
Brandt et al. showed that the nerve conduction velocities of sensory nerves of 6 children 
with Down syndrome were lower than in 10 children without Down syndrome(61). Al-
though this finding could help explain the higher detection thresholds for cold and warmth 
in the children with Down syndrome, the contribution of this single study is limited. It 
would have to be replicated in a larger cohort – combined with evaluation of the nociceptive 
nerve fibres is therefore required. 
Children with Down syndrome: A starting point?
The studies on the COMFORT-B scale and the morphine pharmacodynamics and phar-
macokinetics were conducted in 0 to 3-year-old children with Down syndrome. Future 
studies should therefore include older children with Down syndrome as well. De Knegt and 
Scherder carefully reviewed studies on the pain experience of intellectually disabled adults: 
they concluded that white matter lesions in adults with vascular dementia could cause cen-
tral pain and that adults with Down syndrome face early and progressive degeneration and 
are at high risk of developing Alzheimer’s dementia(54). The effect of progressive neurode-
generation should therefore be carefully taken into account when evaluating pain process-
ing in adults with Down syndrome. 
Moreover, Down syndrome is only one of the many causes of intellectual disability: the 
majority of children with Down syndrome is mildly intellectually disabled whereas other 
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groups might be more profoundly intellectually disabled and experience more problems, 
such as girls with Rett syndrome(55). Was it too straightforward to study children with 
Down syndrome? No, it was not: the high incidence of cardiac surgery and comorbidities 
justified studying children with Down syndrome. Let this thesis be a starting point for stud-
ies in children with autism and other groups of intellectually disabled children. 
Future clinical studies on pain expression and the interaction between analgesics and 
co-medication are needed in intellectually disabled children and adults. Preclinical studies 
in rodents can help to study alterations in nociception and gene expression(56). Over the 
years, several mouse models have been developed for various causes of intellectual disabil-
ity: for example the Ts65Dn mouse for Down syndrome(57) and a mouse model with the 
mutation in the MECP2 gene for Rett syndrome(58). Mouse models also have successfully 
been used for the study of pain behaviour and effects of repeated skin breaking procedures 
at the neonatal age(34). Pain behaviour can be observed in rodents using validated meth-
ods such as the hot plate test or tail flick test. Investigations that are not ethical in humans, 
for example as studying the distribution of the opioid receptor, are feasible in rodents(59). 
Preclinical animal studies and clinical human studies have complementary roles and will 
help to improve pain assessment and management in intellectually disabled children and 
adults. 
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RECOMMENDATIONS FOR CLINICAL PAIN MANAGEMENT
1.  Use valid observational pain and distress assessment tools in non-verbal children and in 
children who cannot provide adequate self-report of pain
2.  Objective tools based on physiological parameters for pain or distress assessment are 
potentially good pharmacodynamic outcome measures, but validity for the use in in-
fants and intellectually disabled children should be evaluated before routine use can be 
recommended
3.  Doses of intraoperative and postoperative analgesics and sedatives do not need to be 
adjusted in children with Down syndrome 
4.  A multidisciplinary pain management and sedation protocol is a prerequisite for ad-
equate pain management. Compliance with the protocol should regularly be evaluated 
RECOMMENDATIONS FOR PEDIATRIC PAIN RESEARCH
1.  Development of standardized international quantitative sensory testing (QST) guide-
lines and meta-analysis of the QST data 
2.  The pain expression of children with Down syndrome and other groups of intellectually 
disabled children should be systematically evaluated and thereafter be integrated with 
clinical pain assessment
3.  Development and validation of a pain assessment tool based on physiological param-
eters that can also be used during general anesthesia and intensive care, especially in 
non-verbal and intellectually disabled children
4.  The studies in Down syndrome should be the starting point for pain research in other 
groups of intellectually disabled children and adults 
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INDIVIDUAL PREDICTION OF PAIN AND ANALGESIA AND 
SEDATION REQUIREMENTS
The above recommendations give direction to clinical pain management and further pedi-
atric pain research. In one of the studies in this thesis, morphine plasma concentrations 
were modelled using NONMEM software in order to estimate population pharmacokinetic 
parameters such as the volume of distribution and clearance. The ultimate goal is to predict 
– for an individual – the amount of pain after surgery and the analgesia or sedation require-
ments. 
Potential predictors:
- Genetic make-up 
-  Age and developmental stage of the patient (both physiological processes as well as 
cognition)
- Presence of relevant comorbidities
- Pharmacokinetics and pharmacodynamics of the analgesic and sedative agents
- Use of comedication that could interact with other medications
-  Preoperative detection and pain thresholds (quantitative sensory testing) and associ-
ated brain activations during fMRI
- Pain coping styles
Carefully developing as well as internal and external validation of those clinical prediction 
models is essential(60). The reliability of the predictions will have to be evaluated and on-
going research will keep improving the predictions. 
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FROM NOCICEPTION TO PAIN BEHAVIOUR
At the start of this chapter, I introduced the four components of pain processing as identi-
fied by Loeser – nociception, pain, suffering and pain behaviour. This thesis addressed pain 
assessment and management in intellectually disabled children. Two studies focussed on 
neonates admitted to the intensive care unit – another group at risk for pain and in which 
self-report of pain is impossible. There even can be overlap between these two groups; neo-
nates with post-hypoxic encephalopathy for example. These children suffer from a variable 
degree of intellectual disability and spasticity – also known as cerebral palsy. Table 3 shows 
a comparison of the components of pain that are affected in intellectually disabled children 
and neonates admitted to the intensive care unit. 
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Intellectually  
disabled children
-  Expression is 
different from what 
caregivers expect
-  Require observational 
pain assessment by 
proxy
-  Only few pain coping 
strategies are used
- More surgery
- More comorbidities
 
Higher brain functions 
are damaged
Analgesia:
-  Possible interaction 
of co-medication  
(e.g. anticonvulsants)
- Normal postoperative 
requirements
Intact 
Neonates admitted 
to intensive care
Observational pain 
assessment by proxy
Repeated skin break-
ing and stressful 
procedures 
At risk for short-term 
hyperalgesia as a 
neonate
Analgesia:
Continuous morphine 
infusion has no long-
term adverse effects 
on pain processing 
Intact
Pain behaviour
Suffering
Pain
Nociception
TABLE 3 Pain processing in intellectually disabled children and neonates admitted to the 
intensive care – according to the pain model by Loeser
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 Nociception is classified as intact in both groups, although it is difficult to evaluate solely 
“nociception” in humans. It is more feasible to study nociception in animal models, using 
invasive techniques such as microneurography. Furthermore, animal studies will enable 
to evaluate structural changes to the peripheral and central nervous system. Those studies 
could provide a more detailed view on the influence of Down syndrome and other causes of 
intellectual disability on nociception. For now there are no indications of altered nocicep-
tion in intellectually disabled children and neonates, based on assessment of thermal detec-
tion and pain thresholds. 
Pain in intellectually disabled children is primarily postoperative pain; as they get older 
their comorbidities can cause pain as well, such as orthopedic problems, gastroesophageal 
reflux disease, constipation, and infections of respiratory and urinary tract. Since many 
intellectually disabled children use medication, for example anticonvulsants, interaction 
with anesthetic, analgesic and sedative agents should be studied in these children in future 
studies. 
Structural changes in the central nervous system can be explored using functional magnetic 
resonance imaging (fMRI), for example to study long-term effects of neonatal pain.
Intellectually disabled children will need surgery; preterm or critically ill neonates will need 
intensive care management with many skin breaking procedures. It is key to reduce suffer-
ing by applying both non-pharmacological and pharmacological interventions. 
As pain behavior of intellectually disabled children and neonates is different from what 
caregivers would expect, more objective methods for the assessment of pain and distress 
are badly needed. This asks joint effort of medical professionals, researchers, the industry 
and even parents. More than a million people in the Netherlands – intellectually disabled 
children, children below the age of 4, and demented elderly –will benefit from improved 
objective methods to measure pain. 
Building on this thesis, we may expect that reliable pain assessment and evidence-based 
pain management will become available to individuals who communicate pain “without 
uttering a word”.  
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SUMMARY
This thesis addressed several studies on pain assessment and management, as well as 
general anesthesia and sedation, in intellectually disabled children with a focus on children 
with Down syndrome.
PART I INTRODUCTION
Previous studies on pain assessment and treatment are discussed in Chapter 2. This review 
showed that observational pain assessment tools for intellectually disabled children have 
become available and that future research should focus on tailoring the pain treatment 
in these children. Chapter 3 presents the results of a survey on the perceptions and prac-
tices of Dutch anesthesiologists concerning pain management in intellectually disabled 
children. One third of the respondents perceived intellectually disabled children as more 
sensitive to pain, but this did not result in higher doses of analgesics for these children. 
Furthermore, they take a different approach when caring for intellectually disabled children 
and they were not aware of the existence of pain observation scales for these children.
PART II ASSESSMENT
The question was if instruments for pain and distress assessment, such as Bispectral Index 
(BIS)-monitoring, the COMFORT-B scale and skin conductance monitoring, are also valid 
in non-verbal infants and children. Anesthesiologists use the BIS monitor during gen-
eral anesthesia to monitor the depth of anesthesia. Chapter 4 is a case report describing 
extremely low awake and perioperative BIS values in two intellectually disabled children. 
These observations prompted the study presented in Chapter 5, which indeed confirmed 
that BIS values measured in intellectually disabled children were significantly lower than 
those of controls. Therefore we advised anesthesiologists to be alert to the fact that BIS 
values in intellectually disabled children may be subnormal, resulting in a risk of misinter-
preting these children’s state of consciousness. 
The COMFORT-B scale is an observational pain and distress assessment instrument devel-
oped for the use in infants and young children after surgery or if they are admitted to the 
intensive care unit. Chapter 6 describes a study that found that the COMFORT-B scale is 
also valid for 0 to 3-year-old children with Down syndrome. This makes it even more useful 
in the pediatric intensive care unit setting. 
The conductance of the skin increases if the sympathetic nervous system is activated, for 
example by pain or distress. This mechanism is reflected by peaks on the monitor. Previous 
studies found variable performance of skin conductance measurement as a pain assess-
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ment tool, with low specificity and a low predictive value reported in some studies. The 
study in Chapter 7 showed that sympathetic neural activity to maintain homeostasis (such 
as autoregulation of skin temperature) also results in skin conductance peaks. Before 
advocating its use in daily practice, the technique should be better defined to increase both 
sensitivity and specificity for the measurement of pain.
PART III QUANTITATIVE SENSORY TESTING
Quantitative sensory testing systematically documents alterations and reorganization in 
nervous system function and, in particular, the nociceptive system. The question was if 
children with Down syndrome show reduced sensitivity to pain according to their parents 
and in experimental pain tests. The pain sensitivity of children and adults with Down 
syndrome has been widely debated but rarely studied. The study in Chapter 8 compared 
thermal detection and pain thresholds between children with Down syndrome and their 
siblings, using qualitative and quantitative methods, as well as parental questionnaires on 
pain coping, pain behaviour and chronic pain. The different sensory tests proved to be fea-
sible in 33% to 88% of children in the Down syndrome group. Parents rated their children 
with Down syndrome as less sensitive to pain, but this was not confirmed by quantitative 
sensory testing. Children with Down syndrome will remain dependent of pain assessment 
by proxy, since self-report was not adequate.
The second study in this part addressed the question whether continuous morphine ad-
ministration at neonatal age affects thermal detection and pain thresholds, chronic pain, or 
neurological functioning at 8-9 years of age.
A cohort of children who as neonates participated in a randomized controlled trial is being 
followed over time. The original study compared continuous morphine infusion with pla-
cebo in preterm and term neonates on ventilatory support. The authors concluded that rou-
tine continuous morphine infusions should not be recommended for neonates on ventila-
tory support. The study in Chapter 9 showed, however, that neonatal continuous morphine 
infusion (10 mcg/kg/hr) has no adverse effects on thermal detection and pain thresholds or 
overall neurological functioning eight to nine years later.
PART IV MANAGEMENT
Previous studies found that intellectually disabled children receive lower doses of analge-
sics during general anesthesia. On the other hand, children with Down syndrome are often 
described more agitated and “difficult to sedate” after surgery. The question was if the 
postoperative analgesia and sedation requirements of children with Down syndrome dif-
fer from other children. Chapter 10 is a retrospective study that compared the pain scores 
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and analgesia and sedation requirements of neonates with and without Down syndrome 
after surgical repair of a congenital duodenal obstruction. We did not observe any differ-
ences between the neonates with and without Down syndrome. This was then confirmed 
in a prospective evaluation, presented in Chapter 11. Approximately 40 to 60% of children 
with Down syndrome have a congenital heart defect and many therefore undergo major 
surgery and postoperative intensive care management at a young age. This study compared 
the pharmacodynamics, i.e. analgesia and sedation requirements and pain and distress 
assessments, as well as the morphine pharmacokinetics between children with and without 
Down syndrome. We found no reasons for different morphine dosing after cardiac surgery 
in children with Down syndrome compared to children without Down syndrome.
PART V GENERAL DISCUSSION
Chapter 12 discussed the studies presented in this thesis and made recommendations for 
clinical pain management and pediatric pain research. 
It concludes with linking the results to the four components of pain processing as identi-
fied by Loeser – nociception, pain, suffering and pain behaviour. 
There are no indications of altered nociception in intellectually disabled children and neo-
nates, based on assessment of thermal detection and pain thresholds. 
Pain in intellectually disabled children is primarily postoperative pain. We found normal 
postoperative analgesia and sedation requirements in children with Down syndrome. Clini-
cians should be aware of potential interaction with co-medication (e.g. anticonvulsants). 
Higher brain functions associated with pain processing appear to be altered. 
Intellectually disabled children are more at risk to suffer, as they require more often surgery 
and have more comorbidities. 
As pain behavior of intellectually disabled children and neonates is different from what car-
egivers would expect, more objective methods for the assessment of pain and distress are 
badly needed. This asks joint effort of medical professionals, researchers, the industry and 
even parents. More than a million intellectually disabled children, children below the age of 
4, and demented elderly in the Netherlands will benefit from improved objective methods 
to measure pain, as self-report may be unreliable or impossible.
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SAMENVATTING
Dit proefschrift beschrijft verschillende studies op het gebied van het meten en behande-
len van pijn bij verstandelijk gehandicapte kinderen – en dan met name kinderen met het 
syndroom van Down. 
DEEL I – INTRODUCTIE
Hoofdstuk 2 geeft een overzicht van de literatuur op het gebied van het meten en behande-
len van pijn. Hieruit blijkt dat er verschillende pijnmeetinstrumenten zijn ontwikkeld voor 
verstandelijk gehandicapte kinderen; de meest gebruikte observatieschalen worden in dit 
overzicht besproken. We mogen concluderen dat toekomstig onderzoek zich zou moeten 
richten op de juiste behandeling van pijn bij deze kinderen.
Hoofdstuk 3 gaat over de resultaten van een enquête onder anesthesiologen in Nederland. 
We vroegen hen onder andere naar hun percepties en beleid rondom het behandelen van 
pijn in verstandelijk gehandicapte kinderen. Een derde van de respondenten meende dat 
verstandelijk gehandicapte kinderen gevoeliger zijn voor pijn, maar vond dit geen reden 
om de dosering van pijnstillers aan te passen. Daarnaast passen de meeste anesthesiologen 
hun beleid aan op de verstandelijk gehandicapte kinderen, maar ze waren niet bekend met 
de verschillende pijnmeetinstrumenten voor deze groep kinderen. 
DEEL II – METEN
We vroegen ons af of de verschillende instrumenten voor het meten van pijn en onrust, 
zoals de Bispectral index monitor, de COMFORT-gedragschaal en de skin conductance 
monitor, ook toepasbaar zijn bij non-verbale kinderen. 
Anesthesiologen kunnen de diepte van de anesthesie meten met de Bispectral index mo-
nitor. In hoofdstuk 4 bespreken we twee gevallen waarin bij een verstandelijk gehandicapt 
kind veel lagere BIS-waarden werden gemeten dan we verwachtten; zowel toen ze wakker 
waren als tijdens de algehele narcose. Deze bevindingen waren de aanleiding voor de studie 
beschreven in hoofdstuk 5. Deze studie bevestigde dat de BIS-waarden van verstandelijk ge-
handicapte kinderen lager waren dan die van niet verstandelijk gehandicapte kinderen. We 
adviseren daarom anesthesiologen er alert op te zijn dat de BIS-waarden bij verstandelijk 
gehandicapte kinderen afwijkend kunnen zijn en dat daarom de diepte van de anesthesie 
verkeerd kan worden geschat. 
Verpleegkundigen gebruiken de COMFORT-gedragschaal om pijn en onrust te observeren 
bij jonge kinderen – na een operatie of als ze behandeld worden op een intensive care afde-
ling. In hoofdstuk 6 bespreken we een studie die liet zien dat de COMFORT-gedragschaal 
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ook te gebruiken is voor kinderen met het syndroom van Down. Deze schaal is daarmee nu 
nog breder toepasbaar op een intensive care afdeling. 
De huidgeleiding verandert als het sympathisch zenuwstelsel wordt geactiveerd, bijvoor-
beeld tijdens pijn of onrust. Deze veranderingen (pieken) zijn te meten met de skin con-
ductance monitor. Eerdere studies lieten zien dat deze niet altijd even betrouwbaar is: in 
sommige studies waren de specificiteit en de voorspellende waarde voor het meten van pijn 
aan de lage kant. Het onderzoek beschreven in hoofdstuk 7 laat zien dat het in standhou-
den van een constant intern milieu (homeostase; bijvoorbeeld het regelen van de lichaams-
temperatuur) ook terug te zien is in de huidgeleiding. De sensitiviteit en specificiteit voor 
het meten van pijn moet verbeteren voordat deze monitor van toegevoegde waarde is voor 
het meten van pijn en onrust in de dagelijkse praktijk. 
DEEL III – QUANTITATIVE SENSORY TESTING
Quantitative sensory testing is het in kaart brengen van veranderingen in het zenuwstelsel 
– en dan vooral het deel dat pijnprikkels verwerkt – door bijvoorbeeld de waarnemings- en 
pijndrempels te meten. We vroegen ons af of deze waarnemings- en pijndrempels voor 
temperatuur anders zijn in kinderen met het syndroom van Down, en of ouders van kin-
deren met het syndroom van Down het idee hebben dat hun kinderen minder pijngevoelig 
zijn. 
Er werd namelijk gedacht dat kinderen en volwassenen met het syndroom van Down 
minder pijngevoelig zijn; dit is nog maar zelden echt onderzocht. In hoofdstuk 8 worden 
de resultaten beschreven van een studie waarin we de waarnemings- en pijndrempels voor 
temperatuur van kinderen met het syndroom van Down vergeleken met die van een broer of 
zus. Daarnaast vroegen we hun ouders vragenlijsten in te vullen over hoe hun kind omgaat 
met pijn en of hun kind last had van chronische pijn. Het percentage van kinderen met het 
syndroom van Down dat de testen begreep varieerde van 33% tot 88% voor de verschillende 
testen. Veel ouders zagen hun kind met het syndroom van Down als minder pijngevoelig. 
Dit werd alleen niet bevestigd met afwijkende pijndrempels. 
Omdat zelfrapportage door kinderen met het syndroom van Down vaak niet voldoende 
betrouwbaar is zullen zorgverleners pijn moeten schatten met bijvoorbeeld een pijnmeetin-
strument. 
In het tweede hoofdstuk van dit deel onderzochten we of toediening van morfine op de 
neonatale leeftijd effect heeft op de waarnemings- en pijndrempels, de incidentie van chro-
nische pijn en het neurologisch functioneren op 8 tot 9 jarige leeftijd. We volgden daarom 
een groep kinderen die als pasgeborene deelnamen aan een gerandomiseerde gecontro-
leerde studie. Deze studie vergeleek een infuus met morfine met een infuus met placebo in 
De helft van een groep preterme en à terme geboren kinderen die beademing nodig hadden 
kreeg een continu infuus met morfine, de andere helft een infuus met placebo en alleen 
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morfine als pijn werd gemeten door de verpleegkundigen. Deze studie vond dat een continu 
morfine infuus niet geadviseerd is voor neonaten die alleen beademd moeten worden. De 
studie in hoofdstuk 9 laat zien dat dit continu morfine infuus (10 mcg/kg/hr) geen nadelige 
gevolgen heeft op de waarnemings- en pijndrempels of het neurologisch functioneren 8 of 
9 jaar later.
DEEL IV – PIJNBEHANDELING
Voorgaande studies lieten zien dat kinderen met een verstandelijke handicap lagere dose-
ringen van pijnstillers kregen tijdens algehele narcose. Daarentegen worden kinderen met 
Down syndroom vaak gezien als onrustiger na een operatie en zouden ze hogere doserin-
gen slaapmedicatie nodig hebben. De vraag is daarom of kinderen met Down syndroom 
andere doseringen pijnstillers en slaapmedicatie nodig hebben na een operatie, vergeleken 
met kinderen zonder het syndroom van Down. 
Hoofdstuk 10 beschrijft een retrospectief onderzoek naar pijn scores en doseringen van 
pijnstillers en slaapmedicatie bij kinderen met en zonder Down syndroom na een operatie 
voor een aangeboren obstructie van de dunne darm. Deze studie liet geen verschillen zien 
tussen kinderen met en zonder Down syndroom. Dit werd bevestigd in de prospectieve 
studie beschreven in hoofdstuk 11. Ongeveer de helft van de kinderen met het syndroom 
van Down heeft ook een aangeboren hartafwijking, en velen ondergaan daarom al op jonge 
leeftijd een ingrijpende operatie met daarna behandeling op een intensive care afdeling. In 
deze studie vergeleken we de farmacodynamiek – de doseringen van pijnstillers en slaap-
medicatie en de pijn/onrust scores – alsmede de farmacokinetiek van morfine (de proces-
sen waaraan morfine in het lichaam wordt onderworpen, tussen kinderen met en zonder 
het syndroom van Down. We concludeerden dat de doseringen van morfine niet te hoeven 
worden aangepast in kinderen met Down syndroom na een open hartoperatie. 
DEEL V – DISCUSSIE 
Hoofdstuk 12 is een reflectie op de verschillende studies in dit proefschrift; daarnaast geef 
ik aanbevelingen voor de behandeling van pijn en voor toekomstige studies op het gebied 
van pijn bij kinderen. 
Ik sluit af met het bespreken van de resultaten aan de hand van het pijn model van Loeser. 
Dit model kent vier componenten: nociceptie, pijngewaarwording, pijnbeleving en pijnge-
drag. 
We hebben geen aanwijzingen gevonden dat de nociceptie van verstandelijk gehandicapte 
kinderen afwijkend is – gebaseerd op de gevonden waarnemings- en pijndrempels voor 
temperatuur. 
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De voornaamste oorzaak van pijn in verstandelijk gehandicapte kinderen is postoperatieve 
pijn. De doseringen van pijnstillers en slaapmedicatie waren hetzelfde voor kinderen met 
en zonder Down syndroom. Zorgverleners moeten alleen wel bedacht zijn op mogelijke 
interactie tussen deze medicijnen en de medicijnen die verstandelijk gehandicapte kinderen 
vaak gebruiken, zoals anti-epileptica. Hogere hersenfuncties die pijnsignalen verwerken 
(bijvoorbeeld het interpreteren van pijn) lijken te zijn aangedaan in verstandelijk gehandi-
capte kinderen. 
Verstandelijk gehandicapte kinderen zullen vaker pijn ervaren. Ze ondergaan namelijk 
vaker operaties en hebben meer aandoeningen zoals infecties of gewrichtsklachten. 
Het pijngedrag van verstandelijk gehandicapte kinderen is anders dan sommige zorgver-
leners verwachten. Daarom zijn objectievere maten voor het meten van pijn en onrust hard 
nodig. Dit vraagt een gezamenlijke aanpak van zorgverleners, onderzoekers, de industrie 
en ook de ouders. In totaal zijn er in Nederland meer dan een miljoen verstandelijk gehan-
dicapte kinderen, kinderen onder de leeftijd van 4, en dementerende ouderen. Zij zullen 
veel baat hebben bij verbeterde instrumenten voor het meten van pijn anders dan door 
zelfrapportage.
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REFERENCES FOR THE POEMS
William Butler Yeats
Yeats (1865 – 1939) was born in Dublin, Ireland. He was a poet, playwright and senator. 
Yeats was influenced by symbolism and Irish legends. His early work is seen as romantic; in 
the 20th century his work became more influenced by politics. In 1923 he was awarded the 
Nobel Prize in Literature. 
Chapter 2: Cuchulain’s Fight with the Sea
Chapter 3: I walked among the seven woods of Coole
Chapter 4: The Statues
Chapter 5: Fergus and the Druid
Chapter 6: A woman’s beauty is like a white
Chapter 7: The Tower
W.B. Yeats. Selected Poems. London: Penguin Classics, 2000
Rutger Kopland
Kopland (1934 – 2012) was born in Goor, the Netherlands. He was a poet and professor of 
psychiatry. His style is described as quiet, conversational and nostalgic. Kopland’s poems 
are reassuring and demonstrate the ‘mechanics of emotion’. He was awarded the P.C. 
Hooft Prize in 1988. 
Chapter 8: Enkele andere overwegingen
Chapter 9: Tijd
Chapter 10: Mijn minnaar en ik
Chapter 11: Enkele andere overwegingen 
Chapter 12: Drie wintergedichten
Rutger Kopland. Verzamelde gedichten. Amsterdam: G.A. van Oorschot, 2010
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DEFINITIONS
Intellectual disability 
A disability characterized by significant limitations both in intellectual functioning and in 
adaptive behaviour, which covers many everyday social and practical skills. This disability 
originates before the age of 18. American Association on Intellectual and Developmental Disabilities
Pain
An unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage. International Association for the Study of Pain
Nociception
The neural process of encoding noxious stimuli. International Association for the Study of Pain
Quantitative Sensory Testing
Determination of thresholds or stimulus response curves for sensory processing under nor-
mal and pathophysiological conditions. Group of psychophysical methods that systemati-
cally document alterations and reorganization in nervous system function and, in particu-
lar, the nociceptive system. Arendt-Nielsen L, Yarnitsky D. The Journal of Pain 2009; 10: 556-572
Method of limits
Scheme for sensory threshold determination. A subject is required to indicate as soon as an 
increasingly strong stimulus is detected. A reaction time inclusive technique. 
Shy ME et al. Neurology 2003; 60: 898 - 904
Method of levels
Scheme for sensory threshold determination. Stimuli of defined intensity levels are tested 
with the subject signalling whether a specific level is detected. Technique is independent of 
subject’s reaction time. Shy ME et al. Neurology 2003; 60: 898 - 904
Pharmacokinetics
The relationship between the dose and the unbound drug concentration at the site of action 
(a drug receptor). It describes the time course of drug concentration in the body. 
Birkett DJ. Pharmacokinetics Made Easy. Australian Prescriber. Sydney: McGraw-Hill, 2010
Pharmacodynamics
The relationship between the unbound drug concentration at the receptor and the drug 
response (the therapeutic effect). 
Birkett DJ. Pharmacokinetics Made Easy. Australian Prescriber. Sydney: McGraw-Hill, 2010
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